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1. Abstract 
 
1.1. Zusammenfassung  
Bispezifische Antikörper können verschiedene molekulare Architekturen umfassen, um Wirkungsmechanismen 
zu erzeugen, die durch monospezifische Antikörper nicht adressiert werden können. Diese 
Wirkungsmechanismen beinhalten unter anderem die Rekrutierung von Effektorzellen oder die erhöhte 
Selektivität durch zielgerichtete gleichzeitige Bindung von zwei Antigenen. Die Antikörperforschung in der 
Pharmaindustrie ist in den letzten Jahren kontinuierlich gewachsen, besonders bispezifische Antikörper mit 
ihren besonderen Eigenschaften stehen im Fokus. Allerdings ist deren Entwicklung sehr herausfordernd, da die 
optimale Kombination aus zwei ursprünglich monospezifischen Antikörpern gefunden werden muss. Daher 
kommt es zu unerwünscht verlängerten Entwicklungszeiten und erhöhtem Kostenaufwand. Für Identifikation 
und Charakterisierung von Kleinmolekülen und klassischen monoklonalen Antikörpern ist mittlerweile das 
Hochdurchsatz-Durchmustern eine ausgereifte Disziplin. Die Bereitstellung der sehr hohen Anzahl möglicher 
bispezifischer Kombinationen für ein solches Vorgehen stellt bis jetzt jedoch einen sehr limitierenden Faktor 
dar. Es kann nur ein kleiner Teil des zu durchmusternden Raumes abgedeckt werden, da die verschiedenen 
Kombinationen erst aufwendig einzeln neu kloniert, exprimiert und gereinigt werden müssen. In der 
vorliegenden Studie wird daher ein neuartiger Hochdurchsatz-Durchmusterungsansatz für bispezifische 
Antikörper vorgestellt, der diese Limitierungen umgeht und den Durchmusterungsraum um ein Vielfaches 
erweitert. Er basiert auf der Fähigkeit des Split Inteins Npu DnaE, Proteine in-trans zu spleißen. 
Antikörperfragmente werden dabei in der Hinge-Region an einen Teil des jeweiligen Split Inteins fusioniert, um 
die zwei Fragmente so in vitro kombinatorisch ligieren zu können. Diese Methode erlaubt die Rekonstitution 
einer großen Anzahl verschiedenster bispezifischer Antikörper in kürzester Zeit unter voll automatisierten 
Bedingungen ohne aufwendige Einzelklonierungen und Herstellungsarbeiten. Verschiedene in dieser Arbeit 
durch Rekonstitution hergestellte Antikörper zeigen im Vergleich zu genetisch fusioniert hergestellten 
Referenzen durchweg vergleichbare Bindeverhalten und funktionelle Eigenschaften. Die erarbeitete 
Rekonstitutionsmethode ist außerdem voll implementierungsfähig für automatisierte Hochdurchsatz-
Durchmusterung. Eine potenzielle Hochdurchsatz Zugänglichkeit für 96-Well und 384-Well Platten wurde 
untersucht und bestätigt und diente als konzeptioneller Beweis für die Funktionsfähigkeit der Methode. Fab-
Fragmente wurden mit verschiedenen Fc-Fragmenten kombiniert, als beispielhafte Screening Anwendung für 
einen schnellen Wechsel der Effektor-Funktion von monoklonalen als auch bispezifischen Antikörpern. Die 
beschriebene Methode könnte es ermöglichen, bispezifische Antikörper im Hochdurchsatz auf Bindung und 
zelluläre Funktionalität zu screenen, um die Entwicklungszeiten stark zu verkürzen und die Wahrscheinlichkeit 
eine optimale bispezifische Kombination zu finden, erhöhen. Diese Methode dient letztlich zur Herstellung 
besserer Biotherapeutika. 
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1.2. Abstract 
The plethora of bispecific antibody architectures can be harnessed to elicit a broad variety of specific modes of 
actions, spanning from enhanced selectivity by simultaneous avid binding to distinct effector cell recruitment, 
all of which cannot be addressed by monospecific antibodies. Pharmaceutical antibody discovery has been 
evolving and continuously growing over the past decades, moving towards the field of complex biologics and 
mostly bispecific antibodies. Despite their high potential value, discovery of bispecific antibodies as the 
identification of the best possible combination of two parental monospecific antibodies, however, remains 
challenging. Discovery of two sets of monospecific antibodies followed by cloning, production and functional 
investigation of combinations is tedious and often resulting in undesired extended development times and 
increased expenses. But although automated high throughput screening approaches have become increasingly 
relevant and mature for pharmaceutical small molecule and classical antibody discovery, screening of bispecific 
antibodies is, however, up to now very limited by laborious preparation of the tremendous number of potential 
bispecific combinations. Therefore, a novel high throughput screening method for bispecific antibodies was 
developed in this study, allowing a full coverage of the large combinatorial screening space and bypass the afore 
mentioned limitations. This achievement is realized by the ability of the split intein Npu DnaE, to splice proteins 
in trans. Antibody fragments are fused within the hinge region to a respective split intein part, capable to 
reconstitute two antibody fragments back to a full-length antibody format in vitro, without extensive cloning 
and manufacturing work. Throughout the study, all reconstituted antibodies remained similarly biologically 
active in several biochemical and functional cell assays when compared to genetically fused references. The 
reconstitution method is furthermore amenable for automated high throughput screening providing the 
possibility to screen for bispecific combinations by combinatorial mixing of antibody fragments. High 
throughput amenability was investigated for 96 well and 384 well plates confirming both high reconstitution 
efficiency and reproducibility. Fab fragments were combined with different Fc fragments as exemplary 
application for fast switch effector function screenings of monoclonal in addition to bispecific antibodies. The 
method described could enable bispecific antibody high throughput binding and functional cellular screenings 
to greatly shorten development times and enhance the probability of identifying the optimal combination, 
ultimately leading to the generation of better biotherapeutics.  
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2. Introduction  
 
2.1. Antibodies – The modern era of targeted therapy, hallmarks and challenges  
The human immune system is the most powerful natural defensive line against threats like pathogens, 
differentiated by the innate and adaptive immune system. Once being invaded by threats, the immune system 
recognizes highly conserved pathogen-associated molecular patterns (PAMPs), resulting in an unspecific 
immediate immune response.1,2 PAMPs are bound by toll-like receptors (TLRs) and expressed on the cell surface 
of macrophages or neutrophilic cells, leading to a distribution of proinflammatory cytokines activating the 
complement system and serving as initial defense mechanism of the innate immune system.3,4 A more specific 
immune response is given by the adaptive immune system, which is more delayed due to specific antibody 
generation by B-lymphocytes. B-lymphocytes carry unique B-cell receptors (BCRs) specifically recognizing 
antigens. Once bound to an antigen, B-cells are activated in the spleen and lymph nodes and differentiate into 
lymphoblasts and subsequently into plasma cells.5 Plasma cells are generating antibodies for the respective 
antigen that are secreted into the blood. The immune system has the advantage to access a huge antibody 
repertoire of 1010 to 1012 possible variants and is therefore known as nature’s own antibody discovery platform. 
Antibodies are able to recognize their targets with high affinity and specificity on the one hand and furthermore 
trigger immune responses and recruitment of other immune cells, while bound to these targets.6,7 These two 
key functions of antibodies are therefore to protect and prevent intruders to invade the immune system. 
Intruders are pathogens in form of antigens, bacteria or viruses, recognized specifically by antibodies and being 
marked for destruction or combated by the immune system. A response can unfold in either neutralizing 
biological activity, target degradation or inducing effector cascades.8 Since the progression of monoclonal 
antibodies (mAbs) by Köhler and Milstein in 1975, mAbs have widely been used as therapeutic agents for cancer 
treatment and various other deaseases.9  
The first approved and marketed mAb for humans is named muromonab-CD3 (OKT3), directed against the 
CD3 receptor, which was derived from mouse immunization in 1985.10,11 Its murine IgG2a backbone caused 
high immunogenicity, leading to the production of human anti-mouse antibodies (HAMA) and neutralization of 
OKT3 antibody. Chimeric mAbs are less sensitive against HAMA recognition, bearing murine variable domains 
grafted on a human antibody backbone.12–14 Humanized mAbs generated by grafting murine complementary 
determining region (CDR) loop structures to a human backbone or fully human antibodies produced by 
transgenic mice after replacement of the appropriate antibody genes to human genes, are advanced ways to 
bypass immunogenicity.15 Rituximab was the first in class approved chimeric mAb for cancer treatment, more 
specifically for hematologic malignancies and approved by the FDA in 1997. Rituximab targets CD20 on the 
cell surface of B lymphocytes to treat low grade non-Hodgkin lymphoma and was a pioneer antibody in targeted 
cancer therapy.16 Other mAbs like Trastuzumab, targeting the growth factor Her2/neu which is overexpressed 
in breast cancer and other carcinomas or Cetuximab, which is targeting EGFR and is upregulated in ovarian or 
colorectal cancer, can specifically address their targets on the cancer cell surface. Not only targets on the cell 
surface can be addressed by mAbs but also blocking cell signaling interactions of the tumor stroma. The vascular 
endothelial growth factor (VEGF), which is responsible for increased neo angiogenesis facilitating tumor 
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growth in metastatic colorectal cancer can be blocked specifically by Bevacizumab, approved in 2004 by the 
FDA, leading to tumor death.17,18,19  
 
2.1.1. Antibodies – Structure and function 
The two key functions of antibodies discussed earlier can be differentiated by the modular structure. Antibodies, 
also known as immunoglobulins (Ig), are secreted into blood serum after activation by identical immune cells 
(B-cells), derived from a unique parental cell. IgG´s are Y shaped heterodimeric glycoproteins and consist of 
two identical heavy (~50 kDa) and light chains (~25 kDa). The flexible region of an antibody, known as hinge 
region, consists of 15 aa, allowing for optimal steric configuration to bind an antigen.20 The hinge region is 
located between the constant heavy chain (HC) regions CH1 and CH2 and connects the two heavy chains via two 
interchain disulfide bonds. Furthermore, HC linkage is accomplished by non-covalent interactions in the CH3 
region. The light chain (LC) is connected to its corresponding heavy chain (HC) within the constant region 
(CH1) via disulfide bond. In humans, two classes of LC´s can be expressed by B-lymphocytes.21 The constant 
region (CL) is subdivided into lambda (λ) and kappa (κ). The full-length IgG format is a monomer with a size of 
~150 kDa forming a two-fold symmetrical axis and most frequently used for clinical applications.22 
Enzymatic fragmentation by papain for example separates the antibody within the upper hinge region into two 
identical Fab (Fragment of antigen binding) fragments, responsible for antigen binding and one Fc (Fragment 
crystallizable) fragment.23 The Fc portion mediates target specific effector functions by interaction with different 
immune cells. Binding to immune effector cells is maintained by expression of Fcγ-receptors on the cell surface, 
allowing the Fc portion to attach.24 Macrophages or neutrophil cells are recruited as a result of Fcγ-receptor 
binding releasing an immune response. Target cell lysis is also triggered by antibody-dependent cell-mediated 
cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC).25 
The Fc portion can furthermore contribute to solubility and stability of the antibody and facilitates a longer 
half-life before being recycled by the membrane located Fc receptor FcRn (neonatal Fc receptor).26 The FcRn is 
mostly expressed by vascular endothelial cells, protecting the antibody from catabolic degradation.27 The 
different effector functions are defined by the constant region (C) of the antibodies HC. 
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Figure 1: General structure of a full-length IgG antibody depicted as 3D model and illustration including all functional groups.  
(A): Cartoon surface model (PDB: 1IGT, colored with PyMOL v. 0.99) of an IgG antibody structure. Variable domains of the heavy 
chain (VH) and the CH1 region is depicted in green. Variable regions of the light chains (VL) and the corresponding CH1 domain is depicted 
in light blue. The flexible hinge region is indicated in orange followed by the CH2 region in cyan and CH3 region in red. A ribbon structure 
of the Fab fragment is highlighted, presenting the complementary determining regions (CDRs) forming loop structures responsible for 
antigen specific binding. (B): Schematic illustration of an IgG antibody structure following the same color code as A. Additionally the 
Fc portion is highlighted, triggering Fc effector functions like ADCC or CDC by binding to FcR. Interchain disulfide bonds are depicted 
in orange within the hinge region and C-terminal between HC and LC. Intrachain disulfide bonds (black square lines) stabilize the 
domains between the Fab fragment. Glycosylation pattern (lilac hexagon) is illustrated at the CH2 domain within the Fc portion (Asn297) 
involved and required for FcγR and complement binding. Red lines N-terminally at the VH and VL region indicates the CDRs for antigen 
recognition. 
 
In general, antibodies belong to the superfamily of immunoglobulins and can be classified into different isotype 
groups: IgM, IgA, IgG, IgD and IgE. The IgG format can further be subdivided into IgG1-4.28 Classical 
antibodies are monospecific and bivalent containing two identical antigen binding sites at the tip of the “Y”, 
known as paratope. The paratope binds specifically a defined epitope of an antigen and is formed N-terminally 
by combination of variable regions from heavy (VH) and light chains (VL) of the Fab fragments. The antibody 
paratope diversity is generated by random genetic recombination of gene segments encoding for the variable 
regions (V) of VH and VL of germline. Improved diversity (D) is accomplished by random mutations (somatic 
hypermutations) within the antibody’s gene segments (VH only). The tremendous number of 108 to 1010 
generated variable regions as a result of genetic recombination, called V(D)J recombination.29,30 More 
specifically, antigen binding is feasible through the combination of 6 hypervariable loop structures (CDR: 
Complementary Determining Region) derived from VH and VL respectively, flanked and stabilized by 4 constant 
framework regions (FRs).31  
 
2.2. Bispecific antibodies 
The idea of bispecific antibodies (bsAbs) was first described in 1960 and it took another 20 years to develop and 
produce the first monoclonal bsAb by hybridoma technology.32 Different from monospecific antibodies, the 
bispecific format consists of two different antigen binding sites and enables the functionality to bind 
simultaneously two epitopes on one cell surface of tumor cells. Moreover, they can address two different epitopes 
on two different cells and are therefore mostly used to redirect specific immune effector cells to tumor cells. 
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Targeting CD3 on CD8+ T cells and EpCAM on human adenocarcinoma cells for example was the first FDA 
approved bispecific format in 2009, known as catumaxomab.33 Additionally, the Fc portion is acting as a third 
binding domain for antigen presenting cells (APC) like macrophages, natural killer cells or dendritic cells via 
Fc receptor. The ability to form a complex between 3 different cells is called “Triomab”.34 Over 100 bsAb formats 
have been engineered and since March 2019, 85 bsAbs have been tested in clinical trials, mostly targeting cancer 
and redirecting immune cells.35 The bispecific format is a combination of two distinct variable regions derived 
from the parental monospecific antibodies. The ability to bind simultaneously two different epitopes enables a 
variety of modes of actions, like an improved cytotoxic potential by bridging cells in-trans, synergistic effects, 
receptor cross-linking and higher binding specificity. T-cell engagers (TCE), for example, facilitate the 
redirection of T-cells to tumor cells to engage the formation of an immunological synapse for T-cell activation 
and target cell killing.36,37 Other effector cell engagers can be generated, like natural killer cells (NK) for tumor 
cell killing.38 Bridging two receptors on one cell surface (in-cis bridging) by biparatopic bsAbs forcing them to 
crosslink, could lead to either receptor inhibition to reduce tumor growth or receptor activation.39,40,41 
Furthermore, bsAbs can act as immune checkpoint inhibitors by binding to proteins, like PD-1 and PD-L1, on 
the cell surface like nivolumab or atezolizumab. These checkpoints are key regulators for the immune system 
and protect the tumor cell from being attacked by effector cells. Inhibition of checkpoints, results in increased 
antitumor responses.42 Usually more than one oncogenic signaling pathway needs to be addressed and inhibited, 
when tackling a cancer disease. Ordinary monoclonal antibodies are restricted to monospecific binding and 
inhibition of only one signaling pathway, unlike bsAbs or combination therapies.43–45 However, clinical 
developments for bsAbs are more time consuming and usually affected by higher manufacturability costs due to 
the safety and efficacy verification of each mAb and in combination.46,47  
BsAbs are classified into two major classes. One includes antibodies containing an Fc portion and the other one 
lacking the Fc region. These classes can hold either a symmetric or asymmetric architecture. Symmetric 
antibodies contain unmodified assembled heavy chain constant regions. Additional antigen binding sites 
(valency) at the C- or N-terminus can be included to form a bi- or tetravalent architecture. Dual targeting will 
influence avidity effects or agonistic properties induced by cross-linking, depending on the valency.35,48 
Asymmetric antibodies contain modifications within the heavy chain constant regions to force correct 
heterodimerization. Alternatively, antibody fragments like single chain variable fragments (scFv) can be fused 
together via linker peptide to achieve bispecificity. In general, generating bispecifics requires two heavy and two 
light chains often resulting in heavy/heavy or heavy/light chain mispairings and homodimerization. Potentially 
16 different combinations can occur during antibody expression. Only a theoretical yield of 12.5% for the 
correctly assembled heterodimer is achieved.49  
 
2.2.1. Engineering bispecific antibodies 
The first generation of bsAbs was achieved by somatic fusion of two hybridoma cell lines developed by Milstein 
and Cuello in 1983.50 Initial issues with correctly assembled heterodimers using these technologies was 
insufficient. Low yields and heterogeneity through product related impurities, inaccessible for therapeutic 
applications, required extensive downstream processing. Cognate heavy chain pairing is triggered by the CH3 
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domains within an IgG molecule, forming a homodimer interface with high affinity (KD = 10 pM). Several 
technologies to avoid chain mispairings have been developed like Knobs into holes, electrostatic steering, 
DuoBody, BiTE, triomab, common light chains or CrossMabs.45,51 Pioneer work in forced heterodimerization of 
two distinct heavy chains was developed by Ridgway and Carter in 1996, inspired by Crick, who proposed a 
model for packing amino side chains for adjacent coiled coils in 1952.52,53 The Knobs into holes (KiH) technology 
is based on the same principle. Traditionally a “knob” is genetically formed by exchanging threonine at position 
366 to a bulky amino acid tyrosine within the CH3 domain of one heavy chain. Additional amino acid exchanges 
at positions Y407T within the CH3 domain of the second heavy chain are forming a “hole”, forcing both heavy 
chains to form a sterically complementary interface during expression.54 The knob and hole forming mutations 
were refined (T366S, L368A and Y497V) in a rational design in combination with phage display screening, 
stabilizing the CH3 heterodimer interface and yielding 92% heterodimer recovery.55,56 An alternative strategy 
for Fc mediated heterodimerization embraces the substitution of positively charged lysines at position D339K 
and E356K in one heavy chain CH3 domain and negatively charged aspartates at position K409D and K392D 
located in the other heavy chain CH3 domain. The altered charged polarity suppresses homodimer formation, 
although not completely and yielded 90% heterodimer formation.57,58 Duobodies are IgG-like bsAbs generated 
by controlled Fab-arm exchange (cFAE) of complementary CH3 mutations. Fab-arm exchange was naturally 
observed in IgG4 antibodies and the concept was adapted to generate IgG1-like bsAbs. Two antibodies are 
expressed separately, while destabilizing complementary mutations K409R and F405L within the CH3 domains 
favors heterodimerization and reassembly into a bispecific format after mild reduction of the antibodies. 
However, this technology is limited to a full-length IgG format.59,60 The strand-exchanged engineered domain 
(SEED) technology offers the prevention of heavy chain homodimerization during antibody expression. The 
sequence divergence of the CH3 portion in the Fc region by combining IgG and IgA species yields in 85 to 95% 
correctly assembled heavy chain pairing.61 Using heterodimeric Fc platforms, reduces the number of different 
potential chain combinations from 10 to 4 during antibody expression. Although using the SEED technology 
often requires an additional purification tag, for instance C-terminally at the CH3 domain, for purification of 
homodimer impurities. 
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Figure 2: Generation of bispecific antibodies using different technologies for correct heavy chain heterodimerization and light 
chain pairing for Fc modified or Fc modified and appended asymmetric bsAbs.  
 
Fc modified asymmetric bsAbs; a: Strand exchanged engineered domains (SEED) technology combines IgG and IgA species within 
the CH3 portion for correctly assembled heavy chains discovered by David and coworkers in 2010. b: Knobs into holes offer correct 
heterodimerization by bulky amino acid residues forming either a hole or a knob respectively within the CH3 domain. c: CrossMabs 
relocate the CH1 domain to the CL region, while the CL is swapped to the CH1 region for correct LC pairing. VH and VL regions are kept 
consistent. In combination with Knobs into holes, CrossMabs offer both correct HC and LC pairing. d: Common light chains (cLCs) can 
pair with more than one HC. e: Duobodies are IgG-like bsAbs generated by controlled Fab-arm exchange (cFAE) of complementary CH3 
mutations. f: Lewis and coworkers introduced mutations in the CH1 and CL domain of a Fab fragment to ensure correctly assembled LC 
pairing. g: Electrostatic steering introduces oppositely charged amino acids in the CH3 domain, while forcing a homodimerization to 
reject. h: A Triomab consists of two half-antibodies derived from two different species, typically a rat/mouse hybrid, for correctly species 
restricted HC and LC pairing. Triomabs can bind to two distinct targets further supported by FcγR binding by the Fc portion, triggering 
effector functions. Fc modified and appended bsAbs: Fab arms can be exchanged to either an scFv or VHH to avoid HC-LC mispairing. 
Variable domain only: BiTEs are lacking the Fc portion and connect dual scFv fragments via peptide linker to avoid all kind of chain 
mispairings.  
 
Nevertheless, the major bottleneck of all Fc-mediated heterodimerization technologies involves incorrect heavy 
and light chain pairing. Remedies for correct assembly of heavy and light chains have been achieved by using 
common light chains, CrossMabs or BiTEs (Bi-specific T-cell engagers). The BiTE technology is lacking the 
Fc portion and connects dual scFv fragments via peptide linker to avoid all kind of chain mispairings. The first 
approved BiTE antibody blinatumomab was a milestone in bispecific engineering in 2015 and is one out of two 
bsAbs on the market for cancer indications.62,63 CrossMabs consist of an exchanged CH1 and CL domain to ensure 
efficient and specific dimerization of heavy and light chain. The CH1 domain is relocated in the CL region, while 
the CL is swapped to the CH1 region. VH and VL regions are kept consistent. In combination with KiH, IgG-like 
bsAbs can be generated without any chain mispairings.45,64 A simple solution to avoid chain mispairing is to 
change the format into a less complex architecture like scFvs or single domain antibodies (VHH) instead of Fabs 
or bsAbs lacking the Fc region. The Fc region can be immunogenic and triggers effector functions like ADCC 
or CDC through activated Fc receptors, which can be beneficial or disturbing depending on the therapeutic 
application. However, the Fc region can contribute to solubility and stability of the antibody and facilitates a 
longer half-life before being recycled by the FcRn receptor. The ability of the Fc region to bind protein A is 
another advantage while purifying antibodies without the addition of distracting purification tags. A prominent 
strategy to generate bsAbs and avoid heavy and light chain mispairings are the application of common light 
chains (cLC). The LC is able to pair with more than one HC and was first described by Merchant et al. in 1998, 
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based on observations that antibodies derived from a phage display campaign, often use the same VL domain, 
when directed against several antigens.54,65 Specific tumor antigen related binders are screened after 
immunization of transgenic rodents carrying a human HC repertoire with a cLC. Bispecific antibody generation 
by protein trans splicing (BAPTS) is the most recent described approach, suppressing incorrect heavy and light 
chain pairing.66 Split inteins are divided into N- and C-terminal fragments. These fragments are able to form a 
reconstituted canonical intein complex after reunification, followed by fusion of two antibody fragments and 
leaving a stable irreversible peptide bond, resulting in correctly paired mAb arms.67  
In summary, the marketability of bsAbs consumed several billion dollars and the clinical development pipeline 
expanded from 5 bsAbs in 2010 to 28 bsAbs in 2019.35 Nevertheless, the right combination of two binding 
domains must be identified for the right biological activity and results in extensive screening campaigns or 
empirical selection strategies. Every combination can affect the design parameters for each arm, which effects 
the affinity, cross-linking and specificity.  
 
2.3. Antibody screening and lead generation  
During the last decades, mAbs were applied very successfully as therapeutic modalities.19 Pharmaceutical mAb 
discovery typically comprises immunization campaigns in transgenic rodents followed by single B-cell cloning 
or display of antibody fragments on the surface of yeast or phage.68 The path of discovering a new therapeutic 
monoclonal or bispecifc antibody underlies several stages, until entering the clinical trials. A traditional antibody 
screening approach starting by either phage or yeast display offers a unique antibody selection of potential 
antibody candidates, typically derived in a scFv or VHH format.69,70 Phage display is based on a bacterial host 
system yielding high amounts of target protein and typically yields in a large repertoire of binders. Therefore, 
high throughput bacterial expression in E. coli in combination with high throughput binding and competition 
assays to their respective antigens leads to a first discrimination of potential antibody hit candidates.71 The hit 
candidates are reproduced in medium throughput expression runs followed by purification and another round 
of binding, competition and first cell-based assays, to further narrow down the best candidates. A re-formatting 
step into a natural full-length IgG format is essential, as already mentioned before, for further validation of 
potential lead candidates. The re-formatting step represents a bottleneck in traditional antibody screening 
campaigns, limited by extensive cloning, expression and purification work of all selected hit candidates.72,73 
Therefore, only a very concise antibody repertoire can be considered to become a final lead candidate.  
The full-length IgG candidates are then expressed and purified in low throughput for concluding cell based 
functional assay validation and finally the generation of the desired lead candidate (Figure 3).74   
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Figure 3: Traditional antibody screening strategy based on a phage display selection until final lead candidate identification.  
Unique hits are generated by in vitro selection tools like phage display and analyzed in biochemical binding and competition assays. After 
optimization, expression and purification generated hits are analyzed in functional cell-based assays for effectiveness. Re-formatting into 
a natural full-length IgG format represents a bottleneck in traditional antibody screening campaigns before the selection of a final lead 
candidate. HT: High throughput, LT: Low throughput, DNA seq: DNA sequencing. Figure is adapted from Xiao et al.74 
 
Although antibodies are well investigated and still a rapidly growing field in drug discovery, mAbs lack 
additional therapeutic potential due to their monospecific nature and limited range of effector functions.75 
Improvements in antibody engineering paved the way for more complex molecules and modified structures for 
extended therapeutic applications. Effector cell recruitment, enhanced selectivity by avid simultaneous binding, 
conditional antagonism and targeted delivery of immunomodulators, is broadening the envisioned mode of 
action to functionalities not supported by mAbs.32 However, finding hit candidates for complex therapeutic 
antibody molecules is challenging and requires defined and extended research activities during lead discovery. 
The next chapter will give insights into bispecific antibody high throughput screening (HTS) for lead discovery. 
 
2.3.1. High throughput screening for bispecific antibodies and complex NBEs 
Nowadays antibody hit discovery is linked to modern age technologies like HTS approaches and automation. 
Since HTS introduction in 1990, a lot of development work was performed and started a new era for improved 
antibody discovery in pharmaceutical industry.76  It is important to apply HTS in the early stage of antibody 
discovery, to increase the chance to enrich hit candidates and selection of lead candidates.77,78–80  Despite 
antibodies showing great success in clinical trials, still a tremendous number of 80 to 85% discovered mAbs and 
also bsAbs are discontinued in lead discovery, due to lack of efficacy. The rate of failing antibodies in clinical 
trials indicate the importance to enlarge the antibody variety for screening. Screening against biological targets 
combined with automation, miniaturization and large-scale data analysis became more suitable and cost efficient 
over the years.81 This is supported by 74 antibody lead candidates in clinical phases extended by two accredited 
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marketed drugs discovered by HTS campaigns since 2003.79,80,82 Nowadays, HTS is the starting point in drug 
discovery and there is a strong demand in screening the increasing numbers of biological targets to find the 
optimal lead candidate.32  
Complex molecules or formats for extended therapeutic applications, like bsAbs, have more clinically relevance 
compared to mAbs and are more difficult to generate and screen for, due to earlier described reasons. Although 
elegant approaches for the generation of bsAbs using knob-into-hole, electrostatic steering, DuoMab, SEED, 
triomab, as well as common light-heavy chain approaches, κλ-bodies or CrossMabs are not suitable for extensive 
combinatorial screening campaigns.32,64,83 These technologies are limited to generated combinations of already 
existing bispecific entities. So far, blinatumomab and emicizumab are only two bsAbs that have been approved 
by the FDA worldwide during the last decades, indicating the need for new screening attempts.41,84 
Furthermore, the full-length IgG format is still predominantly used in clinical development of candidates. Re-
formatting into a full-length IgG-like format, means always a risk in changing the biological and biophysical 
antibody properties, like decreasing affinity or biological activity, which would lead to further engineering or 
optimization work.85 Especially T-cell engagers display a very specific design and need flexibility and space 
between the two antigen binding arms to redirect T-cells to cancer cells to engage the formation of an 
immunological synapse for T-cell activation and target cell killing.86 It would therefore be desirable to use a 
full-length format already in the early stage of antibody discovery.74 Unfortunately, the unique hits, created in 
initial screenings, are usually not based on an IgG like molecule and often derived from bacterial hosts.87 The 
production of full-length antibodies in E. coli usually results in misfolded protein, low yields and the lack of 
glycosylation. Therefore, the most common formats for initial hit screenings are antibody fragments like scFvs 
or VHHs, which fold more efficiently and are being produced in high yields using bacterial hosts.88 Nevertheless, 
non-natural surrogate formats like scFv suffer from aggregation and might result in false positive or negative 
results. Furthermore, they are not compatible to modes of actions, which are dependent on Fc mediated effector 
functions or bivalent binding.89  
Screening and therapeutic development of asymmetric full-length IgG bsAbs requires optimization work 
through molecular engineering for lead candidate generation and selection. To find the best combination of two 
binding moieties for a bispecific antibody, a large number of monospecific antibodies against their distinct 
antigen targets must be identified as a first step. Engineering the two best monospecific variants into a bispecific 
format does not necessarily lead to the best combination for a bsAb approach, to find the final lead candidate. 
Furthermore, higher binding affinities do not automatically lead to higher bio functional activity. After 
screening for binding to the respective antigens of both parental monospecific antibodies, a combination into a 
bispecific format requires antibody engineering methods, like described earlier, for correctly assembled bsAbs. 
Sampei et al. expressed 200 x 200 monospecific antibodies directed against FIXa and FX with different LCs from 
an immunization campaign to generate 40 000 individual bispecific combinations to find their final lead anti-
FIXa/FX bsAb, resulting in massive time-consuming cloning, expression and purification. The full-length 
asymmetric IgG antibody format was preferred due to the ability to bind both targets in combination enabling 
long half-life based on the IgG structure and mimic FVIII cofactor activity.  
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When identifying the single binding moieties of an envisioned bispecific antibody, approaches mainly focus on 
reduction of individual clone numbers by filters such as affinity, target specificity, optimally domain or epitope 
mapping. Most intended modes of actions are not conveyed by a single binding moiety, but through the 
combination to be identified, for example selective effector cell recruitment, target-specific Fc mediated effector 
functions or enhanced selectivity binding by avidity 25,86. When attempting to screen a desirable high number 
of combinations, for example 200 times 200 binding moiety combinations, multiple cloning, expression and 
purification steps represent a bottleneck for the production, even when multi-parallel small-scale expression 
methodologies are in place as shown in the study of Sampei et al. Therefore, the number of combinations or 
bsAbs finally generated is usually only a small fraction of the selected repertoire 74. The group of Sampei et al. 
found 96 bispecific combinations out of 40 000 variants mimicking FVIII activity but suffering from massive 
chain mispairings tending to undergo multidimensional optimization processes to improve manufacturability 
and therapeutic potential. This low number of potential variants indicate the importance to screen for the 
maximum number of combinations to find a lead bsAb.  
 
 
Figure 4: Target screening space during antibody hit discovery for a bispecific format using traditional screening and advanced 
combinatorial screening methods.  
(A) Traditional screening of a bsAb combination filtered and reduced by affinity and target specificity (red box) due to target screening 
space limitations of a traditional screening platform. Covering the whole target screening space (green box) is a bottleneck and leads to 
multiple cloning, expression and purification steps after selection. The optimal combination cannot be identified, based on missing 
screening information of the whole target space. (B) Desired combinatorial screening approach to fully cover the whole target screening 
space with all possible combinations by reassembly both binding moieties directly after discovery. No filters need to be considered. Red 
dots: Hit candidate identifications for several bispecific combinations with different affinities. Green dot: optimal hit candidate; best 
affinity and efficacy for the relevant approach. 
 
Finally, most bsAb engineering approaches include comparisons of several formats to further optimize the 
intended biological mode of action, which in addition enlarge the screening space or efforts, respectively.  
 
2. Introduction  13 
A broadly applicable method enabling high throughput binding and functional cellular bsAb screenings has to 
date not been described but would greatly shorten development times for a wide variety of complex NBEs and 
enhance the probability of identifying the optimal combination, ultimately leading to the generation of better 
biotherapeutics (Figure 4).  
 
2.4. Protein conjugation  
Molecular engineering is a subtle technology for modifying proteins, improving biophysical properties like 
thermostability, solubility or tagging biomolecules with fluorophores, drugs and polymers. Since cytotoxic 
drugs can be efficiently conjugated to antibodies, offering a better safety potential due to the high and specific 
affinity of antibodies compared to non-targeted cytotoxic molecules, protein conjugation techniques expanded 
fundamentally.90 Enzymatic or chemical alteration of biomolecules like antibodies exhibit great potential for 
new therapeutic approaches in cancer therapy.91,92 As previously discussed, screening bispecific antibody 
candidates for the most suitable combination of both binding moieties requires elaborative technologies to gain 
success. The following chapter deals with protein conjugation technologies predominantly used for antibody 
engineering.   
 
2.4.1. Microbial Transglutaminase (mTGase) 
Transglutaminases (TGs) belong to the group of γ-glutamyltransferases and catalyze the isopeptide bond 
formation between two proteins. The transamidation reaction involves the crosslinking of  
γ-glutamyl-glutamine side chains (acyl-donor) and ε-amino groups of lysines (acyl-acceptors) forming a stable 
inter- or intramolecular isopeptide bond.93 However, by-products may also occur when glutamine enters a 
deamidation reaction due to the lack of primary amines or lysine residues forming glutamic acid.94 The enzyme 
purity dictates amongst others the content of side reactions, leading to changes in protein charge and therefore 
protein solubility.95 The first transglutaminase was discovered in 1989 in Streptomyces mobaraensis by Ando and 
coworkers and was widely used in food industry, to improve functional properties.96 The enzymatic reaction is 
well investigated, and transglutaminases are used for cross-linking fibrin in blood coagulation through factor 
XIII for example. Transglutaminases derived from bacteria (mTGase) can be produced in large quantities in 
E. coli and offer several advantages over TGase found in mammalia.97,98 mTGase exhibits a smaller molecular 
weight and is not dependent on any cofactors like calcium, compared to mammalian enzymes. Furthermore, they 
offer improved stability, performance and reduced deamidation activity. mTGase derived from Streptomyces 
mobaraensis is recombinantly expressed with an amino terminal pro peptide, inhibiting TGase activity and 
improving the thermostability.99 The pro peptide is cleaved specifically by metalloproteases supported by a 
tripeptidyl aminopeptidase, releasing the active form of the enzyme to bypass secretion of inactive enzyme.100 
Transglutaminases accept a variety of substrates and are often used for biotechnological applications like 
cross-linking heterogeneous polymers or ligation of biomolecules. They became an important tool for site 
specific conjugation of antibodies to generate antibody drug conjugates (ADCs).101,102  
However, the glycosylation of an antibody is causing sterically obstruction of the transamidation reaction and 
either needs to be removed by deglycosylation enzymes or an additional glutamine recognition tag has to be 
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introduced elsewhere for specific conjugation.103 A prominent recognition tag for antibody conjugation via 
mTGase is LLQGA, but this tag is restricted mostly to conjugations C-terminally of the Fc portion or the LC 
of an antibody. A lot of development work has been performed to engineer the enzyme regarding improved 
catalytic performance and alternative recognition sequences.104 One of the major drawbacks of mTGase is its 
unselective substrate specificity, resulting in unspecific conjugation, making it inaccessible for certain protein 
ligation reactions.   
 
2.4.2. SpyTag/SpyCatcher 
The SpyTag/SpyCatcher system is used as a protein bioconjugation tool derived from the fibronectin binding 
protein (FbaB) of Streptococcus pyogenes. FbaB possesses a collagen adhesin domain (CnaB2) exhibiting an internal 
isopetide bond between amino acids Lys31 and Asp117.105 The domain is split between Lys and Asp into two 
fragments resulting in an N-terminal fragment (SpyCatcher) of 138 aa and a C-terminal fragment (SpyTag) of 
13 aa. Reconstitution of these fragments spontaneously form a peptide bond between Lys and Asp bringing the 
fragments in close proximity and optimal orientation. Reconstitution is initiated by forming a double hydrogen 
bond between Glu77 and Asp117 facilitating the peptide bond formation by nucleophilic attack and forming a 
zwitterionic intermediate. Glu77 is transferring protons to form a neutral tetrahedral intermediate, 
subsequently resolved when water is released. Finally, the peptide bond between Lys31 and Asp117 is 
formed.106–108 The reconstitution of SpyTag and SpyCatcher supports a broad range of pH (5 to 8) values and 
temperatures (4 to 37°C) and works under redox conditions and harsh conditions using solutions with 
detergents. The ligation reaction rate is described as very fast and efficient with t1/2 = 74 s using both fragments 
and a molar concentration of 10 µM.109 The technology is a promising tool for biotechnological applications. 
Recombinant proteins can be ligated through a peptide bond formation, or proteins can be stabilized by protein 
cyclization. The SpyTag/SpyCatcher fragments can either be fused C- or N-terminally to recombinant proteins 
or to internal positions within the protein, unlike split inteins, which are restricted to C- or N-terminal fusions.110 
Furthermore, the SpyTag approach can be used to generate site specific conjugated ADCs with high efficiency.111 
However, the SpyTag/SpyCatcher technology is leaving a peptide imprint by incorporation of 151 aa to the 
protein of interest. A truncated version of an N-terminal SpyCatcher fragment (32 aa shorter) has been 
developed by Li et al. to decrease an immune response in mice and to shorten the incorporated aa between the 
reconstituted proteins. The truncated SpyCatcher version still remains in the reconstituted protein of interest 
and modifies the size by addition of 13 kDa and might lead to conformational changes, obstruction or biological 
functionality.109   
 
2.4.3. Sortase 
Sortases are membrane associated bacterial enzymes and catalyze a reaction called transpeptidation. They are 
located in the plasma membrane of gram-positive bacteria and anchor secreted proteins covalently to the cell 
wall. Sortase A (SrtA) from Staphylococcus aureus is the best characterized sortase and was first described in 2004 
for biotechnological applications. The transpeptidation reaction is most frequently used for protein ligation or 
protein labeling and further known as “Sortagging”.112,113 Protein ligation depends on an acyl donor and 
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acceptor. In presence of a short peptide sequence LPXTG (substrate, acyl donor), while X can refer to any amino 
acid, a cysteine is activated in the active site and peptide bond cleavage between threonine and glycine is 
catalyzed forming a linked thioester acyl enzyme intermediate. The enzyme intermediate is then attacked by an 
amino glycine and resolves in the site-specific ligation of acyl donor and acceptor generating a peptide bond. 
The transpeptidation reaction of wild type SrtA suffers from poor reaction rates and depends on Ca2+ as a 
cofactor to activate the cysteine in the active side.114 Engineered versions of SrtA, by incorporating several 
amino acid exchanges (P94R/D160N/D165A/ K190E/K196T) lead to improved reaction rates up to 120-fold 
faster, compared to wild type SrtA.115 Furthermore, the engineered SrtA is Ca2+ independent which makes it 
more interesting for protein tagging. However, the overall total yield of the wild type version for ligation 
products is still higher and mutated sortase versions tend to higher undesired hydrolytic or oligomeric side 
products.114 A significant molar surplus (1:20) of either the acyl donor or acceptor is needed for efficient protein 
ligation because the reaction is reversible and depends on an equilibrium. Sometimes it can be challenging to 
produce either the acyl donor or acceptor in large quantities and furthermore, byproducts like accumulated 
amino glycine peptide fragments are released, forcing a reversed transpeptidation reaction.116 These byproducts 
can be removed extensively by dialysis or centrifugal filtration, to limit reversibility of the reaction, allowing to 
use ligation partners at nearly equimolar ratios. Changing the recognition sequence from LPXTG to LPXTA 
for example or including an unreactive β-hairpin close to the recognition sequence, can further decrease the 
reversed transpeptidation or formation of byproducts and expand the substrate range.117 Sortagging was 
established for the generation of site specific conjugated antibodies, yet holding notable limitations as mentioned 
before.118  Using split inteins with high sequence specificity and no dependency on any cofactors, external energy 
sources or surplus of reactants, offer a simpler and more elegant way for protein ligation or labeling strategies 
compared to sortases, transglutaminases or similar ligation techniques described before. 
 
2.4.4. Split Inteins 
Inteins are naturally occurring auto catalytic domains found in every organism (archaea, bacteria and 
eukaryotes) and were first discovered in 1988 and described by Hirata et al. and Kane et al. in 1990.119,120 Inteins 
replicate themselves within genomes and have no other known regulatory or functional role for the host 
organism and are therefore often described as “selfish” or “parasites”.121 Intein splicing occurs on the protein 
level and the intervening protein sequences are embedded in host proteins and catalyze the splicing reaction to 
excise the intein out of the host protein very specifically. Inteins undergo a well-known single turnover reaction, 
similar to classical enzyme catalysis, that do not depend on co factors like ATP or energy sources. Flanking N- 
and C-extein sequences are joined together by a native stable peptide bond catalyzed by the intein splicing 
reaction.122 Intein splicing replicates the intein within genomes and has no other known regulatory or functional 
role for the host organism. Therefore, inteins are often described as “selfish” or “parasites”, incorporating 
themselves into the genome and splicing themselves out for replication.121 They are divided into three different 
groups. Classical or bifunctional inteins, split inteins and mini inteins varying in length and mode of action. 
Classical inteins are embedded in their natural host proteins and expressed as one polypeptide chain localized 
on one gene bearing a splicing domain and a homing endonuclease domain, responsible for the lateral transfer 
 
2. Introduction  16 
between genomes.123 Classic inteins are splicing in cis within the same protein. Mini inteins contain only a 
splicing domain lacking the homing endonuclease domain, while split inteins are localized on two different gene 
segments and separately encoding for N- and C-inteins, undergoing an autocatalyzed mechanism called protein 
trans splicing (PTS) after reassembling both intein parts through structural changes of the host protein.124 
Intein splicing is mediated by the N- and C-intein sequences, containing conserved sequence motifs, and the 
first residue of the C-extein followed by four different coordinated replacement reactions. N-terminal splicing is 
activated by an N-S or N-O acyl shift mediated by nucleophilic attack of the first amino acid residue (residue 1) 
of the intein N-terminus and the carbonyl carbon of the flanking N-extein (residue -1), resulting in a linear 
(thio)ester intermediate.125 The amino acid at position +1 typically consists of a cysteine or serine side chain. 
The (thio)ester is then transesterified by nucleophilic attack by the hydroxyl or sulfhydryl group of the first C-
extein residue (+1) consisting of either a cysteine, serine or threonine, forming a branched intermediate. The N-
terminal intein is cleaved and transferred to the N-extein. The third step is the formation of a succinimide ring 
by cyclization of the conserved asparagine residue of the intein C-terminus, attacking the previously formed 
intein-extein junction. Thereby the intein C-terminus is cleaved and finally a spontaneous S-N or O-N acyl shift 
occurs, resulting in a stable native peptide bond ligation between the two esterified exteins. 126–128 
Natural split inteins with N- (Motif A and B) and C- (Motif F and G) terminal splicing domains have typically 
a length between 102 – 123 aa and 30 – 50 aa respectively and are flanked by their natural extein sequences.129 
These blocks of consensus sequences are highly conserved and participate in the protein splicing process.122 In 
between of the splicing domains is the endonuclease domain (Motif C, E and H) which is not essential for the 
splicing reaction but for genetic replication within the host protein. While trans splicing inteins are forming an 
active intein structure, the splicing process can be interrupted due to hydro-/thiolysis of the formed 
ester-/thioester resolving the Asn cyclization.130 The N-terminal extein is cleaved off the pre-cursor protein 
before ligation can occur. Likewise releasing the C-extein and uncoupling the Asn cyclization from step 1 can 
occur spontaneously.131 Alternatively, mutations in the conserved parts or the replacement of the intein into a 
non-native host protein can result in inefficient splicing or uncoupling the splicing reactions, which often results 
in single site N- or C- terminal cleavage without peptide bond formation.132 The mutation of the cysteine at 
position 1 to alanine for example, is blocking the N-terminal cleavage, because alanine is not able to undergo an 
acyl shift, lacking a hydroxyl side.133,134 Although inteins show very low sequence homology, splicing is highly 
efficient because only the terminal regions and the first residues of the N- and C-exteins are needed for the 
protein splicing.135 The splicing rate of naturally occurring or artificially designed split inteins is very fast and 
specific. The best described split inteins are originally from cyanobacteria. Ssp DnaB derived from 
cyanobacterium synechocystis is the first discovered naturally occurring split intein.136 The best characterized split 
intein is the Npu DnaE from cyanobacterium Nostoc punctiforme and one of the fastest split inteins known so far 
and belongs to the category ultra-fast split inteins. The catalyzed trans splicing reaction of Npu DnaE is 
described with t1/2 = 1 min at 37°C temperature optimum. Npu DnaE consists of a 36 aa IntC and a 102 aa IntN 
fragment.137–139 
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Figure 5: Split intein mode of action and structure of the split intein Npu DnaE from Nostoc punctiforme.  
(A) Illustration of the protein trans splicing (PTS) mechanism of split inteins forming a peptide bond between a one-armed SEED and a 
Fab fragment. Green squares attached to the intein parts symbolize a hexahistidine tag with glycine serine linker for purification 
purposes. After reassembly of both intein parts PTS is mediated by four different coordinated replacement reactions. N-terminal splicing 
is activated by an N-S or N-O acyl shift induced by nucleophilic attack, resulting in a linear (thio)ester intermediate. The (thio)ester is 
than transesterified by nucleophilic attack by the hydroxyl or sulfhydryl group of the first C-extein residue (+1), forming a branched 
intermediate. The third step is the formation of a succinimide ring by cyclization of the conserved asparagine residue of the intein  
C-terminus, attacking the previously formed intein-extein junction. Thereby the intein C-terminus is cleaved and finally a spontaneous 
S-N or O-N acyl shift occurs, resulting in a stable native peptide bond ligation between the two esterified exteins. (B) 3D structure model 
of the split intein complex Npu DnaE from Nostoc punctiforme (PDB: 4QFQ, colored with PyMOL v. 0.99). N-terminal intein part (IntN) 
is depicted in yellow, while C-terminal intein part (IntC) is illustrated in orange. Cysteine at position 1 (IntN) and asparagine at position 
131 (IntC) indicate the first and the last amino acid of both split intein parts and further the attachment point of the extein residues. 
 
Split inteins have become popular for biotechnical applications and many engineering strategies have been 
described to improve cis and trans splicing. This powerful toolbox can be used for protein modification or 
labeling, purification and ligation or furthermore cyclization of peptides to change the conformation and gain 
new biophysical properties.140 Expressed protein ligation (EPL) is a classic approach to modify or label proteins 
with small peptides or peptide tags at the C-terminus of a recombinant protein. The intein is not able to undergo 
transesterification in trans. Therefore, the α-thioester at the C-terminus of the peptide is facilitating the ligation 
to an N-terminal cysteine.140,141 The mechanism is similar to native chemical ligation (nCL), although EPL has 
several disadvantages compared to PTS. PTS is not dependent on additional thiols and large quantities of 
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recombinant protein or peptides and furthermore not dependent on the fragment size. Either for EPL or PTS, 
the presence of catalytic cysteines flanking the intein fragments require a reduced state for successful splicing.142 
There are several other reported split inteins described in literature, using a triggered splicing function via pH, 
temperature or light, achieved through intein modifications making processes more applicable, when they are 
sensitive to reducing conditions.143–145 An engineered version of the cysteine free split intein Aes was recently 
described by Bhagawati and coworkers in 2019, exhibiting improved splicing kinetics and yield applicable for in 
vivo splicing approaches, like chemical labeling of cell surface receptors.146  
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2.5. Aim of the study  
Complex NBEs and especially bsAbs with their ability to bind two distinct epitopes on the same or different 
cells give rise to diverse and potent therapeutic modes of action. Full coverage of the multidimensional screening 
space of all possible binding moiety combinations and formats to identify candidates with optimal efficiency 
remains challenging due to excessive cloning, expression and purification steps for bispecific screening. In the 
presented work, a novel screening methodology for bsAbs should be developed, to overcome the current 
screening limitations and enlarge the screening space to increase the number of possible bispecific combinations 
and therefore the chance to find optimal bsAbs. This should be achieved by split intein mediated antibody 
reconstitution enabling industry scale high throughput combinatorial bsAb screenings. For this, antibody 
fragments should be generated as fusion proteins using split intein parts derived from Npu DnaE and in vitro 
reconstituted within the hinge region resulting in bispecific antibody products in the desired format without 
additional cloning and expression steps. The specific design of the precursor antibody fragments including 
hexahistidine tags should allow for a fully automatable high throughput amendable one-pot affinity purification 
via Ni2+ bead addition, resulting in reproducible generation of tag-less high purity bsAb screening candidates 
(Figure 6). This broadly applicable method should enable high throughput binding and functional cellular bsAb 
screenings, would greatly shorten development times for a wide variety of complex NBEs and enhance the 
probability of identifying the optimal combination, ultimately leading to the generation of better biotherapeutics. 
 
 
Figure 6: Schematic illustration of bsAb in vitro reconstitution mediated by split inteins.  
 
Concept of antibody reconstitution depicting antibody Fab and one-armed (oa) SEED fragments fused N- or C-terminally to their split 
intein parts. Antibody fragments are expressed in mammalian cells and purified separately before being mixed again in an equimolar 
ratio for antibody reconstitution. Split intein complex is formed after activation by TCEP and excision of the intein segments takes place 
after several replacement steps by PTS, leaving a reconstituted newly formed bsAb. Purification tags at the N- and C-terminal parts of 
the inteins allow for simply removal of non-reconstituted impurities and leftover excised intein complexes. Antibody fragment mix is 
treated with Ni2+ beads after PTS to trap non reconstituted antibody fragments and excised split intein parts via hexahistidine tag based 
on the specific design. The supernatant containing pure reconstituted antibody is separated from the Ni2+ beads and ready for 
characterization without further treatment. One-pot purification for reconstituted antibodies is applicable for 384 well plates and 
automated HTS.
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3. Materials  
 
3.1. Bacterial strains and human cell lines  
 
Bacterial strains  
E. coli One Shot TOP10 chemically competent cells (#C4040-10, Life Technologies, Karlsruhe, Germany); 
Genotype: F- mcrA Δ (mrr-hsdRMS-mcrBC) φ 80lacZΔ M15 Δ lacX74 recA1 araD139 Δ (ara-leu) 7697 galU galK 
rpsL (StrR) endA1 nupG  
 
E. coli XL1 blue MRF’ chemically supercompetent cells (#200230, Agilent Technologies, Waldbronn, 
Germany); Genotype: (mcrA)183 (mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac [F’ proAB 
lacIqZM15 Tn10 (Tetr)]  
 
Clear Coli® BL21(DE3) electrocompetent cells (#60810-1, Lucigen, Wiscondin, USA); Genotype:  F– ompT 
hsdSB (rB- mB-) gal dcm lon λ(DE3 [lacI lacUV5-T7 gene 1 ind1 sam7 nin5]) msbA148 ΔgutQ ΔkdsD ΔlpxL ΔlpxM 
ΔpagP ΔlpxP ΔeptA  
 
 
Mammalian cell lines  
Cells were obtained from the American Type Culture Collection (ATCC®, Manassas, VA, USA) or the Deutsche 
Sammlung von Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany), or companies as listed 
below (Table 1). 
 
Table 1: List of mammalian cell lines and reporter cells used for the experiments in the present study.  
Cell line Cell type Origin 
A-431 human epidermoid carcinoma ATCC® CRL-1555™ 
A549  human lung carcinoma  ATCC® CCL 185TM  
ExpiCHO-S  chinese hamster ovary  Life Technologies, Darmstadt, 
Germany  
Expi293FTM human embryonic kidney Life Technologies, Darmstadt, 
Germany (A14527) 
EBC-1  human lung carcinoma  JCRB0920 031496  
MKN-45  
 
human gastric adenocarcinoma  
 
DSMZ ACC 409  
CD40 Nf-κB 
Luciferase Reporter 
HEK293 
Human embryonic kidney BPS Bioscience, Cornerstone, San 
Diego 
Recombinant Jurkat 
cells 
Effector cells for ADCC assay Promega, Mannheim, Germany 
(G701A) 
MDA-MB-468 human breast adenocarcinoma  
(mammary gland) 
ATCC® HTB 132TM  
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HT1080 CD40 Human fibrosarcoma ATCC® CCL 121TM 
Jurkat E6.1 T-lymphocyte ATCC® TIB 152TM 
SK-BR-3 human breast adenocarcinoma  
(mammary gland) 
ATCC® HTB-30™ 
 
3.2. Plasmids 
Plasmid maps were generated using SeqBuilder v12.3.1 and exemplarily plasmids for different antibody-intein 
fusion constructs are shown below.  
 
 
 
Figure 7: Plasmid map of pTT5-HC-SEED(AG).  
The pTT5 vector backbone was obtained from the National Research Council of Canada. The vector was used for mammalian expression 
systems in CHO or HEK293 cells. The most important features are highlighted and listed as follows: EBV oriP: Origin of replication; 
Amp: Ampicillin resistance gene (Amp, β-lactamase); pMB1 ori: Bacterial origin of replication; CMV promotor: Cytomegalovirus 
immediate early promoter used for transient expression and high level yields in mammalian expression systems; Adenovirus TPL: 
Adenovirus tripartite leader coding region. The rabbit β-globin polyadenylation signal (pA) is located downstream of the antibody 
sequences. The vector encodes for antibody HC SEED (AG), containing VH-CH1-hinge-CH2-CH3(AG). Restriction enzymes are 
highlighted in green and used for replacing VH antibody regions via standard cloning.  
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Figure 8: Plasmid map of pTT5-His-IntC-huFc(GA).  
The vector encodes for antibody HC SEED (GA), containing His-4x(G4S)-IntC-partial hinge region-CH2-CH3(GA).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Plasmid map of LC.  
The vector encodes for antibody LC, containing VH and CL domain. 
 
 
3. Materials  23 
 
 
Figure 10: Plasmid map of pTT5-Fab-IntN.  
The vector encodes for antibody Fab-IntN, containing VH-CH1-partial hinge-IntN-mycTag-His. Restriction enzymes are highlighted in 
green and used for replacing VH antibody regions via standard cloning. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Plasmid map of pTT5-huFc-IntC.  
The vector encodes for antibody huFc-IntC, containing His-4x(G4S)-IntC-partial hinge region-CH2-CH3. 
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Figure 12: Plasmid map of pTT5-VHH-IntN.  
The vector encodes for antibody VHH-IntN, containing VHH-partial hinge region-IntN-mycTag-His. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 13: Plasmid map of pET11a-VHH-IntN.  
The pET11a vector backbone was obtained from Novagen and the sequence is a convention of the pBR322 plasmid, originally invented 
by Bolivar and Rodriguez in 1977 (University of San Francisco). The vector was used for bacterial expression in E. coli. The most 
important features are highlighted and listed as follows: LacI: LacI-repressor gene of the lactose operon. Bla: β-lactamase conferring 
ampicillin resistance. The vector encodes for antibody VHH-IntN, containing VHH-partial hinge region-IntN-mycTag-His. Restriction 
enzymes are highlighted in green and used for replacing VHH antibody region via standard cloning. 
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3.3. Enzymes and proteins  
Antarctic Phosphatase, calf intestinal (CIP) 
ApaI 
BamHI-HF® 
Benzonase  
 
New England BioLabs, Ipswich, MA, USA 
New England BioLabs, Ipswich, MA, USA 
New England BioLabs, Ipswich, MA, USA 
Novagen, Nottingham, GB  
Bovine serum albumin (BSA), fraction V  
BSA standard solution (2 mg mL-1) 
CD40 Avi His 
CD40L-His, Recombinant human 
(10774H08H50) 
CEACAM5 (35-685) His, Recombinant 
human 
CEACAM6 (35-320) His, Recombinant 
human 
EGFR (1-618) His, Recombinant human 
EcoRI 
Merck, Darmstadt, Germany  
Thermo Scientific, Schwerte, Germany 
Acro Biosystems, Newark, USA 
Thermo Scientific, Schwerte, Germany 
 
Acro Biosystems, Newark, USA 
 
Acro Biosystems, Newark, USA 
 
Merck, Darmstadt, Germany 
New England BioLabs, Ipswich, MA, USA 
HER2, murine Fc His 
HER2 (23-652) His, Recombinant human 
Merck, Darmstadt, Germany 
Acro Biosystems, Newark, USA 
Lysozyme  
NcoI-HF® 
NotI-HF® 
Immobilized papain (agarose resin) 
Roche, Mannheim, Germany  
New England BioLabs, Ipswich, MA, USA 
New England BioLabs, Ipswich, MA, USA 
Thermo Scientific, Schwerte, Germany 
Phosphatase inhibitor set II (#P524625)  Merck, Darmstadt, Germany (Calbiochem)  
Phusion DNA polymerase 
Pfu Turbo DNA polymerase  
New England BioLabs, Ipswich, MA, USA  
New England BioLabs, Ipswich, MA, USA 
Protease inhibitor set III (#P524525)  Merck, Darmstadt, Germany (Calbiochem)  
Recombinant human c-MET ECD-strepII-His  Merck, Darmstadt, Germany  
Recombinant human c-MET SEMA-PSI-
FLAG-His  
Merck, Darmstadt, Germany  
Recombinant human EGF (236-EG/CF)  R&D Systems, Minneapolis, MN, USA  
Recombinant human HGF (294-HGN/CF) 
Rherbb2 murine Fc 
R&D Systems, Minneapolis, MN, USA  
R&D Novoprotein, New Jersey, USA 
T4 DNA Ligase  New England BioLabs, Ipswich, MA, USA  
Quick Ligase         New England BioLabs, Ipswich, MA, USA 
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3.3.1. Antibodies  
 
Reference antibodies  
Cetuximab (Erbitux®, C225)  
 
Merck, Darmstadt, Germany  
anti-hen egg lysozyme (HEL)  
APX005M (Apexigen) 
C5xC6 bispecific antibody  
Trastuzumab (Herceptin®)                 
Merck, Darmstadt, Germany 
Merck, Darmstadt, Germany  
Merck, Darmstadt, Germany 
Roche, Basel, Switzerland 
 
Reference antibodies were kindly provided by Merck, Darmstadt, Germany. 
 
 
Primary antibodies for Western Blot  
 
 
 
Goat anti-human IgG Antibody, F(ab’)2 
Fragment specific 
Mouse IgG1 anti-Penta His Antibody 
(#34660) 
Mouse anti-human IgG, F(ab')2 Fragment 
specific 
Mouse anti-human IgG, Fcg Fragment 
specific 
Rabbit anti c-MET pAb (M3007-13A) 
Rabbit anti EGFR mAb, clone D38B1 
Jackson ImmunoResearch, Suffolk, GB 
 
Quiagen, Hilden, Germany 
 
Jackson ImmunoResearch, Suffolk, GB 
 
Jackson ImmunoResearch, Suffolk, GB 
 
Biomol, Hamburg, Germany  
Cell Signaling Technologies, Cambridge GB 
Rabbit anti phospho-cMET mAb 
(Y1234/Y1235), clone D26 (#3077)  
Cell Signaling Technologies, Cambridge GB  
Rabbit anti phospho-EGFR mAb (Y1173), 
clone E124 (ab32578)  
 
Abcam, Cambridge,GB  
 
 
 
Secondary antibodies for Western Blot 
Goat anti-mouse IgG (H+L) peroxidase 
(HRP) conjugate  
Goat anti-mouse IgG (H+L) AP conjugate 
(#115-055-062) 
 
Jackson ImmunoResearch, Suffolk, GB  
 
Jackson ImmunoResearch, Suffolk, GB 
Alexa Fluor® 680 goat anti-rabbit IgG 
(H+L), A21076  
Rabbit anti-goat IgG (H+L) x AP conjugate 
(#305-056-045) 
Life Technologies, Darmstadt, Germany  
 
Jackson ImmunoResearch, Suffolk, GB 
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Detection antibodies for flow cytometry  
Alexa Fluor® 488 Pure Fab Goat anti-
human IgG (H+L)   
Goat Anti-Human IgG (H+L) Fab 
Fragment, Alexa Fluor® 488 (#109-547-
003) 
 
Life Technologies, Darmstadt, Germany  
 
Jackson ImmunoResearch, Suffolk, GB 
Goat anti-human IgG, Fc specific, FITC 
conjugate  
Jackson ImmunoResearch, Suffolk, GB  
 
Antibodies for ELISA  
Anti-penta-His (POD)  
 
Roche, Mannheim, Germany  
Goat anti-mouse IgG (H+L) peroxidase 
(HRP) conjugate  
Jackson ImmunoResearch, Suffolk, GB  
Goat anti-human IgG, Fcγ fragment 
specific peroxidase (HRP) conjugate  
Jackson ImmunoResearch, Suffolk, GB  
 
HTRF antibodies and conjugates 
pAb anti-human IgG-d2 
pAb anti-human IgG-XL665 
pAb anti-human IgG-Tb cryptate 
Streptavidin-d2  
Streptavidin-XL665 
Streptavidin-Tb cryptate 
 
Cisbio, Bedford, MA, USA 
Cisbio, Bedford, MA, USA 
Cisbio, Bedford, MA, USA 
Cisbio, Bedford, MA, USA 
Cisbio, Bedford, MA, USA 
Cisbio, Bedford, MA, USA 
3.4. Oligonucleotides  
Oligonucleotides were obtained from Eurofins MWG Operon, Ebersberg, Germany. 
 
3.4.1. Primers for site-directed mutagenesis PCR: 
IgG1.4 mutations:   
PVA_UP    CGTGCCCAGCTCCACCTGTGCCGGACCTTCCGTG 
PVA_RP   CACGGAAGGTCCGGCCACAGGTGGAGCTGGGCACG 
 
SS_UP    CAACAAGGCCCTGCCTTCTTCTATCGAGAAAACCATC 
SS_RP    GATGGTTTTCTCGATAGAAGAAGGCAGGGCCTTGTTG 
 
IgG1.6 mutations: 
PVA_UP    CGTGCCCAGCTCCACCTGTGCCGGACCTTCCGTG 
PVA_RP   CACGGAAGGTCCGGCCACAGGTGGAGCTGGGCACG 
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K322A/P329A_UP  
 GAGTACAAGTGCGCGGTGTCCAACAAGGCCCTGGCTGCTCCTATCGAG 
K322A/P329A_RP 
 CTCGATAGGAGCAGCCAGGGCCTTGTTGGACACCGCGCACTTGTACTC 
 
3.4.2. Primers for sequencing: 
pTT5_UP  CTGCGCTAAGATTGTCAGT  
 
pTT5_RP  CCATATGTCCTTCCGAGTG  
 
3.5. Chemicals 
1-StepTM Ultra TMB-ELISA substrate 
solution 
2-Mercaptoethylamine HCl (2-MEA) 
4-Chloro-1-naphtol 
Ammonium sulfate ((NH4)2SO4) 
Acetic acid  
Agar-agar  
 
Thermo Scientific, Schwerte, Germany 
 
Thermo Scientific, Schwerte, Germany 
Sigma-Aldrich, Steinheim, Germany 
Merck, Darmstadt, Germany 
Sigma-Aldrich, Steinheim, Germany 
Merck, Darmstadt, Germany  
Agarose  Life Technologies, Darmstadt, Germany  
Ampicillin, sodium salt 
Acetonitril  
BugBusterHT 
CellLyticTM B 
Life Technologies, Darmstadt, Germany  
Merck, Darmstadt, Germany 
Merck, Millipore, Germany 
Sigma-Aldrich, Steinheim, Germany 
Calcium chloride (CaCl2)  Merck, Darmstadt, Germany  
Coomassie InstantBlueTM  Expedeon Ltd, San Diego, CA, USA  
Coomassie Plus - Bradford AssayTM Reagent 
Cut smart buffer 
L-Cysteine 
L-Dehydroascorbic acid (DHAA)  
Thermo Scientific, Schwerte, Germany 
New England Biolabs, Ipswich, MA, USA  
Merck, Darmstadt, Germany  
Sigma-Aldrich, Steinheim, Germany 
Desocyribonucleotide triphosphates (dNTPs)  Novagen, Nottingham, GB  
Disodium hydrogen phosphate 
(Na2HPO4*2H2O) 
Dithiothreitol (DTT)  
EDTA 
Ethanol 
Eagle Minimal Essential Medium (MEM) 
Expi293TM expression medium 
Gel filtration standards 
Gel loading dye (6x) 
Merck, Darmstadt, Germany  
 
Thermo Scientific, Schwerte, Germany 
Sigma-Aldrich, Steinheim, Germany 
Merck, Darmstadt, Germany 
Sigma-Aldrich, Steinheim, Germany 
Life Technologies, Darmstadt, Germany 
Bio-Rad, Munich, Germany 
Novagen, Nottingham, GB 
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GelRedTM 
Gibco® Dulbecco’s modified eagle medium 
(DMEM) 
Gibco® Dulbecco’s PBS (DPBS, w/o CaCl2, 
MgCl2) 
Gibco® Fetal calf serum (FCS) 
Gibco® Trypsin-EDTA  
Gibco® L-glutamine 
Gibco® sodium pyruvate 
Gibco® RPMI 1640 medium 
Gibco® Opti-MEM 
Glucose 
Guava instrument cleaning fluid (ICF) 
Glycine 
Hydrogen chloride (HCl) 
Imidazole 
Isopropyl-β,D-thiogalactopyranosid (IPTG) 
Kanamycin sulfate 
LPS-EB Ultrapure  
Methanol 
Magnesium chloride hexahydrate 
(MgCl2*6H20) 
Magnesium sulfate heptahydrate 
(MgSO4*7H2O) 
VWR International, Darmstadt, Germany 
Life Technologies, Darmstadt, Germany 
 
Life Technologies, Darmstadt, Germany 
 
Life Technologies, Darmstadt, Germany 
Life Technologies, Darmstadt, Germany 
Life Technologies, Darmstadt, Germany 
Life Technologies, Darmstadt, Germany 
Life Technologies, Darmstadt, Germany 
Life Technologies, Darmstadt, Germany 
Sigma-Aldrich, Steinheim, Germany 
Merck, Darmstadt, Germany 
Merck, Darmstadt, Germany 
Merck, Darmstadt, Germany 
Merck, Darmstadt, Germany 
Merck, Darmstadt, Germany (Calbiochem) 
Merck, Darmstadt, Germany 
InvivoGen, San Diego, California 
Merck, Darmstadt, Germany 
Merck, Darmstadt, Germany 
 
Merck, Darmstadt, Germany 
 
NuPAGE® LDS sample buffer (4x)  Life Technologies, Darmstadt, Germany  
NuPAGE® MES SDS running buffer  Life Technologies, Darmstadt, Germany  
NuPAGE® sample reducing agent  
Nickel(II)sulfate hexahydrate (NiSO4*6H2O) 
Nickel phosphate 
OptiPRO SFM 
Potassium dihydrogen phosphate (KH2PO4) 
Potassium chloride (KCl) 
Life Technologies, Darmstadt, Germany 
Merck, Darmstadt, Germany 
Merck, Darmstadt, Germany 
Life Technologies, Darmstadt, Germany 
Merck, Darmstadt, Germany 
Merck, Darmstadt, Germany 
Peptone  Merck, Darmstadt, Germany  
Phusion HF buffer (5x)  New England Biolabs, Ipswich, MA, USA 
Perfect DNATM markers, 0.1 – 12 kbp Merck, Darmstadt, Germany 
Precision Plus ProteinTM standards  Bio-Rad, Munich, Germany  
Protein standard HiMarkTM pre-stained  Life Technologies, Darmstadt, Germany  
RIPA cell lysis buffer (10x, #9806)  Cell Signaling Technologies, Cambridge GB  
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S.O.C. medium  Life Technologies, Darmstadt, Germany  
See Blue® Plus 2 prestained protein standard  Life Technologies, Darmstadt, Germany  
Skim milk powder  
Sodium azide 
Sodium chloride (NaCl) 
Sodium hydroxide (NaOH) 2N 
Sodium dihydrogen phosphate (NaH2PO4) 
Sulfuric acid (H2SO4) 1N 
TCEP 
Merck, Darmstadt, Germany  
Thermo Scientific, Schwerte, Germany 
Merck, Darmstadt, Germany 
Merck, Darmstadt, Germany 
Merck, Darmstadt, Germany 
Bernd Kraft, Duisburg, Germany 
Thermo Scientific, Schwerte, Germany 
T4 DNA Ligation Buffer (10x)  
Quick Ligase buffer (2x) 
New England BioLabs, Ipswich, MA, USA  
New England Biolabs, Ipswich, MA, USA 
TAE buffer  Life Technologies, Darmstadt, Germany  
Tris(hydroxymethyl)aminomethane (Tris)  Carl Roth, Karlsruhe, Germany  
Tris-hydrochloride (Tris-HCl)  Sigma-Aldrich, Steinheim, Germany  
Tween®20  Merck, Darmstadt, Germany  
Ultra-low IgG FCS  Life Technologies, Darmstadt, Germany  
Yeast extract  Becton Dickinson, Heidelberg, Germany  
 
3.6. Cell culture media  
A549, SK-BR-3, A431 
 
DMEM, 10% (v/v) FCS  
MDA-MB-468, MKN-45, Jurkat E6-1 RPMI 1640, 10% (v/v) FCS, 2 mM L-glutamine, 1 
mM sodium pyruvate  
EBC-1, HEK-NFκB-CD40, HT1080 CD40   MEM Eagle, 10% (v/v) FCS, 2 mM L-glutamine  
ExpiCHO-S  ExpiCHOTM expression medium  
Expi293FTM Expi293TM expression medium  
ADCC assay medium  
 
 
RPMI 1640, 4% (v/v) low IgG FCS (heat 
inactivated at 56°C for 30 min)  
 
3.7. Solutions, media and buffer  
2xTY medium  16 g L-1  peptone, 10 g L-1  yeast extract, 5 g L-1  
NaCl, pH 7.0  
5xTY medium  
Analytical size exclusion chromatography 
(SEC) mobile phase 
 
Affinity chromatography for his-tagged 
proteins (Equilibration buffer) 
10 g L-1  peptone, 50 g L-1  yeast extract, pH 7.0  
PBS, pH 7.4 or 50 mM sodium phosphate 
(NaH2PO4, Na2HPO4), 0.4 M sodium perchlorate, 
pH 6.35 
0.5 M NaCl, 25 mM Na2HPO4 x 2H2O, 25.2 mM 
NaH2PO4 x H2O, pH 7.4 
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Affinity chromatography for his-tagged 
proteins (Elution buffer) 
0.5 M NaCl, 25 mM Na2HPO4 x 2H2O, 25.2 mM 
NaH2PO4 x H2O, 500 mM imidazole, pH 7.4 
BCIP/NBT reagent, Blue/purple, AP 
substrate 
Blocking solution for Western Blot  
 
EDTA solution 
Merck, Darmstadt, Germany 
 
2% BSA in PBS-Tween or 5% skim milk powder in 
PBS-Tween  
0.5 M EDTA, pH 8.0 
FACS binding buffer  
Imidazole buffer  
Kinetics buffer (KB) for BLI  
 
 
LB medium 
LB-A medium 
LB-A agar 
Nickel(II)sulfate solution 
Phosphate buffered saline (10x PBS) 
 
Phosphate buffered saline (1xPBS)  
 
Phosphate buffer (8x) 
1% (w/v) BSA in DPBS 
2 M imidazole, pH 7.4  
0.1% (w/v) BSA, 0.05% (v/v) Tween®20 in PBS 
10 g L-1 peptone, 5 g L-1 yeast extract, 10 g L-1 
NaCl 
LB, 0.1 mg L-1 ampicillin 
LB-A, 15 g L-1 agar-agar 
0.5 M nickel(II)sulfate 
1.5 M NaCl, 84 mM Na2HPO4 x 2H2O,  
16 mM KH2PO4, pH 7.4 
140 mM NaCl, 3 mM KCl,  
8 mM Na2HPO4 x 2H2O, 2 mM KH2PO4, pH 7.4 
4 M NaCl, 199.5 mM Na2HPO4 x 2H2O, 201.5 mM 
NaH2PO4 x H2O, pH 7.4 
Protein A chromatography (Equilibration 
buffer)  
PBS, pH 6.8 – pH 7.0 or  
10 mM Na2HPO4, 10 mM NaH2PO4, 500 mM 
NaCl, pH 7.0  
Protein A chromatography (Elution buffer)  0.1 M sodium citrate, pH 3.0 or  
20 mM acetic acid, pH 3.2  
Protein A chromatography (Neutralization 
buffer)  
3 M Tris/HCl, pH 8.5 or 1 M Tris/HCl, pH 9.0  
Preparative SEC (mobile phase)  
Intein splicing buffer  
PBS, pH 7.4  
PBS, pH 7.4 
Wash solution (PBS-Tween)  0.05% (v/v) Tween® 20 in 1 x PBS pH 7.4  
 
3.8. Kits and laboratory materials  
ADCC reporter bioassay kit  
 
Promega, Mannheim, Germany  
AirPoreTM Tape Sheets, breathable sealing foil  Qiagen, Hilden, Germany  
Amicon®Ultra-15 and 0.5 ml centrifugal filter 
units (10 MWCO) 
BCA protein assay kit 
Merck, Darmstadt, Germany  
 
Thermo Scientific, Schwerte, Germany 
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Cell culture flasks T25, T75   Greiner Bio-One, Kremsmuenster, Austria  
Cell culture flat and round bottom NucleonTM 
delta surface 96 well plates  
Thermo Scientific, Schwerte, Germany  
Cell culture 24 well plates Costar®  
Cell culture microplate 384 well, white, clear 
Thermo Scientific, Schwerte, Germany  
Greiner Bio-One, Kremsmuenster, Austria 
ExpiFectamineTM 293 transfection kit  
ExpiFectamineTM CHO transfection kit 
Life Technologies, Darmstadt, Germany  
Life Technologies, Darmstadt, Germany 
Falcon® tubes, 15 ml and 50 ml  VWR International, Darmstadt, Germany  
FortéBio tips (AHC, FAB2, ProteinA, HIS2K)  Pall ForteBio LLC, Menlo Park, CA, USA  
Gel and PCR clean-up kit NucleoSpin®  
GenElute™ HP Plasmid Midiprep, Maxiprep 
Kit 
Macherey-Nagel, Dueren, Germany  
Sigma-Aldrich, Steinheim, Germany 
HiLoad Superdex 200 pg 26/60 columns  
HiLoad Superdex 200 pg 26/600 columns  
HiLoad Superdex 200 pg 16/600 columns  
HiLoad Superdex 75 pg 16/60 columns  
HiLoad Superdex 200 increase 10/300 GL  
GE Healthcare, Munich, Germany  
GE Healthcare, Munich, Germany 
GE Healthcare, Munich, Germany 
GE Healthcare, Munich, Germany 
GE Healthcare, Munich, Germany 
HiTrap MabSelect SuRe columns, 1 mL and 
5 mL   
HisTrap HP columns, 1 mL and 5 mL  
His GraviTrap (IMAC) 
His Buffer Kit 
GE Healthcare, Munich, Germany  
 
GE Healthcare, Munich, Germany 
GE Healthcare, Munich, Germany 
GE Healthcare, Munich, Germany 
iBind™ Solution Kit (#SLF1020) 
iBlot™ Transfer Stack, Nitrocellulose, mini 
iBlot™ Transfer Stack, PVDF, mini 
iBlot™ Transfer Stack, PVDF, regular 
Life Technologies, Darmstadt, Germany  
Life Technologies, Darmstadt, Germany 
Life Technologies, Darmstadt, Germany 
Life Technologies, Darmstadt, Germany 
JETSTAR Plasmid Purification Kit (Midi and 
Maxi column)  
Genomed, Loehne, Germany  
MaxiSorpTM flat-bottom 96 well microtiter 
plates  
Sigma-Aldrich, Steinheim, Germany  
NuPAGE® 4-12% Bis-Tris gels  
NalgeneTM Rapid-FlowTM bottle top filter 
Life Technologies, Darmstadt, Germany  
Thermo Scientific, Schwerte, Germany 
Polypropylene microtiter plates 96 and 
384 wells, black  
Greiner Bio-one, Frickenhausen, Germany  
Polypropylene microtiter plates 96 and 
384 wells, clear  
Greiner Bio-one, Frickenhausen, Germany  
Polystyrene round bottom 96 well microtiter 
plates  
Greiner Bio-one, Frickenhausen, Germany  
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Pur-A-LyzerTM maxi dialysis kit   
PierceTM Coomassie Plus (Bradford) assay kit 
PierceTM Fab Preparation Kit 
Sigma-Aldrich, Steinheim, Germany  
Thermo Scientific, Schwerte, Germany 
Thermo Scientific, Schwerte, Germany 
Qiaprep® Spin Miniprep kit  Qiagen, Hilden, Germany  
Quick Ligation Kit  New England BioLabs, Ipswich, MA, USA  
QuickChange II site-directed mutagenesis kit  
 
SpectraPor® Dialysis membranes (10 kDa 
MWCO) 
Agilent Technologies, Waldbronn, 
Germany  
Thermo Scientific, Schwerte, Germany 
Steriflip® filter device 0.22 μm  Merck, Darmstadt, Germany  
SteritopTM bottle top filter 0.22 μm  
T-cell activation bioassay (NFAT) 
Merck, Darmstadt, Germany 
Promega, Mannheim, Germany  
Tissue culture 24 well plates  Greiner Bio-one, Frickenhausen, Germany  
TMB peroxidase substrate solution  
The Blocking Solution 
Vector Laboratories, Burlingame, CA, USA  
Candor Bioscience, Wangen, Germany 
TSKgel SuperSW3000 column 
Ultrafree® Centrifugal filter units 
VacuCap 60 PF Filter Unit 0.2 µm Supor 
Membrane 
Wizard® SV Gel and PCR Clean-Up System 
Tosoh Bioscience, Darmstadt, Germany 
Merck, Darmstadt, Germany  
Pall, Menlo Park, CA, USA 
 
Promega, Mannheim, Germany 
Zeba Spin desalting PD-10 columns  
ZymoPURETM Plasmid miniprep kit 
ZymoPURETM Plasmid midi and maxiprep kit 
 
Life Technologies, Darmstadt, Germany 
ZymoResearch, Irvine, California, USA 
ZymoResearch, Irvine, California, USA 
3.9. Equipment  
Analytical balance New Classic MF MS3002S  
BiomekFX 
BioShake XP 
 
Mettler Toledo, Giessen, Germany  
Beckman Coulter, California, USA 
Qinstruments, Jena, Germany 
Cell counter Vi-CELL® XR  Beckmann Coulter, Brea, CA, USA  
Chromatography systems ÄKTAxpress, 
ÄTKAexplorer 100, ÄKTApure  
Cogent® μScale TFF System 
Cytomat 6001 incubator  
GE Healthcare, Munich, Germany 
 
Merck, Darmstadt, Germany  
Thermo Scientific, Schwerte, Germany 
Electrophoresis chambers NuPage® Novex ® 
Gel system 
EnVision 2104 plate reader  
Thermo Scientific, Schwerte, Germany 
 
Perkin Elmer, Boston, MA, USA 
Flow cytometer Guava easyCyte HT 2L  Merck, Darmstadt, Germany  
FortéBio Octet RED  Pall ForteBio LLC, Menlo Park, CA, USA  
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HeraSafe® Clean Bench  Thermo Scientific, Schwerte, Germany  
Hot plate magnetic stirrer IKA® RCT basic  Sigma-Aldrich, Steinheim, Germany  
HPLC Agilent 1260 Infinity, ChemStation LC 
3D  
iBind™ Western System 
Agilent Technologies, Frankfurt, Germany 
 
Life Technologies, Darmstadt, Germany  
iBlot® Dry blotting system  Life Technologies, Darmstadt, Germany  
Incubation shaker Minitron  Infros HT, Bottmingen, Switzerland  
Incubator Heracell 150  Thermo Scientific, Schwerte, Germany  
Megafuge 1.0R, rotor BS4402/A 
Multifuge 3 S-R  
Thermo Scientific, Schwerte, Germany 
Heraeus, Hanau, Germany  
Microplate washer, ELx405TM  BioTeK, Bad Friedrichshall, Germany  
Microtiter plate reader BioTeK SynergyTM 4  BioTeK, Bad Friedrichshall, Germany  
Microtiter plate reader SpectraMax® 
Paradigm®  
MicroLab Starlet liquid handler device 
Mosquito nanoliter liquid handling system 
Multidrop microplate dispenser 
Nanodrop ND-1000 Spectrophotometer 
Nanodrop One Spectrophotometer 
Molecular Devices, Wals, Austria  
 
Hamilton, Nevada, USA 
TTP LabTech, Melbourn, UK 
Thermo Scientific, Schwerte, Germany 
Thermo Scientific, Schwerte, Germany 
Thermo Scientific, Schwerte, Germany 
pH meter 744  Metrohm, Filderstadt, Germany  
Power supply EC 250-90  Thermo Scientific, Schwerte, Germany  
PowerPacTM basic power supply 
Prometheus NT.PLEX nanoDSF 
Synapt-G2 mass spectrometer  
Bio-Rad, Munich, Germany  
NanoTemper Technologies, Munich, Germany 
Waters, Milford, MA, USA 
Table centrifuge 5415D  Eppendorf, Hamburg, Germany  
Tetrad® 2 Peltier Thermal Cycler (PCR)  Bio-Rad, Munich, Germany  
ThermoMixer®  Eppendorf, Hamburg, Germany  
Ultracentrifuge Beckmann OptimaTM LE-80K, 
SW41 TI rotor  
VSpin microplate centrifuge 
Global Medical Instrumentation, Ramsey, MN, 
USA  
Agilent Technologies, FFM, Germany 
XCell SureLockTM gel electrophoresis device  
Xpeel automated plate sealer  
 
Life Technologies, Darmstadt, Germany  
Brooks Life Science, Manchester, UK 
 
Further equipment and laboratory devices, referred as standard laboratory equipment, was used and is not 
listed or specified above. 
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3.10. Software  
Accelrys Draw 4.2 
ÄKTA UNICORN software ver. 5.31 (Build 407)  
BMKFX 3.3 build 14.0 
D300e control 3.2.4  
EnVision 1.12 
 
Biovia, San Diego, CA, USA 
GE Healthcare, Munich, Germany  
Beckman Coulter, California, USA 
Tecan, Männedorf, Switzerland 
Perkin Elmer, Boston, MA, USA 
FortéBio octet data acquisition ver. 8.0  Pall ForteBio LLC, Menlo Park, CA, USA  
FortéBio octet data analysis ver. 8.0  Pall ForteBio LLC, Menlo Park, CA, USA  
Gen5TM microplate reader software ver. 1.11.5  BioTeK Instruments, Bad Friedrichshall, 
Germany  
GraphPad Prism v7 GraphPad Software, La Jolla, CA, USA  
GuavaSoft v3.1.1  Merck, Darmstadt, Germany  
HPLC software ChemStation  Agilent Technologies, FFM, Germany  
Image StudioTM software v2.1 
ImageJ v1.49  
 
LabChipGX Reviwer v5.2 
LI-COR Biosciences, Bad Homburg, Germany  
Wayne Rasband, National Institute of Health; 
Maryland, USA 
Perkin Elmer, Massachusetts, USA 
Lasergene v12.3.1  
Mendeley Desktop ver. 1.19.4 
DNA Star Inc., Wisconsin, WI, USA  
Elsevier, New York, NY, USA 
Microsoft Office 2013  
Mosquito 3.13.0.0 
ParadigmTM Software SoftMaxPro v6.3 
Microsoft Corp., Redmond, WA, USA  
TTP LabTech, Melbourn, UK 
Molecular Devices, Wals, Austria 
Protein Thermal ShiftTM software v1.0  Life Technologies, Darmstadt, Germany  
PyMOL v1.8.6.0  
SAMI Ex 4.0 build 156 
Schrodinger LLC, San Diego, CA, USA  
Beckman Coulter, California, USA 
Vi-CELL® XR v2.04 
VSpin v4.3.0 
Venus 3 v4.4 microlab STAR 
Yasara v17.7.30 
 
Beckmann Coulter, Brea, CA, USA  
Agilent Technologies, FFM, Germany 
Hamilton, Nevada, USA 
YASARA Biosciences, Vienna, Austria 
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4. Methods 
 
4.1. Molecular biological methods 
4.1.1. Plasmid generation 
Split intein Npu DnaE genes encoding for IntN and IntC were subcloned for secretory expression in mammalia 
suspension cells and bacterial expression in E. coli and ordered as gene synthesis from GeneArt Gene Synthesis 
(Thermo Fisher Scientific®) as codon optimized versions according to their expression hosts.147 Npu DnaE 
genes were adapted using a multiple cloning site (mcs) to perform standard cloning techniques for subcloning 
of antibody fragments based on flanking unique restriction sites. Restriction enzymes for subcloning were 
purchased by New England Biolabs. The vector backbone pTT5 was used to subclone IntC and IntN genes via 
BamHI and NotI restriction, serving as a vector template for Fab fragments (pTT5-IntN). EcoRI and BamHI 
was used to subclone the IntC gene into pTT5, serving as template for SEED- and Fc-fragments (pTT5-IntC). 
Further, the IntN gene was inserted via NcoI and BamHI restriction into a pET11 vector backbone, serving as 
a template for VHH fragments (pET11-IntN). The vector templates pTT5-IntN and pET11-IntN were 
additionally modified with an N-terminal myc-tag, followed by a hexahistidine tag, located downstream of the 
IntN for purification purposes. A hexahistidine tag followed by a 4x (G3S) linker upstream of the CH2 domain 
was added for vector template pTT5-IntC. VH antibody regions encoding for anti-CD40, CD3, CEACAM5, 
CEACAM6, c-MET, EGFR and Her2 were flanked by restriction sites ApaI and BamHI and were subcloned 
into the pTT5-IntN template. NcoI and NotI restriction sites were used to subclone VHH antibody regions into 
the pET11-IntN template. The pET11-IntN template consists of a pelB leader sequence for periplasmic 
expression in E. coli. All constructs were validated and identified by sequencing after cloning. For bacterial 
expression, the vector pET11-Her2-VHH-IntN-His6 was transformed into chemically competent One ShotTM  
E. coli BL21(DE3) (Thermo Fisher Scientific) and into electrocompetent ClearColi BL21(DE3) (Lucigen). 
 
4.1.2. Preparation of plasmid DNA 
Plasmid DNA was extracted from 5 mL E. coli Top10 cultures using a plasmid preparation kit from either 
GenEluteTM HP Plasmid Miniprep Kit or ZymoPURETM plasmid Miniprep kit, following the instructor’s 
manual. Elution of plasmid DNA was carried out using 40 µL of MilliQ-H2O. Plasmid DNA for mammalian 
expression was extracted from 150-200 mL E. coli cultures using either GenEluteTM HP Plasmid 
Midi/Maxiprep kit or ZymoPURETM plasmid Midi/Maxiprep kit. Elution of plasmid DNA was carried out 
using 1000 – 2500 µL MilliQ-H2O.   
 
4.1.3. Quantification and quality determination of DNA  
Purified DNA concentration diluted in H2O was measured by UV spectrometry (NanodropTM One/ND1000). 
1.5 µL of DNA sample was used for UV-visible light absorbance measurement at 260 nm and 280 nm wavelength 
based on the Beer-Lambert law. DNA concentration was automatically calculated by nanodrop and recorded in 
ng µL-1. The absorbance ratio between A260/A280 was used to assess DNA quality. The DNA is accepted as pure, 
if the absorbance ratio is around ~1.8. A ratio below 1.8 typically indicates contamination with protein, phenol 
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or other contaminants absorbing strongly in that range. DNA with a ratio below 1.8 was not used for further 
treatment. 
 
4.1.4. DNA sequencing  
All isolated DNA samples (15 µL, 50-100 ng µL-1) were sent to Eurofins MWG Operon (Ebersberg, Germany) 
for sequencing using primers listed in Chapter 3.4.2 
 
4.1.5. Standard Cloning (Subcloning) Restriction and ligation 
Restriction endonuclease enzymes were used for standard cloning into vector backbones pTT5 or pET11a. 
These enzymes were used to assess DNA fragmentation at defined recognition sequences. For each construct, 
1 µg DNA was digested using two different restriction enzymes and the corresponding restriction buffer. 
Preparative digestion was carried out for at least 2 h at the temperature optimum of the respective enzymes 
using a final volume of 30 µL. Restriction enzymes were heat inactivated at 80°C for 20 min, to stop the 
digestion. Vector backbone DNA was further treated with 1 µL calf intestinal Antarctic phosphatase (CIP) for 
45 min at 37°C, to catalyze dephosphorylation at the 5’- end of DNA strands. Dephosphorylation prevents the 
vector backbone from re-ligation. Insert DNA was not treated with CIP to ensure proper insertion into vector 
backbone. CIP was heat inactivated by 65°C for 10 min. To ensure successful ligation of pTT5 vector backbone 
and Fab-IntN, oaSEED-IntC or Fc-IntC or pET11a vector backbone and VHH- IntN, a 1:3 molar ratio of backbone 
DNA to insert DNA was used. The following equation (Equation 1) was used to calculate the appropriate 
amount of insert DNA used for ligation. Typically, 100 ng of dephosphorylated vector backbone DNA was used 
as starting material. 
 
Insert [ng] =
Insert bp
Vector bp
∗ Vector [ng]                           Eq. 1 
 
Sizes of vector backbones pTT5 and pET11a as well as for the inserts are listed in Chapter 3.2. 1 µL 
QuickLigation was supplemented with the respective Ligation buffer and mixed with dephosphorylated vector 
backbone DNA and Insert DNA up to a final volume of 20 µL. Compounds were mixed properly, and the reaction 
was performed for 5 min at 25°C. A negative control was used by replacing the insert DNA with MilliQ-H2O. 
An empty pTT5 or pET11a vector was serving as a positive control for transformation in Top10 cells and 
plating on LB agar plates (Chapter 4.2.1). The ligation mix (1 µL) was transformed into E. coli BL21 (DE) and 
colony PCR was performed to verify the correct insertion of the inserts. 
 
4.1.6. Two-step polymerase chain reaction for site-directed mutagenesis (QuickChange) 
For introduction, deletion or changes of nucleotides, site-directed mutagenesis was performed using a 
QuikChangeII site-directed mutagenesis kit. Aside from the manufacturers protocol, a second PCR protocol was 
developed to avoid primer dimer formation and improved mutagenesis rate. Briefly a master mix (5 μL reaction 
buffer, 1 μL PfuUltra HF DNA polymerase (2.5 U/μL), ddH2O to a final volume of 50 μL) for two-step PCR 
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was prepared in 0.2 µL PCR tubes on ice. All non-enzyme components were thawed at room temperature. Master 
mix components were mixed by pipetting. The master mix was split into 2x48 µL and to each part 0.1 µM of 
either forward or reverse primer was added. Individual first step amplifications were allowed by an initial 
denaturation step at 98°C for 30s, followed by 5 cycles of amplification using a denaturation step at 98°C for 
10s, annealing at 55°C for 30 s and extension at 68°C for 5 min depending on the plasmid size (1 min / 1 kb of 
plasmid). The annealing temperature was adjusted according to the melting temperatures of the used primers. 
Both PCR mixtures including either forward or reverse primers, were mixed and subsequently evenly 
distributed again to 50 µL. A second amplification step was performed using the same conditions as amplification 
step 1 for 14 cycles including an additional final extension step at 68°C for 3 min. PCR mix was incubated on 
ice for 2 min and treated with 1 µL DpnI restriction enzyme for 1-1.5 h at 37°C, to digest parental methylated 
DNA. 1-2 µL of the digested PCR mix was transferred to supercompetent XL1-Blue E. coli cells for 
transformation.  
 
4.1.7. Colony PCR 
The correct ligation of pTT5 vector backbone and Fab-IntN, oaSEED-IntC or Fc-IntC or pET11a vector 
backbone and VHH- IntN was determined by colony PCR. Bacterial colony material (half of a colony) from agar 
plates was picked in 0.2 mL PCR tubes with 50 µL REDTaq® solution containing reaction buffer with MgCl2, 
0.4 nM dNTP mix and 0.06 units µL-1. Components were mixed properly by pipetting and placed in a PCR 
cycler. The insert amplification started with an initial denaturation step at 94°C for 3 min, denaturation at 94°C 
for 30 s, annealing at 55°C for 30 s, extension at 72°C for 1 min and a final extension step at 72°C for 6-10 min. 
Colony PCR products were analyzed via gel electrophoresis according to Chapter 4.1.9. Gel bands were 
expected at the size of the insert for correct ligation. A negative control sample was used by replacing primer 
pairs by MilliQ-H2O.  
 
4.1.8. DNA purification 
DNA fragments derived from Gel extraction or PCR amplification were purified using a gel extraction / clean 
up kit (QIAquick Gel Extraction Kit) according to the manufacturers protocol. DNA was eluted with pre-
warmed H2O (60°C) in a final volume of 10-20 µL. The DNA concentration was determined by UV spectrometry 
(NanodropTM One/ND1000). 
 
4.1.9. Gel electrophoresis and gel extraction 
The migration velocity of DNA fragments depends on molecular weight, conformation, agarose gel 
concentration and strength of the electrical field. Charged molecules migrate with different velocities through 
the gel depending on their molecule sizes. Linear DNA fragments of the vector backbone pTT5 or pET11a were 
separated using a 0.8% agarose gel, while Insert DNA fragments were separated using a 1.5 – 1.8% agarose gel. 
Agarose gels were prepared in TAE buffer and supplemented with GelRedTM solution (1:10 000). DNA samples 
were treated with 6x loading dye and subsequently loaded (6 µL) on agarose gels. A standard Perfect DNATM 
marker (0.1 – 12 kbp) served as a ladder for size determination. Electrophoresis was performed at constant 110 V 
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for 30 to 35 min. The DNA bands were visualized under UV light using the gel imaging system GBX. The 
bands corresponding to the correct size of the linearized vector backbone and insert were excised of the gel 
using a clean scalpel. Gel fragments were transferred to an Eppendorf tube and further prepared for DNA 
extraction following the manufacturers protocol from QIAquick Gel Extraction Kit.  
 
4.2. Microbiological methods 
4.2.1. Transformation in E. coli and plasmid preparation 
50-100 ng of plasmid DNA was added to 50 µL of chemically competent Top10 E. coli cells for heat shock 
transformation. Cells were thawed on ice for 10 min and afterwards supplemented with plasmid DNA followed 
by an incubation on ice for 30 min. Cells were undergoing a thermal shock at 42°C for 45 s followed by another 
incubation step on ice for 2 min. Cells were allowed to recover after addition of 500 µL super optimal broth with 
carbolite repression (SOC) medium at 37°C for 1.5 h. 150 µL transformed cells were plated on LB agar plates 
with selection marker ampicillin. Plates were cultivated over night for at least 18 h at 37°C until further 
treatment or stored at 4°C for at most 4 weeks. Glycerol stocks were prepared in 17% glycerol after cultivation 
of liquid pre-cultures in LB medium (Chapter 4.2.4) for long term storage and kept at -80°C. 
 
4.2.2. ClearColi transformation 
ClearColi® BL21 (DE3) electrocompetent cells were thawed on ice for 10-20 min and afterwards  
25 µL were transferred into a chilled microcentrifuge tube on ice and supplemented with 1 µL plasmid DNA. 
The cell/DNA mix is transferred into a chilled electroporation cuvette avoiding bubbles. Electroporation was 
performed according to the manufacturers protocol (10 µF, 600 Ohm, 1800 V). Cells were supplemented with 
975 µL expression recovery medium and incubated at 37°C for 1.5 h under shaking conditions (200-250 rpm). 
100 µL of transformed cells were plated on LB agar plates with selection marker ampicillin. Plates were 
cultivated for 32 - 40 h at 37°C until further treatment or stored at 4°C for at most one week. Glycerol stocks 
were prepared in 17% glycerol after cultivation of liquid pre-cultures in LB medium (Chapter 4.2.4) for long 
term storage and kept at -80°C. 
 
4.2.3. Culture medium 
All liquid and solid culture medium were autoclaved for 20 min at 121°C and 200 kPa. For selective production 
of bacterial strains, Kanamycin (Kan) or Ampicillin (Amp) with a concentration of 50 µg mL-1 or 100 µg mL-1 
respectively was added to the culture medium after sterilization. Ampicillin was sterilized separately by using 
filter sterilization 0.2 µm (WhatmanTM, Sigma-Aldrich) and added under sterile conditions to the autoclaved 
culture medium at a temperature < 60°C. 
 
4.2.4. Cultivation of liquid pre-cultures in 200 mL scale 
Freshly transformed E. coli BL21(DE3) and ClearColi BL21(DE3) containing pET11-Her2-VHH-NpuDnaEN-
His6 were grown on selective LB-agar plates with ampicillin resistance. One colony was picked and transferred 
into LB medium containing 2% glucose and incubated 16 h over night at 28°C and 160 rpm (50 mm throw). 
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Cryostocks were prepared by adding 17% glycerol to the cells exhibiting an OD600 between 5 and 8 and a pH 
range between 6.2 and 7.2. Cells were stored at -80°C until usage. Cells were thawed at room temperature and 
pre-culture was inoculated with an OD600 of 0.00005 using LB medium supplemented with 2% glucose. Pre-
culture was incubated at 28°C at 160 rpm (50 mm throw) for 16 h overnight. Cells were transferred into 
Superbroth medium (20 g L-1 tryptone, 5 g L-1 yeast extract, 2.4 g L-1 MgSO4, 0.5 g L-1 NaCl, 0.186 g L-1 KCl 
and 20 mM glucose) with a cell density of OD600 0.3 and grown until mid-log phase 0.6 - 0.8 at 30°C and 160 rpm 
(50 mm throw). Cells were induced with 400 µM IPTG and incubated at 35°C for 3 h at 160 rpm (50 mm throw). 
Cells were harvested and prepared for purification.  
 
4.2.5. Cultivation of liquid pre-cultures in MTP´s 
ClearColi BL21(DE3) and E. coli BL21(DE3) cryostocks containing pET11-Her2-VHH- NpuDnaEN-His6 were 
thawed at room temperature and pre-culture was set up in microtiterplates (Greiner) using either SOC medium 
for E. coli BL21(DE3) or Inhouse prepared minimal medium for ClearColi BL21(DE3). 10 µL from cryostocks 
(OD600: 6.4) were transferred into 190 µL expression medium per well and incubated at 37°C and 700 rpm 
overnight. ClearColi pre-cultures were incubated for 48 h. Cells were transferred into Superbroth medium  
(20 g L-1 tryptone, 5 g L-1 yeast extract, 2.4 g L-1 MgSO4, 0.5 g L-1 NaCl, 0.186 g L-1 KCl and 20 mM glucose) 
with a cell density of OD600 0.3 and grown until mid-log phase 0.6 - 0.8 at 37°C and 700 rpm (25 mm throw). 
Cells were induced with 60 µM, 100 µM and 400 µM IPTG and incubated at 34°C for 3-24 h at 700 rpm (25 mm 
throw). Cells were harvested and prepared for analysis and purification. 
 
4.3. Biochemical methods 
4.3.1. Determination of Protein concentration 
The concentrations of purified recombinant proteins were determined by either Bradford assay, absorbance 
measurement or Novagen® BCA protein assay kit. For BCA assay, a stock solution of 2 mg mL-1 BSA dissolved 
in 50 mM Tris-HCl buffer pH 7.5 or PBS pH 7.4 was prepared and diluted to various BSA concentrations as a 
standard. Sample concentration of the target proteins was determined using the equation achieved from 
regression curve corresponding to the standard. Therefore 25 µL of each sample was mixed with 200 µL of the 
BCA solution, and incubated for 30 min at 37°C. The BCA assay is based on the Biuret reaction. Amino acids 
from the target protein form a permanent bond with Cu2+ ions, resulting in a dark violet colored complex. This 
complex is stable enough to avoid precipitation of copper ions in alkaline environment. The color shift is 
detectable at a wavelength of 562 nm with a detection limit of 20 – 2000 µg mL-1 according to the manufacturers 
protocol. After cooldown at RT the absorbance of the samples was measured and analyzed via standard curve 
equation.  Determination of protein concentration via Bradford assay using the PierceTM Coomassie Plus assay 
kit, was performed according to the manufacturers protocol. In brief, a standard calibration curve was generated 
by serial dilutions of 0.1 – 1 mg mL-1 BSA. Samples were diluted to fit the range of the BSA concentrations and 
5 µL of each sample and BSA dilution for standard curve generation was added in duplicates or triplicates into 
a 96 well microtiter plate. Additionally, 150 µL Bradford reagent was added to the samples and mixed by 
pipetting followed by incubation for 30 min protected from light. Absorbance was measured at 595 nm and 
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protein concentrations were calculated via standard curve equation. Protein concentration of purified samples 
was measured by absorbance at 280 nm using the Nanodrop ND-1000 or Nanodrop One based on the law of 
Lambert-Beer. 1.5 – 2 µL of purified sample was added to the Nanodrop pedestal and protein concentration was 
calculated by addition of molecular weight (kDa) and molar extinction coefficient (M-1 cm-1) parameters of the 
sample. 
 
4.3.2. Antibody purification via MabSelect columns 
Cell free Expi293F supernatant including antibody fragments fused to IntC were loaded with 2.5 mL min-1 onto 
a 5 mL HiTrap MabSelect SuRe column (GE Healthcare) after equilibration with 10 CV PBS (pH 7.4) using an 
ÄKTA Pure system. After sample loading and wash out with PBS, elution was carried out isocratically with 
20 mM acetic acid at pH 3.2. Elution fractions were collected as 1 mL fractions and pH was adjusted to pH 6.8 
by using neutralization buffer containing 1 M Tris at pH 8. The fractions containing the protein of interest were 
pooled and concentrated with Amicons (Merck Millipore) for additional purification steps. Purity was analyzed 
by SDS-Gel PAGE and SE-HPLC before further treatment. Concentrated antibody solution was loaded onto a 
HiLoad Superdex 200 pg column (GE Healthcare) for final polishing. Elution was carried out in PBS (pH 6.8) 
and collected as 1 mL fractions in a 96 deep well plate. Fractions containing the protein of interest were pooled 
and filter sterilized (0.2 µm WhatmanTM) before storage.  Purity was monitored by precast SDS-PAGE (Thermo 
Fisher Scientifics) using standard protocols and SE-HPLC, while identity was confirmed by mass spectrometry 
analysis. Purified antibody fragments were stored either at 4°C or treated with liquid nitrogen for storage 
at -80°C. 
 
4.3.3. Antibody purification via MabSelect beads 
25 mL cell free supernatant, containing POI, was treated with 400 µL MabSelect SuRe beads (GE Healthcare) 
with a binding capacity of 35 mg human IgG mL-1 and incubated for 1 h at room temperature under shaking 
conditions. Solution was resting for 30 min, until beads sedimented at the bottom. Supernatant was carefully 
discarded, and beads were resuspended in 5 mL Expi293F Expression medium. Beads were transferred into a 
24 well filter plate (Sigma-Aldrich) or bottle top filter (0.22 µm, Nalgene Rapid-Flow Bottle Top Filter, Thermo 
Fisher Scientific) for larger volumes > 50 mL. Beads were washed 4 times with 1 mL high salt buffer (25 mM 
Sodium phosphate buffer, 0.5 mM NaCl, pH 7.0) by applying vacuum and subsequently washed 4 times with 
1 mL low salt buffer (20 mM Sodium phosphate buffer, 0.15 mM NaCl, pH 7.0. Antibodies were eluted with 4 x 
500 µL elution buffer (20 mM acetic acid, pH 3.2) and pH was adjusted with 200 µL neutralization buffer (0.5 M 
sodium phosphate buffer pH 8.0) directly after elution. Solution was concentrated via Amicons (Merck Millipore) 
and filter sterilized for storage at 4°C.   
 
4.3.4. Antibody purification via Ni-NTA columns 
Cell free Expi293F supernatant including antibody fragments fused to IntN or antibody fragments derived from 
cell free E. coli supernatant after cell lysis (Chapter 4.3.5) were diafiltrated using either the Cogent® μScale 
Tangential Flow Filtration (TFF) System with three Pellicon® 3 88 cm² cassettes (10K Da MWCO) or dialysis 
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membranes (SpectraPor®, 10K Da MWCO) and samples were dialyzed against PBS pH 7.4 over night at 4°C, 
followed by ion metal affinity chromatography (IMAC). IMAC is capable to capture proteins compromising a 
hexahistidine tag by high affinity towards Ni2+. Samples were loaded with 1 mL min-1 onto a 1 mL or 5 mL 
HisTrapTM HP column (GE Healthcare) under native conditions after equilibration with 10 CV buffer A (50 mM 
Na-P, 500 mM NaCl, 20 mM imidazole pH 7.4) using an ÄKTA Pure system. The column matrix consists of 
agarose functionalized with nitrilotriacetic acid (NTA). Additionally, Ni2+ ions are immobilized on the column 
matrix interacting with histidine residues from recombinant proteins and facilitates the affinity binding of these 
proteins. Column bound proteins are displaced by metal binding ligands such as imidazole in relatively high 
concentrations. Supernatant from E. coli cell lysis was treated additionally with 5 mM MgCl2, 25 U/ml 
Benzonase, Protease Inhibitor CocktailSET III 1:1000. Reducing agent was left out in buffer A, to avoid 
unspecific C-terminal cleavage of the fused intein. After sample loading and wash out with buffer A, elution was 
performed by increasing the imidazole concentration stepwise from 20 mM, 50 mM, 100 mM, 150 mM, 250 mM 
to 500 mM. Fractions containing proteins were collected in 1 mL deep well plates and pooled afterwards 
according to the chromatogram. Each pooled fraction was analyzed by precast SDS-PAGE to estimate the 
fractions containing the protein of interest, followed by concentration using Amicons (Merck Millipore) and an 
additional purification step via size exclusion for final polishing. Concentrated antibody solution was loaded 
onto a HiLoad Superdex 200 column (GE Healthcare). Elution was carried out in PBS (pH 6.8 or 7.4) and 
collected as 1 mL fractions in a 96 deep well plate. Fractions containing the protein of interest were pooled and 
filter sterilized (0.2 µm WhatmanTM) before storage.  Purity was monitored by precast SDS-PAGE (Thermo 
Fisher Scientific) using standard protocols and SE-HPLC, while identity was confirmed by mass spectrometry 
analysis. Purified antibody fragments were stored either at 4°C or treated with liquid nitrogen for storage 
at -80°C. 
 
4.3.5. E. coli cell lysis for Ni-NTA purification 
After cell harvest, cells were treated with lysis buffer containing 16 mL Celllytic B per g cell pellet 50 mM Tris-
HCl, 0.5 M NaCl, 10 mM imidazole and 1U benzonase. Lysis was performed for 30 min at 220 rpm (25 mm 
throw incubator) at RT. Cell debris was centrifuged afterwards at 20.000 rpm for 30 min at 4°C (Multifuge 3SR, 
Heraeus). A 1 mL HisTrapTM HP column (GE Healthcare) was equilibrated with 15 CV binding buffer (50 mM 
Tris-HCl, 0.5 M NaCl, 10 mM imidazole). Sample was loaded onto the column and wash out was performed 
with 15 CV binding buffer. Elution was carried out by increasing the imidazole concentration stepwise from 
20 mM, 50 mM, 100 mM, 150 mM, 250 mM to 500 mM (Chapter 4.3.4). Fractions containing proteins were 
collected in 1.5 mL Eppendorf tubes and pooled after SDS-PAGE analysis and concentrated using Amicons 
(Merck Millipore). Protein of interest was determined by western blot analysis and fractions were dialyzed over 
night against PBS pH 7.4 (Pur-A-Lyzer, Sigma-Aldrich) and stored at 4°C for additional experiments. 
 
4.3.6. Size exclusion chromatography (SEC) 
Size exclusion chromatography (SEC) is a chromatography method to distribute proteins in solution by their 
size or molecular weight depending on the length and pore sizes of the column. SEC is mostly the last step 
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within a purification process and therefore known as protein polishing. SEC allows to efficiently separate the 
protein of interest from aggregates or higher and smaller molecular size impurities. This method can be 
distinguished into preparative and analytical SEC. 
 
4.3.7. Preparative SEC 
Preparative SEC was applied to obtain monomeric antibodies and antibody fragments in high purity. Reference 
antibodies and oaSEED fragments were transported in an aqueous solution (PBS pH 7.4) through a HiLoad 
Superdex 26/60 200 pg, Hi Load Superdex 26/600 200 pg or HiLoad Superdex 16/600 200 pg depending on 
the sample volume. Fab fragments were purified using a HiLoad Superdex 16/60 75 pg column. Small sample 
volumes < 500 µL were purified using a HiLoad Superdex 200 increase 10/300 GL column. In brief, all columns 
were equilibrated with 2 CV PBS buffer (pH 7.4) and a flow rate of 1 mL min-1 followed by sample addition via 
sample loop injection. Fractions were collected in a 96 deep well plate in a final volume of 200 – 800 µL 
depending on the used column. Fractions including the protein of interest were pooled and concentrated with 
Amicon® Ultra-15 centrifugal filters (10K Da MWCO). Protein concentration was determined by Nanodrop 
measurement as described in Chapter 4.1.3. Purity was determined by SDS analysis (Chapter 4.3.12) and 
analytical SEC (SE-HPLC).  
 
4.3.8. Analytical SEC 
Antibody purity and molecular size after purification was determined by analytical size exclusion high 
performance liquid chromatography (SE-HPLC). Samples were transported in aqueous solution (mobile phase) 
through a TSK Super SW3000 column using an HPLC Agilent 1260 (ChemStation LC 3D) device. The column 
was equilibrated with mobile phase buffer at a flow rate of 0.35 mL min-1 for at least 45 min, resulting in a stable 
baseline measured by UV detection. 5 molecular weight markers (Gel filtration standard, BioRad) were used for 
correct molecular size determination. Antibody samples were diluted in PBS buffer, if necessary, to a final 
concentration of 1 mg mL-1. A minimum of 10 µg per sample was injected to the system. The UV signal was 
detected at 214 nm and 280 nm followed by peak integration for purity determination (ChemStation software). 
Molecular size was calculated based on obtained retention times of the desired proteins and the gel filtration 
standard.       
 
4.3.9. Split intein mediated antibody reconstitution and purification (molar ratios) 
Fab/VHH- and SEED-fragments fused to IntN and IntC split intein segments were mixed in an equimolar ratio 
(1:1) in splicing buffer (PBS: 10 mM PO43-, 2.7 mM KCl 150 mM NaCl, pH 7.4) for PTS mediated bsAb 
reconstitution. Fab- and Fc- fragments offering 2 ligation sites were mixed in a molar ratio of 1:2, to generate 
bivalent antibodies. TCEP was added to the antibody fragments in a final concentration of 0.5 mM, to activate 
PTS, followed by incubation for 2 h at 37°C or 4 h at RT. After reconstitution, the antibody mixture was treated 
with 30 µL pre-washed HisPure Ni-NTA resin (Thermo Fisher Scientific), offering a total binding capacity of 
1.8 mg, to remove non-reconstituted antibody fragments. Additionally, 10 mM imidazole was added to avoid 
unspecific binding of reconstituted antibodies to the Ni-NTA resin. The mixture was incubated at RT for 1 h 
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under shaking conditions (Thermomixer) at 900 rpm to capture non-reconstituted antibody fragments. The 
supernatant was separated from the Ni-NTA resin and supplemented with a 20-molar excess of dehydroascorbic 
acid (DHAA) over TCEP and incubated at 37°C for 1-2 h or at RT overnight to quench PTS and complete re-
oxidation of the reconstituted antibody. To monitor successful PTS and formation of reconstituted antibodies,  
Samples were taken every 10 to 20 min and supplemented with 4x lithium dodecyl sulfate (LDS) buffer 
(Invitrogen) including 0.1% H2O2 for complete oxidation of TCEP. Samples were boiled at 70°C for 10 min and 
samples were analyzed by SDS-PAGE (4-12% Bis-Tris gels, Novex, Invitrogen) followed by Coomassie Instant 
blue protein staining (Expedeon) according to Chapter 4.3.12 and 4.3.13.    
 
4.3.10.  HT protein analysis  
High throughput protein analysis of reconstituted antibodies was performed by LabChipGXII (PerkinElmer). 
The LabChip and reagents were equilibrated for 30 min at RT. Dye solution was thawed completely and 
vortexed for 20 s at 9300 rcf. 520 µL of Protein express gel matrix was transferred to the provided spin filter. 
20 µL of protein dye solution was added to the gel matrix in the spin filter and mixed gently by inverting. When 
solution is homogeneously mixed, it was spun down at 9300 rcf for 5 min. 250 µL of protein express gel matrix 
was transferred into another spin filter, serving as a destain solution. The solution was centrifuged at 9300 rcf 
for 5 min. Prepared solutions were prevented from light exposure and stored in the dark until ready to use. Each 
wells of the lab chip were aspirated, using an empty pipette tip and applied vacuum to remove storage liquid. 
All wells were rinsed 2 times with distilled water. Each active chip well (1, 2, 3, 4, 7, 8, 9 and 10) was filled either 
with gel dye solution (3, 7, 8 and 10) or destain solution (well 2 and 9). 120 µL of marker solution was transferred 
to chip well 4. Samples for LabChip analysis were prepared in a 96 well PCR plate (Eppendorf). 5 µL of protein 
sample was transferred into the 96 well plate for high sensitivity analysis. 35 µL of Milli-Q® water was added 
to each sample and mixed well by pipetting. Protein express ladder was vortexed for 10 s and centrifuged briefly 
to ensure no precipitation in the solution. 12 µL protein express ladder was transferred into a microcentrifuge 
tube. Samples and protein express ladder were incubated at 70°C for 10 min for denaturation. Samples were 
spun down after boiling at 1200 rcf for 2 min. 120 µL Milli-Q® water was added to the protein express ladder, 
while 750 µL of protein express wash buffer was transferred to the provided buffer tube. Samples, LabChip, 
protein express ladder and protein express wash buffer was placed into the LabChip GXII touch device. High 
throughput analysis was executed and monitored online using the LabChip GX v5.2 software. 
Electropherograms and virtual gels of reconstituted antibody samples were evaluated and analyzed with 
LabChip GX Reviewer v5.2. 
 
4.3.11. Enzyme-linked immunosorbent assay (ELISA) 
ELISA was conducted to confirm binding to recombinant target protein huCD40-avi-his (Merck KGaA). The 
wells of a Nunc 96 well MaxiSorb flat bottom plates (Thermo Fisher Scientific) were coated with 100 ng to 
1 µg well-1 target protein diluted in 100 µL PBS (pH 7.4) and incubated either for 1 h at room temperature or at 
4°C over night. A microplate washer ELx405 (BioTek) washed the coated plate with 3 x 300 µL PBS (pH 7.4 + 
0.05% Tween). Subsequently the wells were blocked with 300 µL blocking solution (PBS, pH 7.4 + 2% BSA per 
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well) and incubated for 1 h at RT, to saturate unspecific binding sites. After incubation the wells were washed 
again with 3 x 300 µL PBS (pH 7.4 + 0.05% Tween) and supplemented afterwards with 10 to 100 ng well-1 
reconstituted CD40 antibodies. Reconstituted antibodies were diluted in blocking buffer in a final volume of 
100 µL and incubated for 1 h at RT. A repeated washing step with 3 x 300 µL PBS (pH 7.4 + 0.05% Tween) was 
conducted followed by addition of detection antibody goat-anti-human conjugated to POD (g-a-h POD), diluted 
1:5000, and incubation for 1 h at RT. The wells were washed again with 3 x 300 µL PBS (pH 7.4 + 0.05% 
Tween). 100 µL of 1-step Ultra TMB ELISA solution (Thermo Fisher Scientific) was added to each well and 
incubated for 1 to maximum 10 min, until a blue color shift was observed. 100 µL of 1 M H2SO4 solution was 
added to each well, resulting in another color shift from blue to yellow. Reference antibodies were used as a 
positive control. Fc-IntC and Fab-IntN single fragments and combined without the addition of TCEP were used 
as a negative control. Wells treated with PBS buffer instead of reconstituted antibodies, served as negative 
controls and to visualize potential background effects of g-a-h POD detection antibody. To confirm positive 
ELISA signaling, the coated target proteins on the plate surface were incubated with anti-penta his (1:1000) and 
goat-anti-mouse POD (1:5000), serving as a coating control. Absorbance after color change was measured at 
450 nm using a ParadigmTM plate reader (BeckmanCoulter). Analysis was performed using a multimode analysis 
software. Binding to other recombinant target proteins confirmed by ELISA, was conducted similar to the above 
described protocol. 
 
4.3.12. SDS-PAGE 
Protein determination and purity was analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE). Proteins are migrating to a NuPAGE® Bis-Tris gel (4-12%) and forced to distribute by molecular 
weight in an electric field. Protein samples for electrophoresis were loaded onto the wells after mixing with 
4x LDS sample buffer and heated up to 70°C for 10 min for denaturation. A protein standard SeeBlue® 
Plus 2 prestained protein marker indicating different protein sizes was added as a marker in one of the wells. 
The chamber was filled with MES(2-(N-morpholino) ethanesulfonic acid) running buffer. The proteins were 
separated using a fixed voltage of 200 V for 38 min. Gels were removed from the cast and stained by using 
Coomassie staining solution (Chapter 4.3.13) or further treated for western blot analysis (Chapter 4.3.14). 
 
4.3.13. Coomassie staining 
Bis-Tris gels were transferred after electrophoresis into Coomassie staining solution (InstantBlueTM). Gels were 
slowly agitated at RT for 45 min. The staining solution was replaced by H2O and incubated under shaking 
conditions for 60 min to visualize the protein bands.  
 
4.3.14. Western Blotting 
Specific protein detection and visualization was performed by western blot analysis. After SDS-PAGE under 
denaturing conditions, gels were transferred to a polyvinylidene difluoride (PVDF) membrane and proteins 
were blotted on the membrane using the iBlot system (program 3, 7 min and 20 V). The membrane was rinsed 
in iBind solution and prepared for specific antibody detection using the iBind system according to the 
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manufacturers protocol. The membrane was treated with a primary antibody, which recognizes and binds to a 
specific target. A second antibody, conjugated to horse reddish peroxidase (HRP) or alkaline phosphatase (AP), 
which recognizes and binds the primary antibody, was used for visualization of the target protein in the sample. 
After antibody treatment the membrane was rinsed with H2O and transferred to a BCIP/NBT detection 
solution. The colorimetric detection mediated by HRP or AP and the corresponding substrate in the detection 
solution resulting in a stained membrane indicating the specific target protein. Blot development was stopped 
by replacement of detection solution and a quick rinse in H2O.   
 
4.3.15. Homogeneous Time Resolved Fluorescence (HTRF) 
HTRF is a combination of a classical Förster resonance energy transfer (FRET) with a time resolved detection 
of fluorescence. The FRET system is based on the energy transfer of two fluorophores in close proximity. One 
fluorophore is acting as a donor, the other one as acceptor. In combination with time resolved measurement, 
this technology allows for elimination of non-specific short-lived background fluorescence caused by sample 
components like buffers, proteins or cell lysates. In brief, HTFR reagents were reconstituted according to the 
manufacturers protocol. Streptavidin-d2 was mixed with 0.3% Tween-20 in terbium buffer in a final 
concentration of 0.1 mg mL-1. pAb anti-human IgG-Tb cryptate was diluted with 0.3% Tween-20 and terbium 
buffer in a final concentration of 0.01 mg mL-1. Each sample was diluted in PBS pH 7.4 and 0.3% Tween-20 to 
a final concentration of 0.1 µM. All samples and HTRF reagents were dispensed automatically (Tecan D300e 
liquid dispenser) in a 1536 well plate. Terbium buffer was used for normalization with 0.3% Tween-20 diluted 
in PBS pH7.4. 0.075 µL of Streptavidin-d2 solution (0.1 mg mL-1) and IgG-Tb solution (0.01 mg mL-1) was 
added to 0.05 µL sample solution (0.1 µM). The final volume in each well contained 5 µL. The plate was sealed 
with a sealing foil to avoid evaporation of the samples. Samples were incubated 4 h at RT followed by 
fluorescence measurement at 337 nm and 665nm/615nm ratio (EnVision 2104 plate reader). To calculate the 
ratio for data reduction for each well, following equations were used: 
 
ratio = 104 ∗
Emission620nm
Emission665nm
                  Eq.2 
 
The ratio calculation was used to minimize well to well variations because the background noise of the donor is 
normalized for each well. 
Minimization of plate to plate variations were calculated by the equation below (Eq.3) normalizing the 
measurement for each well. 
 
ΔF =
ratiosample−rationegative control
rationegative control
                Eq.3 
 
To cross validate the HTRF measurements, HPLC analysis was performed.  
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4.4. Cell biological methods 
4.4.1. Thawing mammalian cell lines and suspension cultures 
Adherent or suspension cell lines were provided in cryovials at -180°C. Cells were thawed in a water bath at 
37°C under slight swirling of the cryovial. Cells were immediately treated with 10 mL pre-warmed medium 
after thawing and transferred into a 50 mL falcon tube. Cells were centrifuged at 250 x g for 10 min at RT to 
remove DMSO and serum components, contained in the cryopreservation medium. The supernatant was 
carefully removed, and cells were resuspended in fresh pre-warmed medium (10 mL). Adherent cells were seeded 
in a T-25 or T-75 flask depending on the cell density and incubated for 3 to 4 days at 37°C, 5% CO2 in a 
humidified atmosphere. Suspension cells were seeded in a 50 mL shaking flask (Corning) for 3 to 4 days at 37°C, 
5% CO2 and 90 rpm (50 mm throw). Adherent cells were split after reaching a confluency of >80% with a 
viability of >90%, while suspension cells were split after reaching >95% viability with a certain cell density 
according to the manufacturers protocol. 
 
4.4.2. Transient antibody expression in Expi293F 
Plasmids were prepared using GenEluteTM HP Plasmid Maxiprep Kit (Sigma-Aldrich) following manufacturer’s 
instructions and sequence was verified by sequencing. Expi293F cells (source) were seeded with 
1.3 x 106 vc mL-1 2 days post transfection. Cells should have reached a cell density of >3.0 x 106 vc mL-1 and a 
viability of >96% at the day of transfection. Cells were diluted to 2.9 x 106 vc mL-1 prior to transfection using 
pre-warmed Expi293F expression medium. Cell counting was determined using Vi-Cell® XR 
(BeckmanCoulter). The DNA was diluted in OptiMEM serum free medium to a final concentration of 1 mg L-1 
and gently mixed. The chain ratio for heavy and light chains was 1:1 for Fab fragments and 1:1:1 for SEED-
molecules. 2.7 µL ExpiFectamineTM 293 Reagent per µg DNA was diluted in OptiMEM serum free medium and 
gently mixed. ExpiFectamineTM 293 Reagent was transferred to diluted DNA and incubated at room 
temperature for 20 min for complexation. The DNA/Fectamine complex was added dropwise to the cells under 
shaking conditions. Cells were incubated at 37°C and 5% CO2 at 80 rpm (50 mm throw). Cells were 
supplemented with 5 µL mL-1 ExpiFectamineTM 293 Transfection Enhancer 1 and 50 µL mL-1 ExpiFectamineTM 
293 Transfection Enhancer 2, 20 h post transfection. Culture was harvested either after 6 days post transfection, 
or when cell viability dropped below 80%. Cells were centrifuged at 4000 x g for 20 min at 4°C and supernatant 
was filter sterilized (0.22 µm, Nalgene Rapid-Flow Bottle Top Filter, Thermo Fisher Scientific) before following 
purification or analysis. 
 
4.4.3. Cell culture 
HT1080 hCD40 (human fibrosarcoma), SK-BR-3 and A549 cells were cultured in DMEM high glucose medium 
supplemented with 10% FCS, 2 mM L-glutamine and 1 mM sodium pyruvate.  
MDA-MBA-468 (human adenocarcinoma), MKN-45 (human gastric adenocarcinoma), Jurkat E6.1 cells were 
cultured in RPMI 1640 medium supplemented with 10% FCS, 2 mM L-glutamine and 1 mM sodium pyruvate. 
CD40 HEK293 stable cell line and EBC-1 cells were cultured in MEM medium with earl salts, 10% FCS, 2 mM 
L-glutamine and 1 mM sodium pyruvate and 1 mM non-essential amino acids. 
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All cell lines were cultured at 37°C in a humidified 5% CO2 atmosphere. Cells were sub-cultured in cell culture 
adherent T75 flasks (Greiner) at 90% confluence and >90% viability monitored by microscopy (Leitz 
LABOVERT, Wetzlar, Germany) and ViCell XR (BeckmanCoulter) analysis. To split cells, conditional medium 
was removed from the flask and cells were washed with pre-warmed PBS. To loosen adherent cells from surface 
attachment, 1 mL of pre-warmed 0.05% trypsin/EDTA was added and incubated for 5 min at 37°C. 
Trypsinization was stopped by adding fresh culture medium, including FCS. Cell density was determined by 
ViCell XR (BeckmanCoulter) analysis and cells were seeded with an appropriate cell density (1:5 or 1:10 
depending on the cell doubling time) to a new T75 flask.   
 
4.4.4. Flow cytometry 
Guava easyCyte HT cytometer was used to perform flow cytometric analysis. Adherent cells were detached 
from the well surface by addition of 1 mL pre-warmed 0.05% trypsin/EDTA, when cells reached a confluency 
of 80-90%, followed by incubation for 5 min at 37°C. Fresh culture medium, containing FCS, was added to stop 
trypsinization, followed by cell counting via Vi-CELL XR. 1 x 105 cells per cavity of a 96 well plate (Greiner) 
were used to investigate cellular binding. Cells were washed in 200 µL FACs binding buffer (PBS pH 7.4, 1% 
BSA) and subsequently distributed to each cavity of the 96 well plate in a final volume of 100 µL. After washing, 
cells were treated with reconstituted antibodies using a final concentration of 10 µg mL-1 and further incubated 
for 1 h on ice. Cells were centrifuged at 250 x g for 10 min at 4°C and washed twice with 200 µL binding buffer. 
Secondary fluorescently labeled detection antibody (Alexa Fluor® 488-conjugated AffiniPure Goat Anti-
Human IgG) was incubated together with cells for 30 min to maximum 1 h at 4°C, protected from light to 
prevent fluorescent activation, to determine cell binding. Finally, cells were washed twice again and resuspended 
in binding buffer, prior to FACS analysis. Software Guava ExpressPro was used for analysis. 
 
4.4.5. Cellular binding of CEACAM bsAb on MKN-45 and HEK293 Nf-κB reporter cell line 
cells 
Flow cytometric analysis was performed using the Guava easyCyte HT cytometer (Chapter 4.4.4). Cellular 
binding of reconstituted and parental CEACAM bsAbs were performed with 1 x 105 cells per cavity in a 96 well 
plate (Greiner). Binding was confirmed by using MKN-45 cells as a positive cell line for CEACAM and 
HEK293 Nf-κB reporter cells as a negative cell line. On the day of flow cytometry analysis, cells were detached 
and distributed to 96 well plates according to Chapter 4.4.3 To detach adherent cells from the well surface, 
1 mL of pre-warmed 0.05% trypsin/EDTA was added and incubated for 5 min at 37°C at a confluency of  
80-90%. Trypsinization was stopped by adding fresh culture medium, including FCS and cells were counted by 
Vi-CELL XR. Cells were washed afterwards in FACS binding buffer (PBS pH 7.4, 1% BSA) and distributed to 
the 96 well cavities in a final volume of 100 µL. Cells were treated with 10 µg mL-1 reconstituted and parental 
CEACAM5 and CEACAM6 bsAb and incubated for 1 h on ice. Cells were centrifuged at 250 x g for 10 min at 
4°C and washed twice with binding buffer. All washing steps were carried out in a final volume of 200 µL. Cells 
were treated with secondary fluorescently labeled detection antibody (Alexa Fluor® 488-conjugated AffiniPure 
Goat Anti-Human IgG) to determine positive or negative cell binding. Secondary antibody was incubated for 
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30 min up to 1 h at 4°C covered from light to prevent fluorescent activation. Cells were washed again in binding 
buffer twice and resuspended before performing FACS analysis. Software Guava ExpressPro was serving as a 
determination tool for cell binding. 
Analogous experiments with flow cytometry were performed for bivalent CD40 agonists binding to 
HT1080 CD40 and MDA-MB-486 cells and cellular binding of c-METxEGFR bsAbs on EBC-1 and A546 cells. 
Cellular binding of a bispecific T-cell engager OKT3xHer2 was conducted by FACS on SK-BR-3 and 
Jurkat E6.1 cells following the above mentioned protocol. 
 
4.4.6. Antibody dependent cell mediated cytotoxicity (ADCC) assay 
Antibody dependent cell mediated cytotoxicity (ADCC) assays were performed by using ADCC Reporter 
Bioassay Core Kit (Promega) according to the manufacturers protocol. Target cells (HT1080 or MKN-45) were 
seeded with 1.25 x 104 viable cells per cavity in an opaque white 96 well plate suitable for cell culture treatment 
(Perkin&Elmer). The inner 60 wells were used for ADCC activity determination, while the outer wells were 
filled with 75 µL ADCC buffer (low IgG FBS heat inactivated (Gibco) diluted in RPMI to avoid edge effects 
during the assay. Cells were incubated for 1 day over night at 37°C, 5% CO2 at humidified atmosphere, to allow 
attachment. Medium was removed carefully and replaced by 25 µL ADCC buffer. Cells were treated with 50 nM 
to 1 µM antibodies diluted in ADCC buffer. Modified Jurkat effector cells were thawed in water bath at 37°C 
and diluted with ADCC buffer. The E:T ratio was set at 6:1 and 25 µL of effector cells (75 000 per well cavity) 
was added to the cells, followed by an incubation step at 37°C, 5% CO2 for 6 h in a humidified atmosphere. 
BioGlo Luciferase substrate was resolved at RT prior to assay and covered from light until usage. After 6h 
incubation time, cells were equilibrated to RT for 15 min, followed by the addition of 75 µL per well BioGlo 
Luciferase substrate. Another incubation step was performed for 5-30 min at RT covered from light. 
Luminescence signal was measured with the Synergy4 (BioTek) at 0.5 s per well using a sensitivity of 170. The 
Gen5 software was used as a tool for ADCC determination. Background luminescence occurring from ADCC 
buffer was subtracted from sample wells and the relative luminescence units were plotted against the logarithmic 
scaled antibody concentration. Dose response curves were fitted using sigmoidal 4PL model by GraphPad 
Prism 7.  
 
4.4.7. CD40 activation assay (CD40 reporter cell line) 
A BPS Bioscience CD40 HEK293 Stable Cell Line (BPS Bioscience) was used to conduct CD40 activation. 
Therefore, CD40 expressing HEK293 cells were detached and seeded afterwards with 2.5 x 104 cells per cavity 
of a 96 well plate suitable for cell culture treatment (Perkin&Elmer). Only the 60 inner wells were used for 
CD40 activation. The outer wells were filled with 75 µL culture medium, to avoid edge effects. After seeding, 
cells were incubated for 1 day at 37°C, 5% CO2 at a humidified atmosphere. After attachment, cells were treated 
with reconstituted antibodies, diluted in assay buffer, using a concentration range between 200 nM and 2 pM. 
Cells were incubated at 37°C, 5% CO2 for 6 h at humidified atmosphere. BioGlo Luciferase substrate was 
reconstituted and adjusted to RT prior to cell treatment and protected from light until usage. Cells were 
equilibrated to RT for 15 min after antibody treatment, followed by addition of 75 µL BioGlo Luciferase 
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substrate per well. Further incubation at RT for 5-30 min was performed and protected from light exposure. 
Luminescence signals were measured at 0.5 s per well and a sensitivity of 170 using the Synergy4 (BioTek). 
Luminescence readout was analyzed with the Gen5 software. Luminescence background noise caused by the 
assay buffer was subtracted from sample wells. The relative luminescence units were plotted against the 
logarithmic scaled antibody concentration and dose response curves were generated and fitted by using a 4PL 
model in GraphPad Prism 7. 
 
4.4.8. T-cell Activation Bioassay (NFAT) 
T-cell activation assays were performed by using a T-cell Activation Bioassay (NFAT) Kit (Promega) according 
to the manufacturers protocol. Therefore, cells were detached and seeded afterwards with 4.0 x 104 cells per 
cavity of a 96 well plate suitable for cell culture treatment (Perkin&Elmer). Only the inner 60 wells were used 
for T-cell activation. The outer wells were filled with 75 µL assay buffer (low IgG FBS heat inactivated (Gibco) 
diluted in RPMI medium, to avoid edge effects. After seeding, cells were incubated for 1 day at 37°C, 5% CO2 
at humidified atmosphere. After attachment of the cells the medium was carefully removed and replaced by 
25 µL assay buffer. Cells were treated with 25 µL reconstituted antibodies, using a concentration range between 
0.01 nM and 100 nM to induce T-cell activation. Jurkat effector cells bearing a modified NFAT-re-luc2 pathway, 
were thawed quickly in a water bath at 37°C and diluted with assay buffer according to the manufacturers 
protocol (Promega). Cells were treated with 25 µL effector cells (1 x 105 cells per well cavity) and incubated at 
37°C, 5% CO2 at humidified atmosphere for 6 h. BioGlo Luciferase substrate was reconstituted and adjusted to 
RT prior to cell treatment and protected from light until usage. Cells were equilibrated to RT for 15 min after 
antibody treatment, followed by addition of 75 µL BioGlo Luciferase substrate per well. Further incubation at 
RT for 5-30 min was performed and protected from light exposure. Luminescence signals were measured at 0.5 
s per well and a sensitivity of 170 using the Synergy4 (BioTek). Luminescence readout was analyzed with the 
Gen5 software. Luminescence background noise caused by the assay buffer was subtracted from sample wells. 
The relative luminescence units were plotted against the logarithmic scaled antibody concentration and dose 
response curves were generated and fitted by using a 4PL model in GraphPad Prism 7. 
 
4.4.9. c-MET and EGFR phosphorylation assay 
The phosphorylation of c-MET and EGFR was determined by western blot analysis using detection antibodies 
specifically directed against phosphorylated c-MET and EGFR. c-MET and EGFR expressing cancer cells 
(A549, EBC-1) were seeded with 1x105 vc per well in a 24 well tissue plate (Thermo Fisher) and incubated for 
1 day at 37°C, 5% CO2 at humidified atmosphere. The medium was replaced by a serum-starvation medium, 
lacking FCS, after a confluency of 80 – 95% was reached. Cells were incubated for another day at 37°C, 5% CO2 
at humidified atmosphere. Cells were treated with 300 nM reconstituted bispecific F06xhu225H and 
B10v5xhu225H antibodies and incubated for 3 h at 37°C, 5% CO2. Cell stimulation was performed by addition 
of 100 ng/mL HGF and EGFR (R&D Systems) followed by incubation for 10 min at 37°C. Cells without HGF 
and EGF stimulation served as a negative control. Cells were treated subsequently with ice cold RIPA buffer 
containing protease inhibitor set III, phosphatase inhibitor set II (Calbiochem) and Benzonase (1:1000, Novagen) 
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under shaking conditions for 1 h at 4°C for cell lysis. Cell lysate samples were supplemented with 4x LDS sample 
buffer and boiled for 10 min at 70°C for SDS-PAGE analysis. The resulting gel was blotted on a PVDF 
membrane (Chapter 4.3.14) and treated afterwards with specific anti-phospho-c-MET (Cell Signaling 
Technologies) and anti-phospho-EGFR antibodies (R&D Systems) for phosphorylation detection. Expression 
levels of c-MET and EGFR were detected after blotting by using specific anti-cMET (Biomol) and anti-EGFR 
antibodies (Cell Signaling Technologies). Western blot analysis was performed according to Chapter 4.3.14. 
 
4.5. Biophysical methods 
4.5.1. Biolayer interferometry (BLI) 
Binding kinetics of purified IgG antibodies and reconstituted IgG antibodies were determined by using the 
Octet RED96 system (ForteBio, Pall Life Science) at 30°C and 1000 rpm agitation speed in a final volume of 
200 µL in black 96-well microplates. 3-5 µg mL-1 of reconstituted antibodies, diluted in PBS buffer (pH 7.4), 
were captured with anti-human IgG Fc (AHC) biosensor tips after equilibration in Dulbecco´s PBS (Life 
Technologies) for 60 s (baseline). Capturing of reconstituted antibodies was performed for 180 s followed by an 
incubation step for 45 s in kinetics buffer (PBS, 0.1% Tween-20 and 1% bovine serum albumin, (BSA). The 
biosensor tips were then transferred into wells containing the appropriate target recombinant antigen, diluted 
in kinetics buffer using a concentration range varying from 200 nM to 3.13 nM. The association step was 
conducted for either 400 s or until the highest concentration showed saturation. Dissociation was performed in 
kinetics buffer for 800 s to determine kon and koff values. A replacement of the antigen by kinetics buffer was 
serving as a negative control (reference measurement). A non-binding isotype control anti-hen egg lysozyme 
(anti-HEL) and an unrelated antigen were used in each experiment to observe potential unspecific binding. The 
reference measurement was subtracted from sample measurements (antibodies) for data fitting. Kinetic 
parameters were determined by using using a 1:1 Langmuir binding model after Savitzky-Golay filtering 
(ForteBio data analysis software 9.1).  
 
4.5.2. Thermal shift assay 
The Prometheus NT.Plex nano DSF (Nano Temper) was used to determine the thermal stability of antibodies. 
The intrinsic fluorescence of tryptophan and tyrosine residues under native conditions are detected and 
measured at 330 and 350 nm. 10 µL antibody sample was used to ensure complete filling of each capillary 
(Standard, Catalog no. PR-AC002, Nano Temper). An initial discovery scan can be performed to ensure 
fluorescence signal detection and excitation power adjustment. Melting temperatures (Tm) were monitored 
online starting from 20°C to 95°C using a temperature slope of 1°C min-1 for 1 h and 15 min. Data was analyzed 
with the PR.ThermControl v2.1 software (Nano Temper).  
 
4.5.3. Automation (Hamilton & BiomekFX) 
The Hamilton MicroLab starlet liquid handler (Hamilton) was used for semi-automated reconstitutions in a 
96 well format. Antibody precursor fragments fused to IntC or IntN, TCEP, Ni2+ beads and DHAA were prepared 
and diluted in PBS pH 7.4 and supplied in reservoir tanks. Ni2+beads were washed at least 3 times manually to 
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remove the ethanol. Antibody precursor fragments were mixed in an appropriate molar ratio, depending on the 
fragments, in final volume of 200 µL by the liquid handler, resulting in 58 µg total protein per well. 25 µL TCEP 
was added using a final concentration of 0.5 mM. The plate was removed manually and incubated for 2 h at 37°C 
after sealing. Addition of 25 µL diluted Ni2+ magnetic beads (Invitrogen) was performed by the liquid handling 
system. The beads are capable to bind 40 µg tagged protein per 25 µL beads according to Invitrogen. Therefore, 
beads were diluted in PBS pH 7.4 to offer a binding capacity of 5 µg his tagged protein per well, which was 
hypnotized to be enough to remove all non-reconstituted antibody fragments. The plate was sealed and 
transferred manually again to an incubator at RT for 1 h under shaking conditions at 700 rpm (25 mm throw, 
Infors HT). After incubation the plate was centrifuged at 4000 x g for 2 min (Multifuge X3R, Thermo Scientific) 
and transferred back to the Hamilton stack holder, which carried a strong magnet plate to capture magnetic 
beads at the well bottom. 200 µL of the reconstitution mixture was transferred into a fresh 96 well plate by the 
liquid handler. The liquid handler was taught to not touch the well bottom to ensure no bead transfer into the 
new plate. Subsequently DHAA was added in a 10-fold molar excess over TCEP by the liquid handler system 
and incubated after sealing for 1-2 h at 37°C or overnight at 4°C (Infors HT) respectively. Reconstitution 
efficiency was analyzed by SDS-PAGE (Chapter 4.3.12) and ELISA (Chapter 4.3.11).  
 
The BiomekFX (Beckman) was used as a fully automated system for antibody reconstitutions in a 384 well 
format. Antibody precursor fragments fused to IntC or IntN, TCEP, Ni2+ beads and DHAA were prepared and 
diluted in PBS pH 7.4 and supplied in 50 mL falcon tubes. Ni2+beads were washed at least 3 times manually to 
remove the ethanol. Antibody precursor fragments were mixed by 2 multidrop systems (Thermo Fisher 
Scientific) in an appropriate molar ratio, depending on the fragments, in final volume of 40 µL by the liquid 
handler, resulting in 14 µg total protein per well. The plate was delivered by a robot arm. 7 µL TCEP was added 
by multidrop dispenser using a final concentration of 0.5 mM. The plates were sealed by a plate sealer for 8 s at 
150°C and mixed afterwards with a Bioshaker at 2200 rpm for 30 s. Plates were transferred into a plate carousel 
and incubated for 2 h at 37°C. After de-sealing 14 µL diluted Ni2+ magnetic beads (Invitrogen) were added by 
multidrop dispenser. The beads offered the same binding capacity as mentioned above. The plates were sealed 
again for 8 s at 150°C and mixed afterwards with a Bioshaker at 2200 rpm for 30 s, followed by incubation for 
15 min at 37°C. Mixing and incubation was repeated 4 times every 15 min to ensure no sedimentation of the 
beads. Plates were centrifuged after capturing non-reconstituted antibodies at 100 rpm for 2 min using a Vspin 
centrifuge. After de-sealing 35 µL of each well were transferred stepwise by the BiomekFX liquid handler to 
fresh 384 well plates. The plate stack holder was adjusted with a strong magnet to ensure immobilization of the 
beads to the well bottom. 17.5 µL were transferred as a first step into the fresh plate and centrifuged afterwards 
to ensure no bead transfer by the liquid handler. Finally, another 17.5 µL was transferred to the fresh 384 well 
plate. 11 µL DHAA was added by multidrop dispenser in a 10-fold molar excess over TCEP to each well, 
containing the reconstituted antibodies. The plates were sealed and mixed with the Bioshaker at 2300 rpm for 
30 s and transferred afterwards to the plate carousel for incubation at 37°C for 1-2 h or at 4°C overnight.  
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For normal distribution calculation, the following equation was used to display f(x): 
 
𝑓(𝑥) =
1
σ√2𝜋
𝑒
−
1
2
(
𝑥−𝜇
𝜎
)
2
              Eq. 4 
 
 
4.5.4. Mass spectrometry (MS) 
ESI-MS (Electrospray ionization mass spectrometry) was performed by a Dionex U3000 HPLC system coupled 
to a Synapt-G2 mass spectrometer, using a Proteomix RP-1000 4.6 mm x 100 mm (Sepax) column. 0.5 µg of 
protein solution was applied in mobile phase H2O and 0.1% formic acid 0.5 mL min-1. A linear gradient of 
acetonitrile (ACN) and 0.1% formic acid was used. Detection of protein fragments was achieved at 214 nm 
measurement and identification was achieved by the online coupled mass spectrometer. 
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5. Results 
 
5.1. Design and generation of antibody intein fusions 
In order to investigate post translational reconstitution of antibody fragments by PTS via split intein Npu DnaE, 
antibody Fab fragments, oaSEED or Fc fragments were fused to split intein parts flanked by their natural 
exteins. Therefore, the flexible hinge region was split in half and intein parts IntC and IntN were fused to the 
partial hinge according to Figure 14. A glycine serine linker (4xGS)4 was inserted upstream of IntC, allowing 
additional flexibility for the following hexahistidine tag for impurity removal of non-reconstituted antibody 
fragments.  
 
 
Figure 14: Schematic illustration of protein sequences for antibody fragments HC and LC fused to split intein parts IntC and 
IntN.  
Schematic HC and LC sequences of huFc IgG, Fab or oaSEED fragments are illustrated fused to IntC or IntN and their corresponding 
exteins within the hinge region. N- and C- terminal exteins are depicted as amino acid sequence (underlined) attached to the partial hinge 
region. Additionally, a glycine-serine linker and a hexahistidine tag is attached upstream to IntC of huFc or oaSEED fragments, while a 
hexahistidine tag is attached downstream of the IntN sequence. (1) HC of huFc IntC fragments. (2)(3) hu225H Fab IntN HC with 
corresponding LC. (4)(5) Reconstituted IgG HC with altered hinge region compared to naturally reference IgG HC. Hinge region of 
both variants are aligned to focus on the amino acid modification based on the respective exteins. (6-9) B10v5 oa SEED IntC HC with 
corresponding HC and LC. Detailed sequence information is listed in the materials section.  
 
Intein sequences were derived from Stevens et al.,147 fused to the corresponding antibody fragments and ordered 
as gene synthesis in a pTT5 vector backbone at GeneArt® (Thermo Fisher Scientific). The antibody VH regions 
were flanked by unique restriction sites BamHI and ApaI, to easily exchange the target specificity by standard 
cloning. VHH coding regions were exchanged by using unique restriction sites NcoI and NotI. Antibody Fab 
fragments fused to IntN and oaSEED or Fc fragments fused to IntC were expressed in mid-scale by transient 
expression of Expi293F cells. Purification of IntC-fusions was performed by Protein A affinity chromatography, 
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while IntN-fusions were purified via IMAC. Analysis of purified antibody fragments was monitored by SDS-
PAGE (Figure S1, Figure S2) and SE-HPLC (Figure S3). Expression yields of several Fab fragments ranged 
from 16.0 to 137.5 mg L-1 after final polishing by SEC. Trastuzumab Fab IntN showed an 8-fold higher yield 
compared to the high affinity variant hu225H Fab IntN and a 3-fold higher yield compared to the low affinity 
variant hu225L Fab IntN. Anti-CD40 Fab IntN as well as C6 Fab IntN showed similar yields within the 90 mg L-1 
range. Highest yield of 137.5 mg L-1 was observed for Trastuzumab Fab IntN, while the lowest yield was 
detected for hu225H Fab IntN with 16.0 mg L-1. Protein purity of the entirety of the Fab fragments was higher 
than 96% monomeric content and all antibodies showed acceptable expression rates. High molecular weight 
impurities like protein aggregates would have an impact on antibody reconstitution and might result in false 
positive or negative results in cellular based functional assays, therefore it is of importance to start with good 
quality precursor material for antibody reconstitution. Expression yields of oaSEED fragments were in the same 
range between 82.0 and 104.8 mg L-1 after purification, except oaF06 IntC showing an expected decreased yield 
of 33.0 mg L-1. Fc fragments showed highest obtained yield in the range of 254 to 403 mg mL-1 with a 
monomeric content of 100% after purification.   
Table 2: Expression yields of antibody fragments fused to split intein parts including purity parameters after purification.  
Antibody fragments fused to either the C-terminal (IntC) part or N-terminal (IntN) part of the split intein Npu DnaE were generated by 
transient transfection of Expi293F cells. Purification was performed by ProteinA affinity chromatography for oaSEED-IntC and Fc-IntC 
fragments, while IMAC was performed for Fab-IntN fragments. Protein yields were calculated as mg L-1 and total yield for 200 mL 
culture volume (mg/200 mL). Protein purity was determined by SE-HPLC analysis after preparative SEC to specify the percentage of 
purified monomer. oa = one-armed   
Antibody fragment Yield  
[mg/200 mL] 
Yield  
[mg L-1] 
Monomer after SEC 
[%] 
C6 Fab IntN 18.2 91.0 96.2 
CD40 Fab IntN 17.6 88.0 96.4 
Trastuzumab Fab IntN 27.5 137.5 98.0 
hu225H Fab IntN 3.2 16 98.8 
hu225L Fab IntN 9.5 47.5 96.2 
    
Antibody fragment Yield  
[mg/200 mL] 
Yield  
[mg L-1] 
Monomer after SEC 
[%] 
oaTrastuzumab IntC 16.4 82.0 96.5 
oaC5 IntC 21.0 104.8 94.6 
oaB10v5 IntC 20.2 101.0 99.0 
oaF06 IntC 6.6 33.0 98.0 
oaOKT3 IntC 19.2 96.0 99.5 
IgG1 Fc IntC 80.1 400.5 100.0 
IgG2 Fc IntC 66.5 332.5 100.0 
IgG1.4 Fc IntC 80.6 403.0 100.0 
IgG1.6 Fc IntC 50.8 254.0 100.0 
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Antibody fragments for bsAb reconstitution and functional characterization are listed in Table 2. Protein yields 
and purity of all antibody fragments were suitable for antibody reconstitution and further characterization of 
reconstitution efficiency and functionality determination. 
 
5.2. Evaluation of reconstitution efficiency for mono- and bispecific antibodies 
In terms of generating several mono- and bispecific antibodies by split intein mediated antibody reconstitution, 
it was tested if the modified hinge region by flanking extein and intein sequences fused to a hexahistidine tag 
were still able to perform PTS. As a proof of concept, several formats were tested under optimized conditions 
for successful antibody reconstitution. All reconstitution reactions were performed at 37°C for 2 hours after 
activation with 0.5 mM TCEP considered as optimal conditions for antibody reconstitution. Monospecific 
antibody anti-CD40 was reconstituted by mixing anti-CD40 Fab fragment and IgG1 Fc fragment in a ratio of 
2:1. PTS was activated immediately after TCEP addition and monitored by SDS-PAGE analysis, as shown in 
Figure 15 A. Samples were taken every 10 min to evaluate reconstitution efficiency. A new band occurred 
already after 10 min at ~50 kDa, indicating the PTS product of both HC antibody fragments through ligation. 
The newly reconstituted HC only occurs after TCEP addition, while no band was observed at 0 min serving as 
a negative control. The gel band at ~40 kDa represents the HC of anti-CD40 Fab fragment fused to IntN, while 
the ~25 kDa gel band represents the HC of IgG1 Fc IntC fragment under reducing conditions. Both bands got 
depleted over time and the reconstituted product increased. A gel band at ~14 kDa occurred, showing the spliced 
IntN part after reconstitution of both HCs derived from antibody fragments. Reconstitution of full length anti-
CD40 antibody was completed after 120 min. The SDS-PAGE analysis showed almost complete conversion of 
precursor antibody fragments (Figure 15 A).  
Bispecific antibody reconstitution efficiency was evaluated by mixing Trastuzumab oaSEED IntC fragment with 
a hu425 Fab IntN fragment in an equimolar ratio (1:1) (Figure 15 B). Again, a new gel band at ~50 kDa occurred 
after TCEP activation and increased over time until antibody fragment depletion based on successful 
reconstitution. Spliced IntN and IntC fragments were increasing over time and indicated at ~12 kDa and ~4 kDa 
respectively.  
 
 
Figure 15: Evaluation of reconstitution efficiency for mono- and bispecific antibodies.  
Different antibody fragments were mixed in an equimolar ratio for bsAbs and in a 2:1 ratio for mAbs and activated with 0.5 mM TCEP 
after PTS optimization and incubated at 37°C. A: Reconstitution of CD40 Fab fragments with an IgG1 Fc fragment via PTS over time. 
The newly occurring gel band at ~50 kDa after 10 min incubation, indicated the splicing product of Fab heavy and Fc heavy chain (RHC: 
Reconstituted HC). B: Reconstitution of a Her2 oaSEED fragment with hu425 Fab. C: Reconstitution of Her2 VHH fragments with an 
IgG1 Fc fragment. Splicing efficiency for all tested formats was fast and mostly completed after 1h with a yield of >90%. 
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In order to proof that antibody reconstitution is not format dependent and does not cause any sterically 
hindrance, purified Her2 VHH IntN derived from an E. coli expression and IgG1 Fc IntC derived from mammalia 
expression were mixed in a molar ratio of 2:1 and successfully reconstituted over time (Figure 15 C). As 
assumed, a new gel band occurred at ~40 kDa indicating the reconstituted HC of both antibody fragments, while 
IntN and IntC were spliced and appeared at ~14 kDa and ~4 kDa. The reconstitution efficiency is comparable to 
monospecific full-length (Figure 15A) and bispecific antibody reconstitution (Figure 15B) and was not limited 
to the antibody format. However, a reconstitution of 100% was not achieved after 120 min while generating 
bsAbs and VHH-Fc antibodies through PTS (Figure 15B, C). Although, it is possible to generate precursor 
antibody fragments in different host cells like E. coli or mammalia, without inhibiting the PTS activity. 
The general reconstitution efficiency over time was calculated by integration of peak areas, determined by pixel 
analysis using ImageJ (Figure S4). SDS-Gel analysis depicted in Figure 15A was used for pixel analysis and 
peak area generation. Integration of the peak areas at different time points were used to generate an extrapolated 
Michaelis Menten kinetic (GraphPad Prism v7). Time point at 0 h exhibited the highest peak value for antibody 
fragments (substrate) and is considered as 100% (Figure 16). Over time depletion of the antibody fragments 
was observed, forming the final reconstituted full-length IgG antibody. Antibody reconstitution was mostly 
completed, yielding ~90% reconstituted mAb after 120 min at 37°C (Figure 16).  
 
 
Figure 16: Antibody reconstitution efficiency by PTS over time.  
Reconstitution of CD40 IgG1 antibody starts immediately after PTS activation through TCEP addition. Antibody fragments depleted 
over time, while the reconstituted full-length antibody is generated by PTS. Left y-axis indicates antibody fragments as substrates for 
antibody reconstitution through PTS. X-axis shows PTS efficiency over time, while second y-axis depicts the reconstituted antibody 
conversion. Values for substrate and reconstituted antibody was calculated from the peak area after pixel analysis of each sample point 
and extrapolated using GraphPad Prism 7 software. The complete data set is located in the supplemental section (Figure S4). 
 
The illustrated example for antibody reconstitution efficiency by calculation was conferrable to upcoming 
reconstitution experiments. It was observed that a format independent overall reconstitution yield of around 
90% can be expected under optimized conditions after 2 h. 
Of note, protein impurities or aggregation often lead to false positive results in functional cellular assays. 
Therefore, the specific design of the antibody fragments offers a purification tag after each intein sequence for 
non-reconstituted antibody removal. Furthermore, TCEP is necessary for antibody reconstitution and the 
disulfide bonds between HC-HC and HC-LC are present in a reduced form. Investigations for a one-pot 
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purification strategy, which is not dependent on extensive elution steps and the re-oxidation of disulfide bonds 
for correctly assembled antibody chains is presented in the subsequent Chapter 5.2.1.  
 
5.2.1. One-Pot purification and identification of reconstituted antibodies 
To demonstrate the purification strategy and setup for non-reconstituted antibody fragments, anti-CD40 Fab 
IntN fragment was mixed with a surplus ratio of 3:1 with IgG1 Fc IntC to ensure non-complete antibody 
reconstitution. PTS was stopped after 120 min due to depletion of IgG1 Fc IntC substrate (Figure 17A; Lane 3). 
After addition of Ni2+ beads and incubation under shaking conditions for 1 h, supernatant was separated from 
the beads, containing reconstituted full-length anti-CD40 IgG without any non-reconstitution impurities in 
form of antibody fragments as shown in Figure 17A (Lane 4). Beads were further eluted with imidazole and 
non-reconstituted antibody fragments were present in the gel fraction after SDS-PAGE analysis, serving as a 
proof of concept for the purification setup and no unspecific binding of reconstituted mAb to Ni2+ beads. 
(Figure 17A Lane 5). The hexahistidine tag downstream and upstream of the respective split intein sequence is 
still accessible for affinity purification and furthermore did not disturb the splicing reaction itself. PTS 
successfully removed the hexahistidine tag, as well as the corresponding split intein part from the ligated 
reconstituted tag-less mAb, which is now masked against IMAC purification via Ni2+ beads. After re-oxidation 
with a 10-fold surplus of DHAA over TCEP, a reconstituted anti-CD40 mAb with intact disulfide bonds was 
achieved without any non-reconstituted antibody fragment impurities, monitored by SDS-PAGE analysis 
(Figure 17A; Lane 6).  
 
 
Figure 17: One-pot purification for reconstituted antibodies.  
Non reconstituted antibody fragments and spliced split intein parts compromising a hexahistidine tag were removed after Ni2+ bead 
addition. A: Antibody reconstitution with a surplus of Fab fragment followed by one-pot purification using Ni2+ beads. Lane 1: Marker; 
Lane 2: Fab IntN and huFc IgG1 IntC mixed with TCEP at 0 h. Lane 3: Fab IntN and huFc IgG1 IntC mixed with TCEP after 2 h 
reconstitution. Lane 4: Reconstituted HC and LC after Ni2+ treatment and non-reconstituted antibody removal. Lane 5: Elution fraction 
using 500 mM imidazole. Lane 6: Re-oxidation of reconstituted mAb (Lane 4) treated with a 10-fold molar excess of DHAA over TCEP. 
(S) Supernatant; (E) Elution; (Ox.) Re-oxidated mAb fraction B: SDS-Gel analysis of reconstituted monospecific anti-CD40 antibody 
under oxidized and reduced conditions to verify successful antibody reconstitution. Full-length antibody occured at ~144 kDa under 
oxidizing conditions (Lane 2), while two bands occured at ~50 kDa for the HC and ~25 kDa for the LC under reducing conditions 
(Lane 3). Lane 1: Marker.   
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Finally, reconstituted anti-CD40 antibody was concentrated and further analyzed by SDS-PAGE analysis under 
oxidizing and reducing conditions (Figure 17B). A gel band at ~50 kDa and ~25 kDa for HC and LC under 
reducing conditions was observed, while a gel band at ~144 kDa was observed under oxidizing conditions. The 
SDS-PAGE analysis gave a first indication of successfully produced reconstituted antibodies by PTS, showing 
all expected antibody chains.  
Further evaluation of the reconstitution efficiency, with respect to reconstituted antibody purity and 
purification, was performed by generating a c-METxEGFR bsAb mediated by PTS and analyzed with 
SE-HPLC at specific time points (Figure 18). Samples were quenched with H2O2, oxidizing the reducing agent 
TCEP, antibody fragments and reconstituted bsAb for quantitative analysis. Antibody reconstitution was 
initiated immediately after TCEP addition, indicating and confirming the fast kinetics of the Npu DnaE split 
intein. Incubation after 10 min at 37°C already yielded in 39% of the reconstituted bsAb, while antibody 
precursor fragments were decreasing over time. Antibody reconstitution was stopped after 1.5 h, resulting in 
12% non-reconstituted antibody precursor fragments. Finally, the non-reconstituted antibody fragments were 
purified with Ni2+ beads, increasing reconstituted bsAb purity up to 94% (Figure 18). Reconstitution efficiency 
and splicing kinetics were comparable to the previously executed SDS-PAGE analysis experiments 
(Figure 16/17A). 
 
 
Figure 18: Determination of the reconstitution efficiency and purification of a bsAb via HPLC analysis.  
Antibody precursor fragments B10v5 oaSEED IntC and hu225H Fab IntN were mixed in an equimolar ratio and incubated for 2 h at 
37°C after addition of 0.5 mM reducing agent TCEP. Samples were taken at specific time points and reconstitution reaction was quenched 
by the addition of H2O2, inactivating TCEP through oxidation. The mixture was treated with Ni2+ beads to remove non-reconstituted 
antibody fragments. Reconstitution efficiency and antibody purity was determined by analytical SE-HPLC analysis.  
 
As SDS-PAGE is not as precise as SE-HPLC or mass spectrometry, further investigations to verify correctly 
assembled HC was demanding. A reconstituted anti-CD40 antibody was analyzed by MS under reducing 
conditions. Figure 19A shows the MS spectrum of the HC and LC as already proofed by SDS-PAGE analysis 
(Figure 17B). The most important fragments of the reconstituted antibodies are the HC parts of the Fab and 
Fc fragment. In case of successful reconstitution, the HC of the Fab fragment is ligated to the HC of the Fc 
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portion and gives valuable information about the correct formed molecule. The spectrum showed clearly a mass 
of 51.9 kDa, indicating the correctly assembled HC after PTS. A higher molecular mass was detected compared 
to the theoretical mass. A N-glycosylation by N-glycan type G0F with a mass of 1445 Da was detected as well 
as an O-glycosylation with a mass of 948 Da and a missing pyroglutamate (pGlu) with 17 Da. The newly formed 
HC exhibited several glycosylation modifications as expected for heavy chains and was matching with the 
theoretical calculated mass (Figure 19B). The LC was detected without any modifications and was matching 
with the expected theoretical mass.  
 
 
Figure 19: Identification of correctly reconstituted heavy chains by mass spectrometry.  
MS spectra of reconstituted anti-CD40 after PTS reaction and one-pot purification. Analysis was performed by ESI-MS. (A) MS 
spectrum of HC and LC after reconstitution reaction under reducing conditions. (B) MS spectrum of HC including modifications. 
Calculated mass is correlating with the measured mass and indicates successful antibody reconstitution by PTS.  
 
MS data confirmed the results obtained from SDS-PAGE analysis for successfully reconstituted anti-CD40 
antibody. Non-reconstituted antibody impurities or false assembled heavy chains were not detected in the MS 
spectrum. Anti-CD40 IgG was used as a proof of concept model for antibody reconstitution based on the less 
complicated format compared to bsAbs. Split intein mediated antibody reconstitution is not format biased as 
already investigated in Chapter 5.2. However, the bispecific format comprises two different heavy- and light 
chains. The addition of TCEP, which resulted in reduced disulfide bonds, followed by re-oxidation with DHAA 
gave reasons to believe that it could be a potentially mismatched chain assembly. Therefore, experiments were 
performed to evaluate correct HC and LC assembly after reconstitution and re-oxidation in a bispecific format. 
 
5.2.2. Correct assembly of HC and LC after bispecific antibody reconstitution 
In order to investigate correct assembly of HC and LC after antibody reconstitution, antibody fragments with  
wrong LCs were produced. A Trastuzumab oaSEED IntC fragment paired with a hu225 LC, was reconstituted 
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with a hu225 Fab IntN fragment, paired to a Trastuzumab LC. Figure 20A shows the different versions, which 
can potentially occur after antibody reconstitution based on the mild reducing environment caused by TCEP. 
This would result in LC shuffling after re-oxidation. Reconstitution of the Her2xEGFR bsAb with wrong LCs 
(Her2xEGFRFC) was completed after 2 h. Antibody fragments Trastuzumab oaSEED IntC and hu225 Fab IntN 
bearing the wrong LC were completely depleted and re-oxidation with DHAA overnight showed a band at 
~147 kDa after SDS-PAGE analysis, indicating a full-length bsAb antibody (Figure 20B).  
 
 
Figure 20: Investigation of potential LC shuffling under mild reconstitution conditions.  
(A) bsAb variants after reconstitution and re-oxidation with potential chain shuffling. In terms of LC inversion one or both binding 
moieties should bind their respective antigen. (B) Trastuzumab oaSEED IntC was produced with a hu225 LC. Hu225 Fab IntN was 
produced with a Trastuzumab LC and both fragments were reconstituted via PTS.  
 
BLI analysis was performed and monovalent Trastuzumab oaSEED IntC paired to the hu225 LC showed no 
binding to recombinant Her2 as expected because of the wrong LC (Figure 21C). Monovalent Trastuzumab 
oaSEED paired to the correct Trastuzumab LC was binding with high affinity to recombinant Her2 and served 
as a positive control. Hu225 Fab IntN paired to Trastuzumab LC was neither binding to recombinant Her2 or 
EGFR as shown in Figure 21A and 21B. It was hypothesized, if LC shuffling occurred during antibody 
reconstitution, Her2xEGFRFC should bind either to recombinant Her2 or EGFR or both, according to the 
shuffling variants depicted in Figure 20A. Her2xEGFRFC was neither binding to recombinant Her2 nor to 
EGFR, revealing that no LC shuffling occurred during the reconstitution reaction (Figure 21A, B). 
Her2xEGFRFC is referred to a reconstituted Her2xEGFR bsAb with false LC paring.  
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Figure 21: BLI analysis of reconstituted Her2xEGFRFC bsAb paired to wrong LCs.  
(A) Panel A shows binding to recombinant Her2. Cetuximab served as a negative control and showed no binding to recombinant Her2, 
while Trastuzumab served as a positive control binding recombinant Her2 with high affinity. Hu225 Fab IntN pairing to Trastuzumab 
LC as well as Her2xEGFRFC showed no binding to recombinant Her2. (B) Panel B shows binding to recombinant EGFR. In this panel 
Cetuximab served as a positive control binding with high affinity to recombinant EGFR, while Trastuzumab is not binding and served 
as a negative control. Hu225 Fab IntN pairing to Trastuzumab LC as well as Her2xEGFRFC showed no binding to recombinant EGFR. 
(C) Monovalent Trastuzumab oaSEED IntC paired to hu225 LC showed no binding to recombinant Her2, while monovalent 
Trastuzumab oaSEED paired with the correct Trastuzumab LC was binding with high affinity to recombinant Her2. 
Her2xEGFRFC: FC = False chains  
 
Reference antibody Cetuximab showed binding with high affinity to recombinant EGFR, but no binding to 
Her2. Reference antibody Trastuzumab showed binding with high affinity to recombinant Her2, but no binding 
to EGFR. The BLI analysis of reconstituted Her2xEGFRFC gave a first hint of correctly assembled LCs during 
antibody reconstitution using a bispecific format. In addition, further investigations for potential LC shuffling 
was verified by ESI-MS analysis. For this, 1 mg of reconstituted F06xhu225L bsAb (c-METxEGFR) was 
digested with immobilized papain for 3 h at 37°C to cleave within the hinge region and separating the Fab 
fragments from the Fc portion. Fab fragments were analyzed by ESI-MS under non reducing conditions to 
evaluate correct assembly of HC and LC. The released Fab with the c-MET (F06) binding moiety exhibited a 
mass of 47.3 kDa and matched with the theoretical calculated mass for pairing the correct F06 LC. The released 
Fab with the EGFR (hu225L) binding moiety exhibited a mass of 47.5 kDa matching the theoretical mass of 
correctly paired hu225L LC (Figure 22). The theoretical masses for a potential LC shuffling during 
reconstitution are illustrated in Figure 22 with a mass of 46.9 kDa for hu225L HC paired with F06 LC and a 
mass of 48.0 kDa for F06 HC paired with hu225L LC. The LC chain mispairing variants were under the level 
of detection according to mass spectrometry analysis and evidence that LC shuffling did not occur during 
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reconstitution. Fab digestion with papain was repeated using reconstituted B10v5xhu225H bsAb to further 
validate correctness of the compiled data (Figure S5). No LC shuffling was observed. 
 
 
Figure 22: Papain digestion of reconstituted c-METxEGFR bsAb for Fab release and LC shuffling investigation by MS analysis.  
Reconstituted bsAb F06xhu225L was treated with Papain and incubated for 3 h at 37°C under shaking conditions for Fab release. Fabs 
were further analyzed by ESI-MS. The expected mass of F06 (c-MET) Fab as well as hu225L (EGFR) Fab correlates with the measured 
mass. The expected masses for both Fabs with an LC switch was depicted in the spectrum but was not detected.  
 
BLI analysis and mass spectrometry experiments specified in this chapter were a proof that the mild reducing 
conditions needed for activation of PTS and bsAb reconstitution did not favor chain mispairing and LC shuffling. 
With this information, a set of various mAbs and bsAbs were reconstituted with respect to investigate 
reproducibility, biophysical and functional characterization. 
 
5.2.3. Split intein mediated generation of various antibody formats  
After verification of correctly assembled HCs and LCs of reconstituted antibodies, several antibody formats were 
produced for further investigation of biophysical properties. Four different reconstituted anti-CD40 antibodies 
were generated with different Fc effector portions, to showcase an easy switch of the effector function (Table 3). 
Protein purity after antibody reconstitution ranged from 88.5% to 95.8%. Highest monomeric content after 
antibody reconstitution was achieved with bsAbs ranging from 94.0% to 99.4%. 
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Table 3: Antibody reconstitution rates after PTS and purification.  
Antibody fragments were mixed in an equimolar ratio for bsAbs and a molar ratio of 2:1 for mAbs and PTS was activated by addition of 
TCEP. Reconstituted antibodies were re-oxidized with DHAA and impurities removed by one-step IMAC through Ni2+ beads and 
dialyzed against PBS pH 7.4 for further biophysical and functional characterization. The purity of reconstituted antibodies was analyzed 
by SE-HPLC and SDS-PGAE and depicted as monomeric content in percent. Correct assembly of HC and LC was confirmed by MS.   
 
Reconstituted antibody  Format Monomer after SEC [%] 
Anti-CD40 IgG1  monospecific 89.4 
Anti-CD40 IgG2  monospecific 95.8 
Anti-CD40 IgG1.4  monospecific 88.5 
Anti-CD40 IgG1.6  monospecific 93.8 
C5xC6 (CEACAM5xCEACAM6)  bispecifc 96.5 
B10v5xhu225L (c-METxEGFR)  bispecifc 99.2 
B10v5xhu225H (c-METxEGFR)  bispecifc 94.0 
F06xhu225L (c-METxEGFR)  bispecifc 99.4 
F06xhu225H (c-METxEGFR)  bispecifc n.D. 
OKT3xHer2 (CD3xHer2)  bispecifc n.D. 
 
Table 3 shows reconstitution reproducibility and purity content of several formats and targets amenable for 
further biophysical and biochemical characterization. SE-HPLC analysis for reconstituted antibodies can be 
reviewed in Figure S6. In addition, mass spectrometry was conducted to determine intact molecules after PTS 
reaction (Figure S7-S10; Table S1).  
 
5.3. Characterization of reconstituted antibodies  
5.3.1. Biophysical characterization of reconstituted antibodies via BLI analysis 
Potential differences in biophysical properties and antibody functionality after PTS caused by the hinge region 
modification, compared to natural reference antibodies, were investigated by characterization via biolayer 
interferometry (BLI) and thermo shift analysis. Parameters were compared to reference antibodies and antibody 
fragments. Reconstituted bsAb C5xC6 resulted in a KD of 0.42 nM binding recombinant CEACAM6 and a KD 
of 0.26 nM binding recombinant CEACAM5. Respectively the reference C5xC6 bsAb presented a KD value of 
0.46 nM binding recombinant CEACAM6 and a KD of 0.43 nM binding recombinant CEACAM5 (Table 4, 
Figure 23A, B). The monovalent C5 oaSEED variant obtained a KD of 0.73 nM while the KD of the single 
C6 Fab fragment was determined with 0.15 nM. Kinetic parameters for reconstituted C5xC6 and reference 
antibody were in the same nanomolar range, signifying that PTS is not compromising the molecular interactions 
to recombinant cognate antigen. Furthermore, no affinity loss was observed after reconstitution of bsAb C5xC6 
compared to the monovalent and bispecific references.  
The binding affinity for reconstituted anti-CD40 was determined with 6.8 nM and compared against reference 
anti-CD40 with a KD value of 5.9 nM (Table 4; Figure S11). Thermostability analysis revealed, that 
reconstituted anti-CD40, exhibited a Tm of 69.3°C and did not differ from the reference anti-CD40 antibody with 
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a Tm of 69.7°C (Table 4; Figure S12). However, a slight difference in thermostability was observed measuring 
Tm of reconstituted C5xC6 with 66.1°C and C5xC6 reference with a Tm of 68.0°C (Table 4; Figure S12). To 
proof conformity, several reconstituted bsAbs and mAbs were compared to their naturally reference antibodies 
and precursor antibody fragments as listed in Table 4. Obtained kinetic parameters and thermostability of 
reconstituted antibodies showed in general similar binding affinities in the nanomolar range to recombinant 
antigens and similar thermostabilities compared to their reference antibodies. 
 
Table 4: Kinetic parameters of reconstituted bsAb compared to parental monovalent oaSEEDbodies, Fab fragments, 
monospecific and bispecific references.  
Reconstituted bsAb were compared to their parental monovalent antibodies, monospecific or bispecific references. Antibodies were 
captured by anti-human Fc biosensor tips and subjected to respective antigen binding. Melting temperatures were analyzed by thermal 
shift assays. (ND: Not defined.) 
Antibody Analyte KD KD error ka ka error kd kd error Tm 
  [M] [M] [M-1 s-1]          [M-1 s-1]           [ s-1]                          [ s-1]                          [°C]                        
C5xC6 Reference                 Ceacam6 4.6E -10 4.7E -12 2.1E +05 1.8E +03 9.5E -05 4.6E -06   68.0 
C5xC6 Reconstituted          Ceacam6 4.2E -10  8.4E -12 4.2E +05 2.9E +03 1.8E -04 3.3E -06   66.1 
C5xC6 Reference                 Ceacam5 4.3E -10 4.5E -12 5.9E +05 2.8E +03 2.6E -05 2.4E -06   68.0 
C5xC6 Reconstituted          Ceacam5 2.6E -10 4.2E -12 5.2E +05 2.9E +03 1.6E -04 2.3E -06   66.1 
oa C5 Ceacam5 7.3E -10 6.3E -12 2.7E +05 1.2E +03 1.9E -04 1.5E -06   ND 
C6 Fab Ceacam6 1.5E -10 1.6E -10 3.8E +04 6.0E +02 3.4E -04 2.4E -06   ND 
CD40 Reference                  CD40 5.9E -09 5.3E -11 4.9E +05 4.2E +03 2.9E -03 8.4E -06   69.7 
CD40 Reconstituted           CD40 6.8E -09 4.5E -11 5.2E +05 3.2E +03 3.6E -03 7.1E -06   69.3 
B10v5xhu225L c-MET 8.9E -10 1.1E -11 1.5E +05 6.4E +02 1.3E -04 1.6E -06   63.8 
B10v5xhu225H c-MET 8.6E -10 9.6E -12 1.8E +05 7.8E +02 1.5E -04 1.6E -06   63.5 
F06xhu225H   c-MET 5.4E -08 3.4E -11 1.5E +06 5.4E +04 8.3E -02 9.9E -04   65.3 
oa F06                                  c-MET 1.1E -08 1.0E -12 4.6E +06 5.4E +04 4.9E -02 2.2E -04   65.1 
oa B10v5                             c-MET 0.4E -10 3.4E -12 3.5E +05 1.1E +03 1.6E -04 1.1E -06   63.3 
B10v5xhu225L EGFR 2.2E -07 2.9E -10 6.1E +05 1.1E +04 1.2E -01 2.8E -03   63.8 
B10v5xhu225H 
Trastuzumab Reference 
Trastuzumab Reconst. 
EGFR 
Her2 
Her2 
1.9E -10 
1.5E -10 
2.5E -10 
3.9E -12 
8-5E -12 
6.5E -12 
3.8E +05 
8.7E +04 
9.3E +04 
1.9E +03 
2.8E +02 
2.4E +02 
7.2E -05 
1.3E -05 
2.4E -05 
1.4E -06 
7.4E -07 
6.1E -07 
  63.5 
  ND 
  ND 
 
In order to evaluate bispecificity for reconstituted antibodies, simultaneous binding of two recombinant antigens 
was performed. A stepwise association of both respective antigens was performed. Reconstituted C5xC6 was 
able to bind both CEACAM5 and CEACAM6 simultaneously as shown in Figure 23C. Recombinant EGFR 
was used as a negative control in a high concentration of 100 nM, to test unspecific binding. No binding to 
recombinant EGFR was observed with C5xC6 antibodies. Reconstituted bsAbs retained their physiological 
properties after PTS and were not inhibited by sterically obstruction during simultaneous binding of two 
distinct antigens.  
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Figure 23: Affinity comparison between reconstituted C5xC6 and reference C5xC6 bsAb binding to soluble CEACAM5 and 
CEACAM6 using BLI analysis.  
BsAbs were analyzed with ProteinA biosensor tips. KD was determined after 400 s association and 1200 s dissociation of the respective 
antigens and monitored with varying concentration of analyte over time, resulting in an interference pattern shift (nm). (A) Similar 
kinetic parameters were detected for reference C5xC6 compared to reconstituted C5xC6 illustrated in (B). (C) Simultaneous binding of 
soluble recombinant CEACAM5 and CEACAM6 by reconstituted bsAb C5xC6. Both antigens CEACAM5 and CEACAM6 are associated 
stepwise. Reference antigen recombinant EGFR was used as a negative control in high concentration of 100 nM, to test unspecific 
binding. No binding to recombinant EGFR was observed by C5xC6. 
 
It was successfully demonstrated that reconstituted antibodies were able to bind to their soluble recombinant 
antigens. Recombinant antigen binding of reconstituted antibodies was the first step to investigate, if the 
reconstitution method has an impact on antibody binding or affinity. Of course, antibodies need to perform on 
the cellular level and need to show antigen binding on the cell surface of certain cancer cell lines to finally fulfill 
their expected biological function and mode of action. To confirm specific cellular target binding, flow cytometry 
(FACS) analysis was conducted and described in the next chapter. 
 
5.3.2. Cellular antigen binding of reconstituted antibodies 
Cellular binding to target expressing tumor cells was investigated using several reconstituted antibodies. Flow 
cytometry analysis was conducted to examine cellular binding properties after antibody reconstitution with 
respect to hinge region modifications. Tumor cells MKN-45 with high cell surface receptor levels of CEACAM5 
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and CEACAM6 were used to determine target binding. A high fluorescence signal was monitored for 
reconstituted C5xC6 bsAb, indicating strong binding to related antigens. To compare potential effects on 
cellular binding behavior based on the altered hinge region after reconstitution, a C5xC6 bispecific reference 
antibody was used containing a natural IgG1 hinge region. The histograms of reconstituted C5xC6 and 
reference antibody are illustrated as overlays in Figure 24, showing similar fluorescence signals and therefore 
similar cellular binding to CEACAM5 and CEACAM6. Additionally, the monovalent antibody fragments 
C5 oaSEED and C6 Fab were used as control antibodies, resulting in slightly lower fluorescence signals 
compared to the bsAbs (Figure 24). Isotype control anti-HEL was used as a negative control and showed no 
binding to MKN-45 cells. Fluorescent signal was not detected after treatment of HEK293 Nf-κB cells with 
reconstituted C5xC6 and reference C5xC6, since HEK293 cells were not expressing CEACAM5 or CEACAM6 
(Figure 24). 
 
  
Figure 24: Cellular binding of reconstituted C5xC6 bsAb and non-reconstituted antibody fragments to cancer cell line MKN-45.  
MKN-45 cells were seeded with 1x105 vc/well and incubated with 10 µg mL-1 antibodies for 1 h. Antibodies were detected with Alexa 
Fluor 488-conjugated anti-human IgG (H+L) Fab via FACS analysis. Binding was detected with reconstituted C5xC6 bsAb and its 
corresponding monovalent antibody fragments C5 oaSEED and C6 Fab. The fluorescence signal for reconstituted C5xC6 was similar to 
the C5xC6 reference, while no signal was detected for both bsAbs on negative cell line HEK293 Nf-κb. Analysis was conducted using 
the green fluorescent channel with adjusted forward and side scatter (Guava easyCyte HT cytometer). Green: Reconstituted C5xC6; 
Blue: C5xC6 Reference; Red: oaC5-SEED-IntC; orange: C6-Fab-IntN; Black: Non-related isotype control (anti-HEL). 
 
In addition to FACS analysis of C5xC6 bsAbs, several c-METxEGFR bsAbs were investigated. Binding was 
detected with reconstituted B10v5xhu225H, B10v5xhu225L and F06xhu225H and the corresponding 
monovalent antibody fragments B10v5 oaSEED and hu225H Fab on c-MET/EGFR expressing cancer cell 
lines A549, EBC-1 and SK-BR-3. A549 cells present a medium cell surface receptor level of human c-MET  
(18.0 ± 0.6 x 103) and human EGFR (39.6 ± 0.6 x 103), while EBC-1 cells exhibit high levels for human c-MET 
(261.6 ± 1.1 x 103) and medium levels for human EGFR (62.2 ± 1.1 x 103). Weaker binding was observed with 
the monovalent antibody controls indicating that reconstituted antibodies are able to bind simultaneously to 
c-MET and EGFR (Figure 25). Reconstituted B10v5xhu225L showed low detection signals compared to 
B10v5xhu225H on A549 cells as presented in Figure 25, based on the weak affinity profile of the hu225L 
binding moiety, determined by BLI analysis (Figure S13). This pattern was observed and confirmed as well for 
binding to SK-BR-3 cells. Furthermore, a lower fluorescence signal was detected with F06xhu225H compared 
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to B10v5xhu225H consisting of different c-MET binding moieties F06 and B10v5 (Figure 25). The observation 
of lower detection levels of F06xhu225H was confirmed by BLI analysis (Figure S13). 
 
 
Figure 25: Cellular binding of reconstituted c-METxEGFR bsAbs and non-reconstituted antibody fragments to several cancer 
cell lines.  
Cells were seeded with 1x105 vc/well and incubated with 10 µg mL-1 antibodies for 1 h. Antibodies were detected with Alexa Fluor 488-
conjugated anti-human IgG (H+L) Fab via FACS analysis. Binding was detected with reconstituted c-METxEGFR bsAbs 
B10v5xhu225H, B10v5xhu225L and F06xhu225H and the corresponding monovalent antibody fragments B10v5 oaSEED and hu225H 
Fab on c-MET/EGFR expressing cancer cell lines A549, EBC-1 and SK-BR-3. Cetuximab served as an additional positive control and 
anti-HEL was used as an isotype negative control. Light green: B10v5xhu225H; Dark turquois: F06xhu225H; Dark green: 
B10v5xhu225L; Turquois: Cetuximab (positive control); Red: B10v5 oaSEED; Blue: hu225H Fab; Black line: Non-related isotype control 
(anti-HEL). 
 
In congruence, cellular binding of reconstituted anti-CD40 mAbs bearing different Fc portions were compared 
to reference anti-CD40 mAb on CD40 expressing HT1080 cancer cells, obtaining overlapping histograms and 
therefore similar detection levels after FACS analysis (Figure S14). As expected, no binding was observed by 
incubating anti-CD40 mAbs with CD40 negative MDA-MB-468 cells.  
The altered hinge region of reconstituted mAbs and bsAbs did not compromise binding to cellular targets and 
was comparable to reference antibodies. It has been proved that reconstituted antibodies bind similar to their 
specific recombinant and cellular antigens compared to their references. The final and most important question 
leads to the preservation of biological functionality after antibody reconstitution, addressing a specific mode of 
action.   
 
5.3.3. Biological functionality of reconstituted antibodies 
Biological functionality of reconstituted antibodies was evaluated in several functional cellular assays, like CD40 
surface receptor agonism, T-cell activation or c-MET and EGFR receptor phosphorylation. Reconstituted anti-
CD40 mAbs consisting of different IgG Fc backbones were compared against the published CD40 agonistic 
antibody APX005M (Apexigen). APX005M was reproduced as bivalent IgG1. An IgG1, IgG1.4, IgG1.6 and an 
IgG2 Fc backbone was used for reconstitution with anti-CD40 Fab to simulate easy effector function switch 
using split inteins. The reconstituted anti-CD40 mAbs showed similar dose response curves compared to the 
reference APX005M, resulting in an IC50 value range of 2 – 7 nM (Figure 26). A slightly higher IC50 value 
was observed using anti-CD40 IgG 1.4 with 7.3 nM compared to all other tested mAbs (Figure 26). However, 
the maximum signal asymptote for reconstituted mAbs was not as high compared to APX005M, likely through 
varying cell levels per well, responsible for luminescence signals. Furthermore, saturation of dose response 
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curves for all variants was not clearly reached. Antibody concentrations must be adjusted to reach signal 
saturation for a better IC50 value statement (Figure 26). Differences in signal detection could also potentially 
be evidence for the modified hinge region after PTS. 
 
 
Figure 26: CD40 activation by reconstituted anti-CD40 agonist antibodies.  
CD40 expressing HEK293 cells containing a modified Nf-κb pathway triggering luciferase production were seeded with 2.5x104 vc/well 
and treated with reconstituted anti-CD40 antibodies in different concentrations ranging from 0.002 nM to 200 nM. BioGlo Luciferase 
substrate was added for luminescence readout. Luminescence signal was monitored and relative luminescence units (RLU) are 
representing normalized luminescence to untreated cells. Tested reconstituted anti-CD40 antibodies showed similar luminescence 
signals for CD40 activation. Reference antibody APX005M showed slightly higher detection signal and was used as a positive control 
while Trastuzumab was used as a negative control. LPS is known to influence certain cell assays and was added up to a concentration of 
500 nM as an assay control, showing no signal detection. TCEP and DHAA were added to see potential luminescent signal interference. 
Number of measurements: Triplicates for each concentration. 
 
Lipopolysaccharide (LPS) was added in different concentrations from 0.005 nM to 500 nM to observe potential 
luminescence signaling based on the assumption that LPS is known to interfere with several cellular assays 
(Figure 26). In addition, TCEP and DHAA was added in dose concentrations to eliminate false positive 
signaling. LPS, TCEP and DHAA or their mix did not lead to luminescence signal elucidation and therefore not 
influencing the cell assay readout. 
BsAbs CD3xHer2 either bearing a Her2 Fab binding arm or a Her2 VHH binding moiety were reconstituted 
and used to evaluate the ability of reconstituted bsAbs to trigger an often-desired mode of action. T-cell 
activation was assessed by effector cell engagement to Her2 overexpressing cancer cells SK-BR-3 after 
incubation with reconstituted bsAbs. Jurkat effector cells with a modified NFAT pathway initiated a luciferase 
reporter readout. Specific cellular binding to human T-lymphocyte expressing CD3 Jurkat E6.1 cells and Her2 
expressing SK-BR-3 cells by reconstituted CD3xHer2(Fab) was preliminary proved by flow cytometry 
(Figure S15). Reconstituted CD3xHer2(Fab) and CD3xHer2(VHH) T-cell engagers performed with similar 
potencies after T-cell activation within an EC50 range between 0.3 nM and 0.5 nM (Figure 27). Treatment 
with monospecific CD3 oaSEED alone with effector and cancer cells was not elucidating strong signal increase, 
although a slight increase at a concentration of 100 nM was observed, likely through clustering of CD3 oaSEED 
(Figure 27). Cetuximab was used as a negative control and was not triggering luminescence signaling, as 
expected based on the lacking CD3 paratope. The influence of TCEP and DHAA was not altering the assay 
signal readout (Figure 27). 
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Figure 27: T-cell activation through reconstituted CD3xHer2 bsAbs.  
SK-BR-3 cancer cells exhibiting high levels of surface receptor Her2 were used as antigen presenting cells and were incubated with 
reconstituted CD3xHer2 Fab (blue) and CD3xHer2 VHH (green) in different concentrations ranging from 0.01 nM to 100 nM. Cancer 
cells and reconstituted antibodies were treated with TCR/CD3 (NFAT) effector cells (Jurkat) and incubated for 6 h. CD3xHer2 bsAbs 
are able to bind Her2 on SK-BR-3 and CD3 on modified Jurkat cells, stimulating NFAT luciferase activity. BioGlo Luciferase substrate 
was added for luminescence readout. Luminescence signal was monitored and relative luminescence units (RLU) are representing 
normalized luminescence to untreated cells. TCEP (red), DHAA (dark orange) and their mix (dark red) was added in dose concentrations 
to evaluate potential signal increase and assay interference. Cetuximab (orange) was used as a negative control not comprising a CD3 
binding moiety. Monospecific anti-CD3 oaSEED (grey) was used as negative control for potential elucidation of luminescence signaling. 
 
Further evidences for reconstituted bsAb functionality was achieved and demonstrated by inhibition of c-MET 
and EGFR phosphorylation. A549 cancer cells, offering moderate c-MET and EGFR expression levels, were 
treated with c-METxEGFR bsAbs B10v5xhu225H and F06xhu225H and stimulated with or without HGF and 
EGF. Retained phosphorylation inhibition of c-MET (p-c-MET) and EGFR (p-EGFR) was observed by 
B10v5xhu225H and F06xhu225H without treatment of EGF and HGF, as already described in literature,84 
indicating functionality of c-METxEGFR bsAbs after reconstitution (Figure 28).  
 
 
Figure 28: Inhibition of c-MET and EGFR phosphorylation by reconstituted c-METxEGFR bsAbs.  
A549 cells with moderate c-MET and EGFR expression levels were used to verify c-METxEGFR bsAb functionality by inhibiting 
receptor phosphorylation. Cells were incubated with 300 nM bsAbs B10v5xhu225H, F06xhu225H, Cetuximab and isotype control anti-
HEL after starvation (medium without FCS) of the cells and stimulation with or without recombinant EGF (50 ng/well) and HGF 
(30 ng/well).  Cells were treated with RIPA buffer for 1 h and cell lysates were prepared for SDS-PAGE and Western Blot analysis. 
Phosphorylated c-MET and EGFR was detected by specific AP-labeled phospho-c-MET or phospho-EGFR secondary antibodies. 
B10v5xhu225H and F06xhu225H showed successfully inhibition of c-MET and EGFR simultaneously. Cetuximab showed only 
phosphorylation inhibition of EGFR but no inhibition for c-MET, while isotype control anti-HEL showed no inhibition for both. Control: 
No antibody treatment. 
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Cetuximab was used as a positive control for p-EGFR inhibition, while no inhibition of p-c-MET was observed 
(Figure 28). Anti-HEL was used as an isotype negative control showing no inhibition of either p-c-MET or 
p-EGFR. 
In summary, biological functionality of reconstituted mAbs and bsAbs was successfully demonstrated using 
several different cellular assays and antibody combinations. The reconstitution method can produce functional 
antibodies without restrictions in activity but downscaling for the implementation into an HTS platform must 
be ensured. Before an automated method can be set up, it must be ensured that transferring the reconstitution 
method to a plate format does not affect the antibody properties. 
 
5.4. Downscaling of antibody reconstitution to 96 well format and automation suitability 
Antibody reconstitution of mAbs and bsAbs was transferred and miniaturized into a 96 well plate format to 
make the technology amenable for HTS. In order to investigate if antibody reconstitution still works in small 
volumes, a manual pipetting approach was conducted and compared against a semi-automated experiment using 
the Hamilton MicroLab Starlet liquid handler system. Furthermore, the reconstitution efficiency was 
investigated between both approaches. As a proof of concept, a surplus of anti-CD40 Fab IntN fragments were 
mixed with an IgG1 Fc IntC portion by manual pipetting, resulting in reconstituted anti-CD40 mAb, using a 
final volume of 200 µL. All wells were analyzed for reproducibility. Figure 29 shows a subset out of n = 80 
replicants after antibody reconstitution. The whole 96 well plate analysis is shown in Figure S16.  
 
Figure 29: Electronical SDS-PAGE analysis of antibody reconstitution used to demonstrate downscaling and reproducibility 
in a 96 well format.  
A subset of the whole 96 well plate is illustrated and a surplus of anti-CD40 Fab IntN was used in a ratio 3:1 over huFc IntC. A1: Single 
anti-CD40 Fab IntN (61.5 kDa). B1: single huFc IntC (63.5 kDa). A2 to A9: Antibody fragments anti-CD40 IntN and huFc IntC were 
mixed in a ratio 3:1 and 0.5 mM TCEP was added for PTS activation. Reconstituted antibodies were separated from non-reconstituted 
antibodies anti-CD40 Fab IntN and huFc IntC by addition of 25 µL Ni2+ beads with a binding capacity of 40 µg 25 µL-1 and further treated 
with a 10-fold molar excess of DHAA over TCEP for re-oxidation. Gel bands for reconstituted anti-CD40 antibodies were observed at 
145.7 kDa under non-reduced conditions. A10-A11: Not treated with Ni2+ beads after reconstitution reaction, resulting in reconstituted 
anti-CD40 antibody as well as antibody fragments anti-CD40 IntN and huFc IntC. A12: Antibody fragments anti-CD40 IntN and 
huFc IntC after TCEP treatment without the addition of Ni2+ beads and DHAA (control). Gel band at 1 kDa (green): Lower Marker 
(LM). Blue band below 16 kDa: System Peak. The whole gel panel of the 96 well plate analysis is shown in Figure S16. 
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Wells A12 and B12 were not treated with Ni2+ beads and DHAA after PTS reaction, serving as a negative 
control (Figure 29). Wells A2-A11 and B2-B11 contained full-length reconstituted anti-CD40 mAb, indicated 
by a gel band at 145.7 kDa and monitored by SDS-PAGE analysis. However, the band sizes of the final product 
in the gel were not uniform, likely through manual pipetting and resulting volume variations in each well upon 
normalization of the reconstituted antibody concentration. Non-reconstituted antibody Fab IntN fragments 
(61.8 kDa) were still present in wells not treated with Ni2+ beads and captured successfully in wells treated with 
Ni2+ beads, indicating the importance of the purification strategy (Figure 29, wells A10-11, B10-11).  
Binding of reconstituted anti-CD40 mAbs to recombinant human CD40 was conducted and confirmed by ELISA 
(Figure 30). The absorbance signal at 450 nm was slightly varying and non-uniform throughout the whole 
96 well plate, as already observed by SDS-PAGE analysis for manual antibody reconstitution (Figure 29, 
Figure 30B). For negative controls and wells without TCEP treatment or lacking the monovalent Fab IntN and 
Fc IntC counterparts, no signals were observed (Figure 30A/B).  
 
 
Figure 30: ELISA readout of reconstituted anti-CD40 mAbs in 96 well format semi-automated by Hamilton MicroLab Starlet 
liquid handler compared to manual pipetting.  
 
Antibody reconstitution was performed in 96 wells, mixing anti-CD40 Fab IntN with huFc IntC in a 3:1 molar ratio with 0.5 mM TCEP 
in a final volume of 200 µL resulting in a total protein amount of 58 µg. Non-reconstituted antibody fragments anti-CD40 Fab IntN and 
huFc IntC were removed by 25 µL Ni2+ beads with a binding capacity of 40 µg/25 µL supported by a strong magnet (semi-automated 
(A)) and reconstituted anti-CD40 mAbs were supplemented with a 10 fold molar excess DHAA over TCEP for re-oxidation. ELISA was 
performed after binding recombinant human CD40 with reconstituted mAbs and detected with a Fc specific goat-anti-human IgG 
conjugated to peroxidase at absorbance 450 nm. (A) Overall absorbance signal of semi-automated antibody reconstitution in 96 well 
plate format after ELISA. (B) Overall absorbance signal of manual generated antibody reconstitution in 96 well plate format after ELISA. 
Negative controls anti-CD40 Fab IntN, huFc IntC and both fragments combined without TCEP treatment showed no absorbance signal. 
 
The semi-automated reconstitution was compared against the manual reconstitution, to avoid errors and 
variations observed as slightly uniformity throughout the 96 well plate after SDS-PAGE and ELISA analysis. 
A normal distribution was generated from the ELISA readout with n = 80 replicates (Figure 31). The 
reconstitution efficiency was improved up to 15% using the semi-automated system by calculating the mean 
variation of the overall signal absorbance of each experiment, estimated by ELISA (Figure 31). The overall 
signal absorbance of the semi-automated reconstitution showed a more precise uniformity after ELISA readout, 
compared to the manual reconstitution, indicating the importance and demand of an automated system.  
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Figure 31: Comparison of reconstitution reproducibility between semi-automated and manually generated mAbs in 96 well 
format.  
ELISA was conducted manually and semi-automated via Hamilton liquid handler after reconstitution of anti-CD40 Fab IntN and huFc 
IntC fragments in 96 well plate format. A normal distribution of both experiments with n = 80 antibody reconstitutions was generated 
via GraphPad Prism v7. The calculated mean variation of each conducted experiment was compared with each other giving a 15% 
improvement of reconstitution reproducibility by semi-automation. The amplitude displays the density function f(x) calculated with 
equation 4 (Chapter 4.5.3). 
 
It was successfully demonstrated that neither antibody reconstitution is compromised by downscaling into a 
96 well plate format, nor the purification strategy to remove non-reconstituted antibody fragments. An 
automated system improves the reconstitution efficiency and therefore improves the accuracy of generating 
bsAbs for HTS. HTS platforms serve as massively cost and time saving applications and therefore an even 
smaller plate format of 384 wells and a fully automated system is desired. A fully automated system further 
benefits the operating expense. The next chapter describes a fully automated reconstitution approach and the 
investigation to further miniaturize the reconstitution method into a 384 well plate format without the 
limitations of a semi-automated approach. 
 
5.5. Fully automated production of reconstituted antibodies designed for HTS in a 384 well 
format 
Based on the investigations described in Chapter 5.4, antibody reconstitution was transferred into a 384 well 
plate format and generated fully automated, using the BiomekFX HT platform. To compare the reconstitution 
results of Chapter 5.4, anti-CD40 mAbs were used again as a proof of concept. Each well was supplied with 
anti-CD40 Fab IntN fragments and IgG1 Fc IntC portion for antibody reconstitution and tested for 
reproducibility. ELISA was used as a readout for reconstituted anti-CD40 mAbs after binding to recombinant 
human CD40. Similar overall absorption signals were observed for the 384 well plate reconstitution compared 
to the semi-automated reconstitution in 96 well plates (Figure 32A). A slight non uniform absorbance signal 
was observed and is depicted in Figure 32A as a heat map, illustrating each single well of the whole plate. The 
automated pipetting for antibody reconstitution molecules and reagents was conducted row by row and might 
lead to concentration variations in each well. Furthermore, reconstituted antibody concentration was 
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normalized and could account for absorption signals inconsistencies, although the signal range variation is 
negligible small. 
 
Figure 32: Fully automated anti-CD40 mAb reconstitution and functionality determination in 384 well using the BiomekFX 
HT platform.  
Antibody reconstitution was performed in 384 wells, mixing anti-CD40 Fab IntN with huFc IntC in a 2:1 molar ratio with 0.5 mM TCEP 
in a final volume of 40 µL resulting in a total protein amount of 14 µg. Non-reconstituted antibody fragments anti-CD40 Fab IntN and 
huFc IntC were removed by 14 µL magnetic Ni2+ beads with a binding capacity of 40 µg/25 µL supported by a strong magnet and 
reconstituted anti-CD40 mAbs were supplemented with a 10 fold molar excess DHAA over TCEP for re-oxidation. ELISA was 
performed after binding recombinant human CD40 with reconstituted mAbs and detected with a Fc specific goat-anti-human IgG 
conjugated to peroxidase at absorbance 450 nm. (A) Overall absorption signal of fully automated antibody reconstitution (E-V) in 
384 well pate format after ELISA. Each column starting from E to V represents a cluster of 16 wells including the mean with standard 
deviation for each cluster. The heat map shows signal detection at 450 nm after performed ELISA for each well in the 384 well plate. (B) 
Antibody functionality of automated reconstituted anti-CD40 mAbs was determined by CD40 activation assay. Human CD40 expressing 
HEK293 cells were treated with 4 nM reconstituted antibodies (E-V), 200 nM APX005M (positive control) and 200 nM Trastuzumab 
(negative control) for 6 h activating an engineered Nf-κB pathway for luciferase transcription. Luminescence signal was recorded and 
relative luminescence units (RLU) are representing normalized luminescence to untreated cells. The heat map illustrates CD40 activation 
for each single well on the plate. Error bar: Mean with standard deviation (SD). 
 
Pharmaceutical antibody development highly demands broad functional screening capacity and therefore, 
reconstituted anti-CD40 mAbs, generated from fully automated 384 well reconstitution, were used without 
further treatment to perform a feasibility study in a functional CD40 activation cell assay (Figure 32B). Parental 
CD40 agonist APX005M and Trastuzumab were used in a concentration of 200 nM as references showing 
expected activation signal or no signal respectively. All reconstituted anti-CD40 mAbs were inducing CD40 
activation at a concentration of 4 nM, as already investigated previously (Figure 26). The overall luminescence 
signal after CD40 activation seemed to show well dependency, as indicated by the heat map depicted in 
Figure 32B, likely through varying cell levels per well by manual pipetting. However, antibody reconstitution 
was successfully miniaturized to 384 well plate format and furthermore improved by a fully automated platform 
amenable for HTS and enlarged screening capacities, including biological functionality of the tested 
reconstituted antibodies.  
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5.6. Quantification for HT antibody reconstitution by HTRF analysis suitable for 1536 well 
format 
HT reconstitution of antibodies offers a full spectrum of molecules in different formats being produced and 
screened. Therefore, a critical look into the products and byproducts and also the amounts of undesired products 
remaining following reconstitution have to be considered. One way to prove efficient and reproducible 
reconstitution rates is the determination by Homogenous Time Resolved Fluorescence (HTRF) quantification 
suitable for 1536 well plate format. Biotin labeled Fab IntN fragments were reconstituted with oaSEED IntC 
fragments and quenched at specific time points to track the reconstitution rate (Figure 33A). Antibody 
reconstitution was not compromised by Fab IntN fragments labeled with biotin, as detected by SE-HPLC 
analysis used for cross validation of reconstituted bsAb (Figure 33B). Antibody reconstitution was stopped after 
3 h yielding >90% non-purified bsAb, determined by SE-HPLC. A similar pattern was observed after HTRF 
analysis and fluorescence signal reached its maximum after 3 h (Figure 33C). No fluorescence signal was 
detected using negative controls single oaSEED IntC and single biotinylated Fab IntN after treatment with anti-
human IgG-Tb and Strepdavidin-d2. Fluorescence signal will only be detected, when both antibody fragments 
are present.  
 
 
Figure 33: Quantification of HT antibody reconstitution efficiency determined by cross validation of SE-HPLC and HTRF 
analysis in 1536 well format.  
Antibody fragment Fab IntN with a molar concentration of 0.1 mM was biotinylated with a molar excess (1:10) of NHS-PEG4-Biotin 
and incubated at RT for 0.5 h. Residual non-reacted NHS-PEG4-Biotin was removed by Zeba Spin desalting columns. Biotinylated Fab 
IntN fragment was reconstituted with an oaSEED IntC fragment in an equimolar ratio and quenched at different time points with H2O2 
to stop PTS. HTRF was performed by adding reconstituted bsAbs diluted at 0.1 µM with terbium buffer, PBS pH 7.4 and 0.3% Tween-20 
to each well. Strepdavidin-d2 (100 µg mL-1) and IgG-Tb (10 µg mL-1) was added to a final volume of 5 µL per well and incubated for 4 h. 
(A) BsAb reconstitution with biotinylated Fab IntN and oaSEED IntC attached to anti-human IgG-Tb cryptate. Successful reconstitution 
resulted in FRET signaling. (B) HPLC analysis of reconstituted bsAb at several time points quenched with H2O2 for cross validation. 
(C) HTRF fluorescence detection at several time points. Data reduction was performed by normalization of background noise of the 
donor for each well, minimizing well to well variations and normalization of the measurements, to minimize plate to plate variations. 
The fluorescence signal was measured at 620 nm and 665 nm. (D) Correlation between HPLC and HTRF analysis calculated as standard 
curve and coefficient of determination.  
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The fluorescent signal increase over time, indicated that energy transfer of the fluorophores will only occur if 
biotinylated Fab IntN is in close proximity to anti-human IgG-Tb attached to the Fc portion of oaSEED IntC. 
Figure 33C illustrates the fluorescence signal increase over time after reconstitution of both antibody fragments 
bringing both fluorophores to the demanded distance. The addition of TCEP and DHAA needed for antibody 
reconstitution was not influencing the HTRF assay system. A correlation between HPLC and HTRF data shows 
a high coefficient of determination with R2 = 0.992, indicating that HTRF analysis displays comparable amounts 
of reconstituted bsAb and therefore suitable for reconstitution quantification and generation in a 1536 well 
format (Figure 33D). 
Antibody reconstitution was conducted in 96 and 384 well plate format and could potentially be used in a 
1536 well format revealed by HTRF quantification observations. Reproducibility and biologically functional 
anti-CD40 mAbs were generated in a high throughput manner and tested in functional assays. The ultimate 
goal is to address the reconstitution technology to screen for bsAb combinations to find a possible lead candidate 
out of a huge antibody repertoire. It is of importance to investigate the screening potential of this method, which 
is described in detail in the following chapter. 
 
5.7. Combinatorial screening of reconstituted antibodies for possible lead candidate 
identification  
Antibody reconstitution was proved to be amenable for fully automated HT (Chapter 5.5) and was further 
investigated with respect to combinatorial screening. Several bsAbs were reconstituted simultaneously, bearing 
different binding moieties, to demonstrate screening potential based on higher and lower affinity profiles 
(Figure 34). Reconstituted bsAbs were analyzed by BLI, flow cytometry or ELISA for retained binding 
properties. Reconstituted c-METxEGFR bsAbs B10v5xhu225L and B10v5xhu225H showed similar 
biophysical binding properties for B10v5 with a binding affinity of 0.8 nM against recombinant c-MET 
(Figure S13). Binding to recombinant EGFR of the hu225H Fab arm was detected with 0.18 nM and had 
considerably higher affinity compared to hu225L with 0.2 µM (Figure S13). Stepwise association to 
recombinant c-MET and EGFR using reconstituted bsAbs B10v5xhu225L and B10v5xhu225H, confirmed 
simultaneous binding of both antigens after BLI analysis. Monospecific B10v5 oaSEED was used to determine 
unspecific binding to EGFR, but only binding to c-MET was observed, as expected (Figure S13). Cellular 
binding of cell surface receptor antigens c-MET and EGFR was confirmed by incubating reconstituted bsAbs 
B10v5xhu225L, B10v5xhu225H and F06xhu225H with several cancer cell lines, offering moderate to high 
expression levels of antigen, as described previously (Chapter 5.3.2, Figure 25). ELISA was performed after 
reconstitution of bsAbs to illustrate differences in signal detection and therefore screening capability for 
different bispecific combinations. F06xhu225H showed lower signal absorbance after binding recombinant 
c-MET, compared to B10v5xhu225H after ELISA analysis based on a much lower affinity profile of F06 over 
B10v5 (Figure 34). No signal detection was observed with B10v5xhu225L, binding to recombinant EGFR 
based on the low affinity profile of 0.2 µM (Figure 34), which was confirmed by BLI analysis (Figure S13). 
High signal detection was achieved with B10v5xhu225H based on the high affinity to EGFR.       
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Figure 34: Antibody reconstitution using different formats and combinations to investigate screening feasibility.  
Several bsAbs B10v5xhu225L, B10v5xhu225H, F06xhu225H, C5xC6 and mAbs anti-CD40 IgG1 were reconstituted simultaneously in 
96 well plate format, according to previously described reconstitution conditions. The absorbance signal at 450 nm was measured after 
binding of bsAbs and mAbs to their respective recombinant antigens after detection with POD labeled anti-human Fc specific antibody. 
Reconstitution reproducibility was ensured by 4-7 replicants of each reconstituted variant.  
 
Binding to recombinant CEACAM6 was successfully demonstrated by reconstituted bsAb C5xC6 exhibiting 
strong binding affinities against the recombinant antigen, as determined previously (Chapter 5.3.1, Figure 23).   
Furthermore, reconstituted anti-CD40 mAbs showed reproducible absorbance signals, when compared to above 
mentioned experiments (Chapter 5.5, Figure 32A). Reconstitution reproducibility was confirmed by 
4-7 replicants as illustrated in Figure 34. Several in parallel reconstituted bsAbs and mAbs were showing 
expected signal detection after binding to their respective antigens, indicating that antibody reconstitution by 
PTS in different formats and combinations is feasible for HT.
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6. Discussion  
 
6.1. Generation of reconstituted antibodies in different formats mediated by PTS 
The evaluation of complex NBEs such as bispecific antibodies for therapeutic development remains challenging 
due to extensive cloning steps followed by expression and purification until the optimal lead candidate is 
discovered. Furthermore, chain mispairings and homodimerization occurs during antibody expression, leading 
to low product quality and yields. In course of this study, the recombination of antigen binding arms is forced 
by the attachment of split intein parts introduced in the hinge region fused to their native exteins, activating 
PTS in a mild reducing environment. The split intein mediated bsAb reconstitution offers a way to bypass above 
mentioned limitations by fusing a single Fab fragment to a one-armed heterodimeric Fc fragment on the protein 
level in vitro. Split intein parts are fused N-or C-terminally within the hinge region and remain distal from the 
Fc portion and the paratope region of the Fab, providing no alteration of effector functions and antigen binding. 
Therefore, it is not surprising, that bsAb functionality is retained after reconstitution, as the split intein parts 
are excised out of the combination partners giving rise to stable bsAbs. 
The relatively large distance between Fab arms and Fc portion due to separation by the hinge region allows for 
the most appropriate space and flexibility to perform PTS.30,31 It was successfully demonstrated that the addition 
of TCEP in the nanomolar concentration range, as needed for PTS activation, does not lead to LC shuffling 
during generation of bsAb reconstitution with two different LCs. These observations were confirmed by the 
study of Han et al. To create a reducing environment, TCEP was used based on its properties to be compatible 
with Ni2+ IMAC affinity purification, unlike dithiothreitol (DTT), which was also been successfully tested and 
used for PTS ligation in this study and by others. Furthermore, TCEP is a milder reducing agent compared to 
DTT, primarily reducing interchain disulfide bonds.148 
A re-oxidation step to recover disulfide bridging is usually carried out gently by dialysis over time to strip out 
the reducing agent and supply the antibody solution with fresh buffer. To make the reconstitution technology 
suitable for HTS, dialysis is not the first choice for re-oxidation, although several filters or desalting columns 
are available even for HT scale to perform buffer exchanges. In this study, TCEP is inhibited in its power by 
the addition of a 10-fold molar excess of DHAA over TCEP to avoid excessive desalting steps. Furthermore, 
TCEP is not very stable at neutral pH in phosphate buffers and tend to oxidate within 72 h which favors the re-
oxidation process. Although studies have shown that DHAA can be reduced by TCEP as well and long-term 
stability investigations of reconstituted antibodies have to be performed to check intact disulfide bonds over 
time.149 In addition, antibody oxidation can affect structural functionality (Methionine oxidation) and must be 
investigated. Reference antibody APX005M reached a higher signal level compared to reconstituted anti-CD40 
mAbs conducting CD40 activation experiments. The addition of TCEP and DHAA might cause effects on cell 
viabilities during treatment with these reagents. Alternative split inteins, not dependent on reducing 
environments to perform PTS, could be a potential solution to bypass antibody re-oxidation. Similar splicing 
kinetics compared to the well characterized and fast split intein Npu DnaE were achieved and reported in several 
studies by using other split intein variants without the dependency on a reducing environment.150 PTS is 
initiated by either a pH shift or a temperature shift and sufficient for high splicing efficiency. The cysteine-less 
 
6. Discussion  79 
split intein Aes, recently engineered by Bhagawati et al., combines optimal reaction conditions with good splicing 
properties and might be an alternative for reconstituted bsAbs, like T-cell engagers.146 The effector cell 
recruitment, extracted from human blood, is very sensitive and might not be compatible with TCEP or DHAA 
during screening campaigns.146 
Other groups like Alam et al., described in an elegant way to reconstitute monospecific antibody fragments in 
different formats using a SpyTag/SpyCatcher protein ligase system.107 The system can be extended by other 
ligase systems to generate bispecifics. However, the generation of bsAbs using the SpyTag/SpyCatcher 
technology is leaving a significant imprint of 23 amino acids within the molecule after protein ligation.108,151  
T-cell engagers offer the ability to rearrange target and effector cells by simultaneous attachment through their 
binding moieties and therefore, the format matters in terms of flexibility and paratope distances, to achieve high 
potency engagement.152 Reconstituted bsAbs using the SpyTag/SpyCatcher technology, would drastically 
increase the flexibility and the paratope distances compared to the naturally IgG format and alter the 
engagement potential. Reconstitution with split inteins leaves by far a decreased scar of 6 amino acids within 
the molecule after performing PTS. Furthermore, this scar can be reduced to 2 – 3 amino acids at position +1 
to +3, only leaving the C-terminal Extein “CFN” or “CF” respectively, inside the molecule. The N-terminal 
Extein “AEY” at position -1 to -3 seems to have no significant impact on splicing efficiency and recognition of 
the N-terminal split intein part.153,154 Of note, altering the native extein sequences can lead to side reactions in 
terms of C- or N-terminal pre cleavage not able to achieve the desired product anymore.138  
Therefore, antibody reconstitution mediated by split inteins allows for closer in-format bsAbs and improves the 
chance to efficiently engage target and effector cells. Reconstituted T-cell engagers mediated by split inteins 
are providing good or even better potency engagement compared to a classic produced reference, as investigated 
by Han et al.66 Cytotoxic potential in the presence of tumor and T-cells initiating T-cell activation was reported 
and successfully demonstrated in vitro and in vivo. These observations support the aspect that cellular functional 
assays can be conducted using reconstituted antibodies resulting in high potencies. However, the addition of a 
non-native amino acid sequence in form of exteins attached to each split intein part must be considered and 
might cause molecular structural alteration and therefore modifications in biological functionality. 
Computational modeling could be used to define which amino acid residues could be omitted within the hinge 
region in order to achieve the same length and flexibility in screening with the required residues, as later in the 
genetically correctly fused molecule. This would allow for final format and functional screening of bsAbs. 
Furthermore, C-terminal fusions at the Fc portion commonly extended by GS-linkers would be conceivable. 
Labrijn et al. 2013 published a technology to generate bsAbs efficiently by controlled Fab-arm exchange former 
known as DuoBodies.43,44 Duobodies are forming full-length in format bispecific IgGs, but however they are 
restricted to a full-length IgG format. The split intein technology presented in this study, allows for 
reconstitution in several formats, changing the valency and specificity of bivalent IgGs, heterodimeric Fc 
bispecifics and IgG fusion with Fabs and VHHs. Split inteins are not limited to antibodies and furthermore, non-
antibody Fc fusions like cytokine traps can be added to the format portfolio. Since the optimal format and 
combination for a new biological entity with a specific mode of action is unknown, split inteins offer the 
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possibility to screen not only for the best combination of paratope moieties but also for the best format itself to 
access the desired mode of action.  
The manufacturability of antibody fragments fused to split intein parts as starting material for antibody 
reconstitution, more specifically the secretion yield after transfection of HEK293F cells, is comparable to 
antibody fragments lacking a split intein partner. Although it was observed that some antibody fragments, like 
hu225H Fab IntN and other fragments attached to the N-terminal split intein part are lower in expression yield.  
The split intein parts IntN and IntC are not forming a conformational complex unless PTS is activated. The IntN 
part exposes a high content of hydrophobic patches, which potentially could lead to aggregation or degradation 
because of the long unfolded protein structure of the split intein sequence, linker and purification tag. In case of 
a mis- or unfolded protein, several antibody fragments fused to IntN and IntC have been produced at higher 
concentrations ranging from 1 mg mL-1 up to 13 mg mL-1 to show robustness of the starting material. 
Aggregation was not observed for constructs used in this study and allowed for good yields with high 
monomeric content. However, the production of VHH or scFv fragments fused to IntN in E. coli highly favors 
inclusion body formation (data not shown).  
 
6.2. Evaluation of reconstitution efficiency, biophysical and functional characterization 
Han et al. already demonstrated initial success in generating a bsAb reconstituted by split inteins. Therefore, 
the development of an HTS platform for bsAbs was the focus of this project and offers an advanced purification 
strategy optimized for automation. One of the main differences compared to the study of Han et al. is the 
construct design and therefore the purification strategy ensured by fused hexahistidine tags upstream and 
downstream of the respective split intein parts, which are removed again after PTS. Han and coworkers needed 
to purify their split intein constructs by two extensive purification steps via Protein A purification followed by 
IMAC to remove non-reconstituted antibody fragments. Here, a molecular design was described, allowing for a 
one step purification via IMAC by addition of Ni2+ beads, without buffer exchange or elution of the desired 
reconstituted antibody. The reconstituted antibody remains tag less after PTS, while spliced split inteins still 
carry the hexahistidine tag for purification. The purification of product related impurities during bsAb 
production remains a manufacturing challenge. Especially small-scale expressions for screening applications 
cannot be supported by extensive purification steps.41,155 Therefore, non-reconstituted antibody fragments and 
processed split intein can be trapped with high affinity by Ni2+ beads. It was successfully demonstrated that non-
reconstituted antibody fragments, as well as the spliced intein parts were removed after Ni2+ bead treatment, 
boosting the monomeric content of the desired reconstituted product to good quality and yield. A high 
monomeric content of reconstituted antibodies also depends on the correct molar ratio of the precursor antibody 
fragments.  Especially for mAb reconstitution the molar ratio of 2:1 antibody fragments IntN and IntC 
respectively is important. If the molar ratio is unbalanced, the chance of half-bodies might occur, bearing only 
one Fab fragment fused to the Fc portion. With respect to HTS amenability, it is of importance to analyze 
byproducts and product related impurities like half-body formation, which might compromise functional 
screening assays. Choosing the optimal molar ratio of precursor antibody fragments fused to their intein parts 
showed quantitatively conversion as demonstrated in this study.  
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Furthermore, the long stretch of 26 amino acids containing a 4x G4S-Linker plus hexahistidine tag attached to 
the IntC, is not compromising the PTS reaction. Split intein parts still had enough space to form a conformational 
complex. However, Npu DnaE is known to complete splicing within minutes. In this study, antibody 
reconstitution was completed after 2 h yielding a high monomeric content of reconstituted antibody. The 
additional linker and purification tags might lead to a slower PTS reaction by disturbing the split inteins to 
form a fast-conformational structure. Despite of these potential drawbacks, high reconstitution yields, and more 
importantly correct final molecule assembly were confirmed by intensive biochemical characterization and mass 
spectrometry.  
Reconstituted bsAbs and mAbs were generated in several formats and were further characterized in terms of 
their biophysical and biochemical properties compared to their previously reported parental antibodies84,156, 
providing similar kinetic properties, thermostability, and biological functionality. Slight variations in 
thermostability were observed for reconstituted bsAb C5xC6 compared to reference C5xC6, likely through the 
modified hinge region based on remaining extein sequences. Inhibition of p-c-MET and p-EGFR, T-cell 
engagement, CD40 activation and bispecific binding was demonstrated for several reconstituted antibodies 
resulting in comparable functionalities compared to their references. The impact of used reagents TCEP and 
DHAA in several biophysical and biochemical experiments did not lead to a false positive signal increase or 
disturbance of the assays itself. The high dilution rates to picomolar or nanomolar concentrations used for 
reconstituted antibodies in functional cellular assay systems might extenuate the use of these reagents. 
Noteworthy, the concentrations used for reconstitution reagents TCEP and DHAA did not lead to a 
luminescence signal detection after conducting CD40 activation but may have an effect on cell viabilities of 
CD40 expressing HEK cells. The lower detected signal of reconstituted anti-CD40 mAbs compared to the 
APX005M reference antibody might result from insufficient cell levels based on these concentration ranges. 
Furthermore, the modified hinge region by an additional cysteine derived from the extein could potentially lead 
to newly formed disulfide bonds during the reduction and re-oxidation conditions after antibody reconstitution 
and therefore leading to a geometrically change and flexibility of the molecule compared to the natural 
unmodified IgG reference. Formation of byproducts with different HC-HC or HC-LC pairing might occur and 
account for the different maximum detection levels after CD40 activation. Further investigation of the potential 
influence of reconstituted anti-CD40 mAbs for CD40 activation or the used reagents TCEP and DHAA would 
be needed with critical look into byproduct formation. Various reconstituted bsAbs have confirmed the 
applicability of split inteins for bispecific functional HTS in various assays not specifically screened for 
compatibility. All conducted cell assays were suitable for reconstituted antibody functional screening not 
causing any obstruction.  
 
6.3. Miniaturization and high throughput feasibility of antibody reconstitution  
It is a growing trend to miniaturize biological assay systems and implement automated systems and robotic 
technology based on the rapidly growing repertoire of new promising therapeutic targets in pharmaceutical 
industry. The advantages of automated systems combined with HT feasibility are cost reducing and offer the 
possibility to screen for an increased number of hit candidates in less time. DNA and protein microarrays are 
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one of the best examples for assay miniaturization. Antibody reconstitution by split intein mediated PTS was 
miniaturized starting from manual low throughput to industrialized robotic HTS by applying the technology 
to 96, 384 and 1536 well formats. Downscaling the reaction volumes for each well format did not compromise 
the reconstitution efficiency and the reaction itself. It was successfully demonstrated that Ni2+ beads can be 
distributed in each well of a 384 well plate been able to trap non-reconstituted antibody fragments and spliced 
intein parts. The ELISA readout provided a minor signal variation throughout the plate, likely from 
concentration differences for each well upon automatic pipetting but delivers robust signal to noise ratio for 
broad HTS campaigns. 
The one pot purification described for non-reconstituted antibody purification might be further applicable for 
unpurified antibody fragments directly after secretion with unknown concentrations. The split intein Npu DnaE 
is able to perform PTS in conditioned medium after antibody fragment expression without further purification 
(Figure S17). Potentially an already purified antibody fragment can be spiked into the expression of the 
counterpart antibody fragment for reconstitution or a combination of both antibody fragment expressions could 
be mixed for reconstitution without extensive preliminary purification steps. Non-reconstituted antibody 
fragments are removed by Ni2+ beads as discussed above. Small scale implementation for automated antibody 
fragment expression prior to antibody reconstitution could extend and improve the automation setup. 
HTRF analysis offered a fast and efficient data set about antibody reconstitution rates in 1536 well format. 
Although not detecting impurities in form of non-reconstituted antibodies, HTRF experiments revealed that 
antibody reconstitution is amenable for 1536 well format. Adaption of the developed purification design to 
1536 well format warrants further investigation of factors as Ni2+ beads addition potentially suffering from the 
well geometry, low volumes of maximum 12.5 µL, sample evaporation, inhomogeneous stirring of the beads and 
separating reconstituted antibodies from Ni2+ beads. A tradeoff between the enormous number of antibody 
combinations that can be screened in a 1536 well format and the loss of single antibody combinations through 
a higher content of non-reconstituted antibodies exists but seems acceptable based on the highly enlarged 
screening space. To get a better idea of the HTRF output, a cross validation was performed using SE-HPLC 
analysis correlating well with HTRF analysis. The low concentrations and volumes required for HTRF analysis 
describe a perfect analytical tool for 1536 well formats compared to SDS-PAGE and SE-HPLC analysis. 
However, precursor antibody fragments Fab IntN have to be labeled with biotin, making it non-convenient to 
use HTRF as a standard analytical tool for reconstitution efficiency. A more elegant way would be a biotin 
labeled antigen directed against the reconstituted Fab arm to enable HTRF. 
Implementation of a fully automated system for antibody reconstitution confirmed improved accuracy of 
reconstitution as measured by antigen binding ELISA signal, when compared to a manual conducted approach. 
In addition, more antibodies can be generated in a less amount of time. Over 330 reconstituted anti-CD40 mAbs 
were generated fully automated with high reproducibility in less than one day, providing functional CD40 
activation as a proof for HTS compatible functional screening. Up to 40 000 reconstituted bsAbs could 
potentially be generated in one week and screened for functionality when applying a full extent industry scale 
screening approach.   
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6.4. Application of combinatorial high throughput screening  
The investigation of a novel screening technology for a large set of potential combinations of paratope moieties 
provided in a bispecific format to bypass current screening limitations and broaden up the target screening space 
was the primary goal of this study. Pharmaceutical development of bsAbs is supplied by several screening 
methods during discovery for the best combinations out of two paratope binders. However, the target screening 
space is limited indebted by the tremendous amount of biological paratopes and combinations. Sampei et al. 
demonstrated an impressive screening approach to find the best combination for a FIXa/FX bsAbs. They 
screened 200 x 200 monoclonal antibodies separately against FIXa and FX, leading to 400 single cloning steps. 
Finally, they generated 40 000 different bispecific combinations with extensive expression and purification steps 
to discover the best hit candidate. Ten different byproducts in form of mispaired HC-HC or HC-LC species were 
observed during bsAb production, decreasing the yield of the desired product and demanding on a multistep 
purification strategy.157,158 Currently HTS for bsAbs is very limited by cloning, expression and purification steps 
reducing the huge potential capacity of the screening space. The presented novel combinatorial HTS technology 
in this study opens the possibility to widen this major bottleneck in conventional screening approaches. The 
combination of antibody fragments in vitro allows for a combinatorial setup overcoming the need for individual 
expression and purification for each combination. Generating 40 000 individual bsAb combinations by fully 
automated antibody reconstitution in a 384 well plate format would significantly decrease the number of 
expressions from 40 000 to 400 variants. In addition, this method allows for a massive cut in time management 
and manufacturing costs during generation and screening of bsAbs. Screening of 40 000 variants could have 
potentially done within one week using the split intein approach.   
Hit discovery and development of clinical candidates predominantly prefers a full-length IgG format. However, 
most of the formats derived from early stage screening campaigns are based on a scFv, VHH or Fab format 
selected by for example yeast surface display or phage display derived from bacterial hosts. A re-formatting step 
is obliged to achieve the final format but means a risk in losing or altering biological functionality like decreased 
affinity or biological potency. Re-formatting, re-testing and maybe re-engineering is needed, potentially 
reducing candidate numbers and increasing timelines and costs. Functional screening already in the desired full-
length IgG format would bypass extensive reformatting steps and alteration of potential biological functionality. 
Generation of full-length IgG antibodies in bacterial hosts like E. coli is challenging and mostly results in 
misfolded protein or low yields without glycosylation compared to scFv, VHH or Fab fragments. Fusing these 
antibody fragments to split inteins prior to phage or yeast display selection would allow for the possibility to 
directly change the format by antibody reconstitution before hit identification and make these molecules 
accessible for modes of action, which are dependent on Fc mediated effector functions or bivalent binding. A re-
formatting step into a bivalent or bispecific IgG-like format after hit candidate generation would bypass multiple 
cloning, expression and purification steps aside from the economy of time. Furthermore, re-engineering and 
optimizations to retain biological functionalities could be omitted. VHH fragments fused to IntN and produced 
in E. coli followed by reconstitution to an oaSEED molecule or Fc portion was demonstrated in this study and 
affirmed the above-mentioned hypothesis.  
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The investigation of two distinct split inteins without cross reactivity to each other during PTS, provides the 
possibility for orthogonal reconstituted antibody variants originated from multiple antibody building 
blocks.159,160 Undesired combinatorial ligation can be avoided by finding a split intein pair offering simultaneous 
orthogonal PTS activity leading to a dual split intein screening approach for either multifunctional antibody 
formats or the discovery of bispecific antibody-drug-conjugate (ADC) variants. The opportunity to generate 
antibodies out of three antibody building blocks increases the combinatorial screening setup for bispecific or 
trispecific formats in parallel. In addition, Fc portions could be potentially linked to toxins with a fixed DAR 
and reconstituted with Fab fragments to generate and screen for bispecific ADCs. Pizer et al. has demonstrated 
that split inteins are suitable for the ligation of immunotoxins C-terminally to Fc antibody portions.161  
In conclusion, antibody reconstitution mediated by split inteins provides a powerful combinatorial and 
functional screening tool for the generation of bsAbs in a fully automated setup. In future, this technology could 
be used in pharmaceutical antibody discovery to support a fast and efficient identification of optimal binder 
combinations in a bispecific format or other complex formats to address the desired mode of action. 
 
6.5. Outlook 
The technical proof of concept for industry scaled automated HT generation of bsAb variants supported by 
potential combinatorial functional screening was successfully demonstrated. Next development steps should 
include the methodology application for a combinatorial full binder repertoire bsAb discovery campaign for 
broad coverage of the large screening space. Furthermore, functional screenings could be extended to additional 
bsAb formats such as VHH-IgG fusions or non-IgG architectures to broaden up the application range. Of note, 
Weber et al. successfully demonstrated that the natural IgG antibody architecture is not necessarily the best 
option to achieve a unique mode of action, which is still undiscovered.162 In their study, they generated a brain 
shuttle mAb by fusing a brain shuttle module to the C-terminal constant region of the Fc portion, still retaining 
bivalent antigen binding against beta-amyloid. This unnatural design offered improved target engagement and 
efficacy and furthermore the molecule was able to become fully active through an inverted binding mode.163 
These observations show that it is highly important to screen not only for the best combination on the one hand 
but simultaneously screen for the optimal format, always keeping in mind that the natural antibody structure 
might not be the best option for the desired mode of action. The split intein reconstitution technology potentially 
allows to screen for the best combination of two binding moieties and compares different formats at the same 
time to find the best architecture for a unique mode of action. 
Further implementation of small-scale expression prior to antibody reconstitution and HTS would power up 
the whole set up. A critical look into products, product related impurities, and the amounts of undesired products 
upon reconstitution is needed as well as further development of suitable HT analytical tools. The conducted cell 
assays illustrated the suitability of intein mediated reconstitution for functional interrogation of envisioned 
specific modes of action. A closer look into assay compatibilities would be desirable especially with regard to 
T-cell engagers. The antibody HTS platform could be extended with a dual split intein approach screening for 
functional screening of selectivity optimized bispecific ADCs,84 or trispecific antibodies.164,165 With a plethora of 
potential applications in future therapeutic antibody discovery, the method described in this thesis could enable 
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bispecific antibody high throughput functional screenings for enhanced probability of identifying optimal 
combinations and formats, which could ultimately lead to the generation of better biotherapeutics.
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8. Appendix 
 
8.1. Protein sequences  
Amino acid sequences of used antibody-intein fusions and parental reference antibodies based on commercially 
available antibodies or in house generated antibodies are shown below. DNA sequences of antibody-intein 
fragments for plasmid generation in pTT5 vector backbone were codon optimized for mammalian expression 
systems and obtained from GeneArt (Life Technologies).  
 
IgG1 Fc IntC 
HHHHHHGGGGSGGGGSGGGGSGGGGSMIKIATRKYLGKQNVYDIGVERDHNFALKNGFIASNCFN
THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK
TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPG 
 
IgG2 Fc IntC 
HHHHHHGGGGSGGGGSGGGG SGGGGSMIKIATRKYLGKQNVYDIGVERDHNFALKNGFIASNCF
NTHTCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAK
TKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSR
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQG
NVFSCSVMHEALHNHYTQKSLSLSPG 
 
APX Fab IntN HC 
QVQLVESGGGVVQPGRSLRLSCAASGFSFSSTYVCWVRQAPGKGLEWIACIYTGDGTNYSASWAKG
RFTISKDSSKNTVYLQMNSLRAEDTAVYFCARPDITYGFAINFWGPGTLVTVSSASTKGPSVFPLAPS
SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
CNVNHKPSNTKVDKRVEPKSCDKAEYCLSYETEILTVEYGLLPIGKIVEKRIECTVYSVDNNGNIYTQ
PVAQWHDRGEQEVFEYCLEDGSLIRATKDHKFMTVDGQMLPIDEIFERELDLMRVDNLPNAAAEQ
KLISEEDLSHHHHHH 
 
APX Fab IntN LC 
DIQMTQSPSSLSASVGDRVTIKCQASQSISSRLAWYQQKPGKPPKLLIYRASTLASGVPS RFSGSGSGT
DFTLTISSLQPEDVATYYCQCTGYGISWPIGGGTKVEIKRTVAAPSVFIFP PSDEQLKSGTASVVCLL
NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSS
PVTKSFNRGEC 
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CEACAM5 (AG) SEED 
EVQLVESGGGLVKPGGSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVK
GRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKETIPTYLAAVVPFDYWGQGTLVTVSSASTKGPSV
FPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG
TQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCV
VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA
LPAPIEKTISKAKGQPFRPEVHLLPPSREEMTKNQVSLTCLARGFYPKDIAVEWESNGQPENNYKTT
PSRQEPSQGTTTFAVTSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKTISLSPGK 
 
CEACAM6 (GA) SEED 
EMQLVQSGAEVKKPGASVKVSCKASGYTFTGFYIHWVRQAPGQGLEWMGRINLNSGVRNYVQKFQ
GRVTMTRDTSIGTAYMELSGLRSDDTAVYYCATPTYYDILTGPFDYWGQGTLVTVSSASTKGPSVF
PLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS GVHTFPAVLQSSGLYSLSSVVTVPSSSLG
TQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCV
VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA
LPAPIEKTISKAKGQPREPQVYTLPPPSEELALNELVTLTCLVKGFYPSDIAVEWLQGSQELPREKYL
TWAPVLDSDGSFFLYSILRVAAEDWKKGDTFSCSVMHEALHNHYTQKSLDRSPGK 
 
cLC 
EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSG
TEFTLTISSLQSEDFAVYYCQQYNNWPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLL
NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSS
PVTKSFNRGEC 
 
huFc IntC (GA) SEED 
HHHHHHGGGGSGGGGSGGGGSGGGGSMIKIATRKYLGKQNVYDIGVERDHNFALKNGFIASNCFN
THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK
TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPPS
EELALNELVTLTCLVKGFYPSDIAVEWLQGSQELPREKYLTWAPVLDSDGSFFLYSILRVAAEDWKK
GDTFSCSVMHEALHNRFTQKSLDRSPG 
 
CEACAM6 Fab IntN 
EMQLVQSGAEVKKPGASVKVSCKASGYTFTGFYIHWVRQAPGQGLEWMGRINLNSGVRNYVQKFQ
GRVTMTRDTSIGTAYMELSGLRSDDTAVYYCATPTYYDILTGPFDYWGQGTLVTVSSASTKGPSVF
PLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT
QTYICNVNHKPSNTKVDKRVEPKSCDKAEYCLSYETEILTVEYGLLPIGKIVEKRIECTVYSVDNNGNI
YTQPVAQWHDRGEQEVEYCLEDGSLIRATKDHKFMTVDGQMLPIDEIFERELDLMRVDNLPNAAA
EQKLISEEDLSHHHHHH 
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hOKT3 Fab (AG) SEED 
QVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVK
DRFTISRDNSKNTAFLQMDSLRPEDTGVYFCARYYDDHYCLDYWGQGTPVTVSSASTKGPSVFPLA
PSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
YICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD
VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA
PIEKTISKAKGQPFRPEVHLLPPSREEMTKNQVSLTCLARGFYPKDIAVEWESNGQPENNYKTTPSR
QEPSQGTTTFAVTSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKTISLSPG 
 
hOKT3 LC 
DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGT
DYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQITRTVAAPSVFIFPPSDEQLKSGTASVVCLLN
NFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSP
VTKSFNRGEC 
 
Trastuzumab Fab IntN  
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKG
RFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPL
APSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
TYICNVNHKPSNTKVDKRVEPKSCDKAEYCLSYETEILTVEYGLLPIGKIVEKRIECTVYSVDNNGNIY
TQPVAQWHDRGEQEVFEYCLEDGSLIRATKDHKFMTVDGQMLPIDEIFERELDLMRVDNLPNAAA
EQKLISEEDLSHHHHHH 
 
Trastuzumab LC 
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSG
TDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLL
NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSS
PVTKSFNRGEC 
 
c-MET B10v5 (AG) SEED 
EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKG
RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRRITHTYWGQGTLVTVSSASTKGPSVFPLAPSSK
STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
VNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH
EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE
KTISKAKGQPFRPEVHLLPPSREEMTKNQVSLTCLARGFYPKDIAVEWESNGQPENNYKTTPSRQEP
SQGTTTFAVTSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKTISLSPGK 
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c-MET B10v5 LC 
EPVLTQPPSVSVAPGETATIPCGGDSLGSKIVHWYQQRPGQAPLLVVYDDAARPSGIPERFSGSKSGT
TATLTISSVEAGDEADYFCQVYDYHSDVEVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLV
CLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGS
TVEKTVAPTECS 
 
c-MET F06 AG SEED 
QVQLQQSGAEVKKPGSSAKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGR
VTITADESTSTAYMELSSLRSEDTAVYYCARDQRGYDYYYYYGMDVWGQGTTVTVSSASTKGPSV
FPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG
TQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCV
VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA
LPAPIEKTISKAKGQPFRPEVHLLPPSREEMTKNQVSLTCLARGFYPKDIAVEWESNGQPENNYKTT
PSRQEPSQGTTTFAVTSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKTISLSPGK 
 
c-MET F06 LC 
QLVLTQSPSVSVAPGKTARITCGGNNIRNVGVHWYQKKPGQAPILVVYDDDDRPSGVPERFSGSNSG
NTATLTISRVEAGDEADYYCQVWDSATDQRVFGGGTKLTVLGQPKAGPSVTLFPPSSEELQANKAT
LVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHE
GSTVEKTVAPTEC 
 
hu225H Fab IntN 
EVQLVQSGAEVKKPGASVKVSCKASGFSLTNYGVHWMRQAPGQGLEWIGVIWRGGNTDYNTPFTS
RVTITSDKSTSTAYMELSSLRSEDTAVYYCARALTYYDYEFAYWGQGTLVTVSSASTKGPSVFPLAP
SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
CNVNHKPSNTKVDKRVEPKSCDKAEYCLSYETEILTVEYGLLPIGKIVEKRIECTVYSVDNNGNIYTQ
PVAQWHDRGEQEVFEYCLEDGSLIRATKDHKFMTVDGQMLPIDEIFERELDLMRVDNLPNAAAEQ
KLISEEDLSHHHHHH 
 
hu225H LC 
DIQMTQSPSSLSASVGDRVTITCRASQSIGTNIHWYQQKPGKAPKLLIKYASESISGVPSRFSGSGYGT
DFTLTISSLQPEDVATYYCQQNNNWPTTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLL
NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSS
PVTKSFNRGEC 
 
hu225L Fab IntN 
EVQLVQSGAEVKKPGASVKVSCKASGFSLTNYGVHWMRQAPGQGLEWIGVIWSGGNTDYNTPFTS
RVTITSDKSTSTAYMELSSLRSEDTAVYYCARALDYYDYEFAYWGQGTLVTVSSASTKGPSVFPLAP
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SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
CNVNHKPSNTKVDKRVEPKSCDKAEYCLSYETEILTVEYGLLPIGKIVEKRIECTVYSVDNNGNIYTQ
PVAQWHDRGEQEVFEYCLEDGSLIRATKDHKFMTVDGQMLPIDEIFERELDLMRVDNLPNAAAEQ
KLISEEDLSHHHHHH 
 
hu225L LC 
DIQMTQSPSSLSASVGDRVTITCRASQSIGTNIHWYQQKPGKAPKLLIKYASESISGVPSRFSGSGYGT
DFTLTISSLQPEDVATYYCQQNNEWPNTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLN
NFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSP
VTKSFNRGEC 
 
IntC  
SGGGGSMIKIATRKYLGKQN VYDIGVERDH NFALKNGFIASNCFN 
 
IntN 
AEYCLSYETEILTVEYGLLPIGKIVEKRIECTVYSVDNNGNIYTQPVAQWHDRGEQEVFEYCLEDGS
LIRATKDHKFMTVDGQMLPIDEIFERELDLMRVDNLPN 
 
8.2. Supplemental Figures 
 
  
Figure S 1: SDS-PAGE analysis of precursor antibody fragments fused to the respective intein part after final purification step 
via SEC.  
(A) Non-reduced SDS-PAGE analysis of precursor fragments. Lane 1: Marker; Lane 2: hOKT3 Fab (AG) aHer2 VHH (GA) SEED; Lane 
3: hOKT3 Fab (AG) huFc IntC (GA) SEED; Lane 4: huFc IgG1 IntC; Lane 5: huFc IgG1.4 IntC; Lane 6: huFc IgG1.6 IntC; Lane 7: huFc 
IgG2 IntC. (B) Reduced SDS-PAGE analysis of precursor fragments for HC and LC detection. Lane 1: Marker; Lane 2: hOKT3 Fab (AG) 
aHer2 VHH (GA) SEED; Lane 3: hOKT3 Fab (AG) huFc IntC (GA) SEED; Lane 4: huFc IgG1 IntC; Lane 5: huFc IgG1.4 IntC; Lane 6: 
huFc IgG1.6 IntC; Lane 7: huFc IgG2 IntC. 
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Figure S 2: SDS-PAGE analysis of precursor antibody fragments fused to the respective intein part after final purification step 
via SEC.  
(A) Non-reduced SDS-PAGE analysis Lane 1: Marker; Lane 2: hu225H Fab IntN; Lane 3: hu225L Fab IntN; Lane 4: oaC5 SEED IntC; 
Lane 5: C6 Fab IntN; Lane 6: Marker; Reduced SDS-PAGE analysis: Lane 7: hu225H Fab IntN; Lane 8: hu225L Fab IntN; Lane 9: oaC5 
SEED IntC; Lane 10: C6 Fab IntN (B) Non-reduced SDS-PAGE analysis: Lane 1: Marker; Lane 2: oa B10v5 SEED IntC ; Lane 3: oa F06 
SEED IntC ; Reduced SDS-PAGE analysis: Lane 4: Marker; Lane 5: oa B10v5 SEED IntC ; Lane 6: oa F06 SEED IntC . (C) Non-reduced 
SDS-PAGE analysis: Lane 1: Marker; Lane 2: Trastuzumab Fab IntN ; Lane 3: oa Trastuzumab SEED IntC; 
 
 
 
Figure S 3: Analytical size exclusion chromatography (SE-HPLC) of precursor antibody fragments in different formats fused 
to split inteins.  
Purified antibody fragments were concentrated to 1 mg mL-1 and analyzed by HPLC using 10 µg of protein and a TSKgel Super SW3000 
analytical size exclusion column. High monomeric content of B10v5 oaSEED IntC, CD40 Fab IntN and huFc IntC was achieved with 
98.9%, 96.4% and 96.0% respectively. 
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Figure S 4: Antibody reconstitution over time and efficiency determination.  
(A) Precursor antibody fragments anti-CD40 Fab IntN and huFc IntC were mixed in a molar ratio of 2:1 and PTS was activated by the 
addition of 0.5 mM TCEP followed by incubation for 2 h at 37°C. (B) Peak areas of precursor antibody fragments (substrate) and 
reconstituted antibody product were determined over time by pixel analysis using ImageJ. Highest peak point of precursor antibody 
fragments at 0 h were considered as 100%. Conversion of antibody fragments into reconstituted anti-CD40 product mediated by PTS 
was observed over time and depletion of antibody fragments was almost completed after 120 min. (C) Peak areas were used to generate 
an extrapolated Michaelis Menten kinetic by GraphPad Prism v7 analysis. A reconstitution efficiency of around 90% was achieved. 
 
 
Figure S 5: Papain digestion of reconstituted c-METxEGFR bsAb B10v5xhu225H for Fab release and LC shuffling 
investigation by MS analysis.  
Reconstituted bsAb B10v5xhu225H was treated with Papain and incubated for 3 h at 37°C under shaking conditions for Fab release. 
Fabs were further analyzed by ESI-MS. The expected mass of B10v5 (c-MET) Fab as well as hu225H (EGFR) Fab correlates with the 
measured mass. The expected masses for both Fabs with an LC switch was depicted in the spectrum but was not detected. 
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Figure S 6: Analytical size exclusion chromatography (SE-HPLC) of different reconstituted bsAbs and 
mAbs.  
 
Reconstituted antibody samples were diluted to 1 mg mL-1 in PBS and 10 µg of protein sample was injected onto a TSKgel 
Super SW3000 analytical size exclusion column. Monomeric content of reconstituted bsAbs and mAbs are listed in Table 3. 
 
 
Figure S 7: Intact mass determination of reconstituted bsAb B10v5xhu225L by TOF-MS analysis under non-reduced conditions.  
 
(A) Illustration of a full m/z spectrum for reconstituted bsAb B10v5xhu225L. (B) Intact reconstruction spectrum of reconstituted bsAb 
B10v5xhu225L. 
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Figure S 8: Intact mass determination of reconstituted bsAb B10v5xhu225L by TOF-MS analysis under reduced conditions.  
 
(A) Illustration of a full m/z spectrum for reconstituted bsAb B10v5xhu225L. (B) Intact reconstruction spectrum of reconstituted bsAb 
B10v5xhu225L. 
 
 
Figure S 9: Intact mass determination of reconstituted bsAb B10v5xhu225H by TOF-MS analysis under non-reduced 
conditions.  
 
(A) Illustration of a full m/z spectrum for reconstituted bsAb B10v5xhu225H. (B) Intact reconstruction spectrum of reconstituted 
bsAb B10v5xhu225H. 
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Figure S 10: Intact mass determination of reconstituted bsAb B10v5xhu225H by TOF-MS analysis under reduced conditions.  
 
(A) Illustration of a full m/z spectrum for reconstituted bsAb B10v5xhu225H. (B) Intact reconstruction spectrum of reconstituted bsAb 
B10v5xhu225H. 
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Figure S 11: Affinity comparison between reconstituted anti-CD40 mAbs and reference anti-CD40 (APX005M) binding to 
soluble recombinant human CD40 by BLI analysis.  
Antibodies were analyzed with ProteinA biosensors. KD was determined after 300 s association and 600 s dissociation with recombinant 
human CD40 and monitored with varying concentration of analyte antigen over time resulting in an interference pattern shift (nm). (A) 
KD determination of reference antibody APX005M. (B) KD determination of reconstituted anti-CD40 IgG1. (C) KD determination of 
reconstituted anti-CD40 IgG1.4. (D) KD determination of reconstituted anti-CD40 IgG1.6. (E) KD determination of reconstituted anti-
CD40 IgG2. All reconstituted anti-CD40 mAbs showed similar kinetic parameters to reference antibody APX005M. 
 
Figure S 12: DSF analysis of several reconstituted antibodies.  
(A) Melting points of reconstituted anti-CD40 mAbs, reconstituted bsAb C5xC6 (B) and reconstituted bsAbs B10v5xhu225H and 
B10v5xhu225L (C) were determined by the maximum of the first peak at F330nm/F350nm ratio and compared to their reference 
antibodies. 
 
9. Affirmations  106 
  
Figure S 13: Affinity determination of reconstituted c-METxEGFR antibodies B10v5xhu225H and B10v5xhu225L binding to 
soluble recombinant c-MET and EGFR by BLI analysis.  
BsAbs were analyzed with ProteinA biosensor tips. KD was determined after 400 s association and 1200 s dissociation of the respective 
antigens and monitored with varying concentration of analyte over time resulting in an interference pattern shift (nm). (A) KD 
determination for reconstituted B10v5xhu225H bsAb binding to respective recombinant antigens. (B) KD determination for reconstituted 
B10v5xhu225L bsAb binding to respective recombinant antigens. (C) Simultaneous binding of soluble recombinant c-MET and EGFR 
by reconstituted bsAb B10v5xhu225H. Both antigens c-MET and EGFR are associated stepwise. Reference antigen recombinant CD40 
was used as a negative control in high concentration of 100 nM, to test unspecific binding response. No binding to recombinant EGFR 
was observed by monovalent oa B10v5 SEED. 
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Figure S 14: Cellular binding of reconstituted anti-CD40 mAbs and anti-CD40 reference antibody (APX005M).  
CD40 expressing cancer cell lines HT1080 and negative cell line MBD-MB-468 were incubated with 10 µg mL-1 antibodies for 1 h. 
Antibodies were detected with Alexa Fluor 488-conjugated anti-human IgG (H+L) Fab via FACS analysis. (A) Binding was observed 
with several reconstituted anti-CD40 mAbs. (B) Comparison of binding levels between reconstituted anti-CD40 IgG1 and reference anti-
CD40 (APX005M). (C) Determination of unspecific binding for reconstituted antibodies on negative cell line MBD-MB-468. Analysis 
was conducted using the green fluorescent channel with adjusted forward and side scatter (Guava easyCyte HT cytometer). Blue: 
Reference anti-CD40 IgG (APX005M); Green: Reconstituted anti-CD40 IgG1; Red: Reconstituted anti-CD40 IgG1.4; Light blue: 
Reconstituted anti-CD40 IgG1.6; Orange: Reconstituted anti-CD40 IgG2. 
 
 
  
Figure S 15: Cellular binding of reconstituted bsAb CD3xHer2 TCE and monovalent oa CD3 SEED.  
Her2 positive SK-BR-3 cancer cells and CD3 expressing Jurkat E6.1 cells were incubated with 10 µg mL-1 antibodies for 1h. Antibodies 
were detected with Alexa Fluor 488-conjugated anti-human IgG (H+L) Fab via FACS analysis. Binding was observed with reconstituted 
bsAb CD3xHer2 TCE on both antigens expressed on SK-BR-3 cancer cells and Jurkat E6.1 cells, while monovalent oa CD3 SEED was 
only binding to CD3 on Jurkat E6.1. Analysis was conducted using the green fluorescent channel with adjusted forward and side scatter 
(Guava easyCyte HT cytometer). Blue: Reconstituted CD3xHer2; Red: oa CD3 SEED; Black: Non-related isotype control (anti-HEL). 
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Figure S 16: Miniaturization of antibody reconstitution in 96 well format and demonstration of one-pot purification strategy. 
 A surplus of anti-CD40 Fab IntN is used in a ratio 3:1 over huFc IntC. Example for Panel A: A1: Single anti-CD40 Fab IntN (61.5 kDa). 
B1: single huFc IntC (63.5 kDa). A2 to A9: Antibody fragments anti-CD40 IntN and huFc IntC were mixed in a ratio 3:1 and 0.5 mM 
TCEP was added for PTS activation. Reconstituted antibodies were isolated from non-reconstituted antibodies anti-CD40 Fab IntN and 
huFc IntC by addition of 25 µL Ni2+ beads with a binding capacity of 40 µg 25 µL-1 and further treated with a 10-fold molar excess of 
DHAA over TCEP for re-oxidation. Gel bands for reconstituted anti-CD40 antibodies were observed at 145.7 kDa under non-reduced 
conditions. A10-A11: Not treated with Ni2+ beads after reconstitution reaction, resulting in reconstituted anti-CD40 antibody as well as 
antibody fragments anti-CD40 IntN and huFc IntC. A12: Antibody fragments anti-CD40 IntN and huFc IntC after TCEP treatment 
without the addition of Ni2+ beads and DHAA (control). Gel panels B to H contain the same molecules compared to panel A. Gel band 
at 1 kDa (green): Lower Marker (LM). Blue band below 16 kDa: System Peak.  
 
 
Figure S 17: Reconstitution determination directly during antibody fragment expression in conditioned HEK293 and ExpiCHO 
expression medium.  
Purified antibody fragment anti-CD40 Fab IntN was spiked into huFc IntC expression after 5 days and treated with 2 mM TCEP to 
activate PTS. Spiking into conditional ExpiCHO expression medium: Lane 1: Marker; Lane 2: Antibody fragments anti-CD40 Fab 
IntN and huFc IntC at 0 h after TCEP addition. Lane 3: 1 h after TCEP addition; Lane 4: 2 h after TCEP addition; Lane 5: 24 h after 
TCEP addition; Lane 6: Treatment with 10 fold molar excess of DHAA over TCEP for 2h (re-oxidation); Spiking into conditional 
HEK293 expression medium: Lane 7: Antibody fragments anti-CD40 Fab IntN and huFc IntC at 0 h after TCEP addition. Lane 8: 
Reconstitution after 1 h; Lane 9: Reconstitution after 2 h; Lane 10: Reconstitution after 24 h; Lane 11: Treatment with 10-fold molar 
excess of DHAA over TCEP for 1h (re-oxidation); Lane 12: Treatment with 10-fold molar excess of DHAA over TCEP for 2 h (re-
oxidation). 
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8.3. Supplemental Tables  
Table S 1: Reconstituted mAbs and bsAbs and antibody fragments fused to their N-terminal or C-terminal split intein part 
were analyzed by mass spectrometry. 
 
Antibody Conditions Theoretical mass 
[Da] 
Measured mass 
[Da] 
C5xC6 Reconstituted     
B10v5xhu225L 
B10v5xhu225H 
F06xhu225L 
Anti-CD40 IgG1 Reconstituted 
Anti-CD40 IgG1.4 
Reconstituted 
Anti-CD40 IgG1.6 
Reconstituted  
     
Intact 
Intact 
Intact 
Intact 
Intact 
Intact 
Intact 
 
147919 
145837 
145810 
146888 
146462 
146184 
146004 
147926 
145840 
145815 
146891 
146461 
146184 
146006 
oa C5 IntC GA 
oa C5 IntC AG 
oa C5 IntC LC 
 
Reduced 
Reduced 
Reduced 
32474 
50084 
23390 
32475 
50084 
23390 
 
C6 Fab IntN HC 
C6 Fab IntN LC 
 
Reduced 
Reduced 
 
38951 
23390 
38951 
23390 
 
oa F06 IntC GA 
oa F06 IntC AG 
oa F06 IntC LC 
                             
Reduced 
Reduced 
Reduced 
32474 
50208 
22711 
32475 
50208 
22711 
oa B10v5 IntC GA 
oa B10v5 IntC AG 
oa B10v5 IntC LC 
 
hu225H Fab IntN HC 
hu225H Fab IntN LC 
 
hu225L Fab IntN HC 
hu225L Fab IntN LC 
 
CD40 Fab IntN HC 
CD40 Fab IntN LC 
 
huFc IgG1 IntC HC 
                             
Reduced 
Reduced 
Reduced 
 
Reduced 
Reduced 
 
Reduced 
Reduced 
 
Reduced 
Reduced 
 
Reduced 
32474 
49278 
22590 
 
38411 
23425 
 
38465 
23397 
 
38288 
23226 
 
32078 
32474 
49278 
22590 
 
38411 
23425 
 
38466 
23397 
 
38288 
23226 
 
32079 
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8.6. Abbreviations  
aa  Amino acid  
ADC  Antibody-drug conjugate  
ADCC  Antibody-dependent cellular cytotoxicity  
AF488  Alexa Fluor 488  
Amp 
APC  
Asn 
Ampicillin 
Antigen presenting cell  
Asparagin 
BCA  Bicinchoninic acid  
BCR  
BiTE 
B-cell receptor  
Bispecific T-cell engager 
BLI  Biolayer interferometry  
BSA  
BsAb 
Bovine serum albumin  
Bispecific antibody 
C225  Cetuximab  
CDC  Complement-dependent cytotoxicity  
CDR  
cFAB 
c-MET 
C5 
C6 
CD3 
CD40 
Complementarity determining region  
Controlled Fab arm exchange 
Tyrosine protein kinase / hepatocyte growth factor 
CEACAM5; Carcinoembryonic antigen-related cell adhesion molecule 
CEACAM6 
Cluster of differentiation 
Cluster of differentiation 
CH1-3  
CIP 
Constant domain 1-3 of the heavy chain  
Antarctic phosphatase 
cLC 
CnaB2 
Common light chain 
Collagen adhesion domain 
CTLA4  Cytotoxic T lymphocyte-associated antigen 4  
CV  Column volume  
Da  Dalton  
DAR  Drug-to-antibody ratio  
dH20  Distilled water  
DNA 
DnaE  
DTT 
Deoxyribonucleic acid  
Catalytic α subunit of DNA polymerase III 
Dithiothreitol  
ECD  Extracellular domain  
E. coli  Escherichia coli  
EGFR  Epidermal growth factor receptor 
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ELISA  
EPL 
EpCAM 
Enzyme-linked immunosorbent assay  
Expressed Protein Ligation 
Epithelial cell adhesion molecule 
Fab  Fragment antigen binding  
FACS  
FbaB 
Fluorescence activated cell sorting  
Fibronectin binding protein 
Fc  Fragment crystallizable  
FcRn  Neonatal Fc receptor  
FcγR  Fcγ receptor  
FCS  Fetal calf serum  
FDA  
FR 
HAMA 
Food and Drug Administration  
Framework 
human anti-mouse antibodies 
h  Hour  
HC  Heavy chain  
HCC  Hepatocellular carcinoma  
HER  Human epidermal growth factor receptor  
HGF Hepatocyte growth factor 
HIC  Hydrophobic interaction chromatography  
His-tag  Histidine tag, usually composed of six histidines  
HPLC  High performance liquid chromatography  
HRP / POD  
HT 
HTS 
HTRF 
Horseradish peroxidase  
High throughput 
High throughput screening 
Homogenous Time Resolved Fluorescence 
hu   Human  
Ig  Immunoglobulin  
IMAC 
IntN 
IntC  
Immobilized metal ion affinity chromatography  
N-terminal split intein part 
C-terminal split intein part 
ka  Association rate constant  
KB  Kinetics buffer  
KD  Equilibrium dissociation constant  
kd  
KiH 
Dissociation rate constant  
Knobs into holes 
LB medium  Luria-Bertani medium  
LC  
LDS 
Light chain  
Lithium dodecyl sulfate 
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mAb / pAb  Monoclonal antibody / polyclonal antibody  
MALDI-TOF  Matrix-assisted laser desorption/ionization time of flight mass 
spectrometry  
MS  Mass spectrometry  
MCS  Multiple cloning site  
mTGase  Microbial transglutaminase  
mu  Murine, mus musculus  
MWCO  
NBE 
Molecular weight cut-off  
New biological entity  
n.d.  Not determined  
NC  
nCL 
Nitrocellulose  
Native chemical ligation 
NEAA  Non-essential amino acids  
NK   
Npu 
Natural killer cells  
Cyanobacterium Nostoc punctiforme  
oa  One-armed  
OD 
OKT3  
Optic density  
Orthoclone; Muromonab-CD3 
PAMPs  Pathogen-associated molecular patterns  
PBS  Phosphate buffered saline  
PCR  Polymerase chain reaction  
PD-1  Programmed cell death protein 1  
PD-L1  Programmed cell death protein ligand 1  
PDB  Protein Data Bank  
PVDF  
PTS 
Polyvinylidene fluoride  
Protein-trans-splicing 
RFU  Relative fluorescence units  
RIPA buffer  Radioimmunoprecipitation assay buffer  
rpm  Revolutions per minute  
RT  Room temperature  
scFv  Single-chain variable fragment  
s.d.  Standard deviation  
SDS  Sodium dodecylsulfate  
SEC  Size exclusion chromatography  
s  second  
SEED  Strand exchange engineered domain  
Srt  
Ssp 
Sortase  
Cyanobacterium synechocystis 
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TCEP  Tris(2-Carboxyethyl) phosphine  
TCR  
TG 
T-cell receptor  
Transglutaminase 
TFF  Tangential Flow Filtration  
TLR  Toll-like receptor  
Tm  Melting temperature  
TME  Tumor microenvironment  
Tris  Tris(hydroxymethyl)aminomethane  
US  United States  
v/v  
VDJ 
Volume per volume  
Somatic recombination 
VEGF  Vascular endothelial growth factor  
VH  Variable domain of the heavy chain  
VL  Variable domain of the light chain  
w/v  Weight per volume  
wt  Wild type  
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